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Abstract: Cardiovascular disease is the number one cause of death worldwide, 
representing 31% of all global deaths. Among them, over 14 million are due to ischemic 
coronary heart disease and stroke. Additionally, peripheral artery disease is the major 
cause of limb amputations in the US. Type 2 diabetic patients are at highest risk of 
mortality and morbidity due to ischemic cardiovascular disease. Arteriogenesis is the 
normal physiological response to occluded blood vessels by structural remodeling of 
preexisting collateral arteries. Although, arteriogenesis is vital for diabetic patients, 
diabetes inhibits this process with poorly known mechanism. 
Placenta growth factor (PLGF) is a key mediator of arteriogenesis. Genetic deletion of 
PLGF reduced arteriogenesis while over expression resulted enlarged stable vessels 
making it a suitable therapeutic target for compromised arteriogenesis in diabetes. 
However, little is known about PLGF regulation. Our previous work suggests that PLGF 
is sensitive to reactive oxygen species. Since physiological oxidative balance is altered in 
diabetes, PLGF expression and regulation may be affected by diabetes contributing to 
reduced arteriogenesis in diabetes.  
Here, we report that PLGF is down regulated in mouse heart, skeletal muscle and pig 
coronary arteries and upregulated in mouse aorta under diabetes related metabolic 
conditions. PLGF inhibition in vivo is highly correlated with hypercholesterolemia, 
oxidative stress (heart and coronary arteries) and hyperinsulinemia (skeletal muscle). In 
vitro finding suggests advanced glycated end product mediated inhibition of PLGF in 
multiple cell types. In a physiologically relevant model of hind limb ischemia, we found 
that PLGF is shapely elevated in skeletal muscle. However, this stimulation is severely 
hampered in the presence of diabetes associated metabolic conditions.  
In conclusion, the research presented in this dissertation identifies key metabolic 
parameters that affect PLGF expression under basal level as well as in the presence of 
arteriogenic stimulus. Our data from large animal, small animal and multiple cell types 
are consistent and strongly suggest similar mechanisms of PLGF inhibition occur in 
diabetic patients. These findings benefit the research aiming to minimize ischemic 
cardiovascular disease in diabetic patients. 
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Vascular system and homeostasis 
 Vascular growth creates the first functional organ system during vertebrate 
organogenesis (1). The functional circulatory system is a prerequisite for embryogenesis. 
Failure of vascular growth results in embryonic death by E10 in mice (2). During 
gastrulation, the vascular system develops from the mesoderm, where hemangioblast 
differentiation and formation of immature blood vessels occurs to form the primary vascular 
plexus. This process is known as vasculogenesis (1). Angiogenesis refers to capillary 
formation, which is also important in embryogenesis establishing blood supply to ectoderm 
derived organs (3). Post-natally, blood vessel growth (mainly angiogenesis) continues to be 
important in growth and development. In addition to angiogenesis, blood vessel growth in 
adults also involves a related process referred to as arteriogenesis or collateral remodeling. 
Rather than proliferation of capillaries, arteriogenesis mediates formation of functional 
arteries from preexisting anastomoses. Temporal, tissue specific and genetic variation of 
regulation of wide range of mediators, along with environmental cues, governs the 
development and maintenance of a functional circulation system. Dysfunction of the adult 
vasculature is implicated in the majority of leading causes of mortality.  
  The primary goal of the vascular system is to deliver nutrients and oxygen to tissue. 
The blood supply to tissue is variable, allowing it to fluctuate primarily according to the 
vastly divergent needs of tissue for oxygen according to their metabolism. Moreover, 
maintaining oxygen and nutrient homeostasis in the internal fluid environment that surrounds 
and exchanges materials with cells requires dramatic changes in blood flow in time scales 
varying from seconds to months or years. For instance, during exercise additional blood is 
delivered to skeletal muscles to meet their increased metabolic needs. This increase happens 
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in seconds by a process called active hyperemia. Acute changes in blood flow such as this are 
due to release of vasoactive mediators or changes in vascular tone which result in local 
arteriolar dilation. In contrast, chronic changes to a blood flow to an organ require long term 
vascular changes, both during normal growth and development and upon pathological 
vascular obstruction. However, both acute and chronic adaptations are complementary and 
are driven by similar environmental variables, which include local oxygen tension and 
hemodynamic forces such as shear stress. After birth, there are two such major mechanisms 
of vascular remodeling: angiogenesis, which generates neovessels, mainly capillaries; and 
arteriogenesis, growth and expansion of existing collateral arterioles leading to formation of 
large conductance arteries as a compensatory route when the major supply artery is occluded. 
Despite the high clinical versatility of arteriogenesis in ischemic cardiovascular diseases, the 
mechanism governing the arteriogenesis remains unknown. Stimulating arteriogenesis in 
ischemic cardiovascular disease is rapidly developing area of research.  
Arteriogenesis is inhibited in diabetes by an unknown mechanism. Dysregulation of 
arteriogenic growth factors is a major area of research aiming to uncover the basis of this 
inhibition. The overall goal of the research presented in this thesis is to characterize the effect 
of hyperglycemia and hyperlipidemia on the regulation of placenta growth factor, an 
arteriogenic growth factor. The initial part of the chapter one covers the introduction of key 
concepts and up-to-date literature review. The objectives and the hypothesis will be 
summarized at the end of chapter one. 
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Arteriogenesis 
 First identified by Longland (4), collateral arterioles are small vessels that connect the 
perfusion zone of one conductance vessel with the perfusion zone of another neighboring 
conductance vessel. Later, Fulton (5) reported the existence of coronary collaterals in normal 
hearts as well as in those with heart disease. He also demonstrated a caliber increase of the 
collaterals, from 10-200 m in the absence of coronary artery disease to 100-800 m in the 
presence of such underlying pathology. Under normal conditions, little flow passes through 
these vessels, due to their narrow diameter and correspondingly high resistance. However, in 
response to occlusion of one of the upstream supply arteries, collaterals can enlarge and 
accommodate a significant level of blood flow. This process is known as arteriogenesis (6), 
to distinguish it from the related process of capillary formation or angiogenesis. 
 Arteriogenesis is an adaptive physiological response to vascular obstruction which 
attempts to preserve blood flow to tissue at risk of ischemia by enlarging and remodeling 
preexisting collaterals to increase their flow capacity (Figure 1.1)(7;8). This survival 
mechanism aims to improve oxygen and nutrient supply to the affected tissue, thereby 
decreasing the chance of tissue damage due to vascular blockage. For instance, arteriogenesis 
helps to circumvent the blood flow limitation due to atherosclerosis in coronary arteries, 
which can otherwise lead to myocardial infarction. Thus, it is a natural bypass mechanism 
that can compensate for occlusion in a supply artery by enlarging preexisting collateral 
bridges originating from a non-occluded artery. In their unchallenged state, collaterals in the 
heart would be classified as elements of the microcirculation, ranging from 30 to 100 m in 
diameter. This is comparable to 7.5% total cross sectional area of the normal coronary artery, 
with a flow capacity of 1.5% of normal arterial conduction in canine model (9). However, 
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during arteriogenesis an arteriole can remodel to become an artery of up to 12 times its 
original cross sectional area (10).Indeed, these vessels show a propensity to remodel into 
parts of the macrocirculation and can become arteries larger than 1000 m in diameter when 
appropriately stimulated (11). Furthermore, this type of vessel structural remodeling is 
dependent on endothelial cell and smooth muscle proliferation, and is therefore distinct from 
vasodilation (6;8).  
In addition to the arteriogenic response to pathologic vascular occlusions, increased 
metabolic demand of tissue due to physical activity can also induce arteriogenesis. For 
instance, exercise training increases collateral-dependent blood flow to tissues at risk of 
ischemia and enhances and demonstrate therapeutic benefits. 
Key early findings on arteriogenesis 
The presence of a collateral circulation in human tissues and its functional benefits 
were debated for decades. More than two centuries ago, William Heberden, a physician, 
described a patient who had been nearly cured of his angina pectoris by sawing wood daily 
which later described as first effort angina (12). This phenomenon highlighted the 
importance of coronary collaterals flow as an adaptive response to overcome myocardial 
ischemia (13).  In 1911, Matas reported collateral-dependent limb blood flow in 145 human 
subjects by occluding major arteries with a tourniquet. The limb tissue below the arterial 
obstruction turned pale and colder; however, some patients were able to restore faint color 
and temperature even though the main artery remained occluded. The later observation was 
explained by the presence of efficient collateral circulation below the level of the occlusion 
(14). Later in 1946, Prinzmetal quantitatively demonstrated the existence of collateral vessels 
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in post-mortem hearts by perfusing them with radioactive erythrocytes and glass beads. This 
study reported the existence of collaterals with a diameter of 70-180 m (15). 
Functional benefits of collaterals have been demonstrated in many recent studies with 
acute myocardial infarction patients (Figure 1.2). The size of infarction following acute 
myocardial infarction was significantly affected by the presence or absence of well 
developed, angiographically documented collateral vessels in human patients.  Beneficial 
effect of collateral flow was independent of site of coronary occlusion. Furthermore, cardiac 
function at hospital discharge, as measured by left ventricular ejection fraction, was 
significantly higher in patients with well-developed collateral vessels (16). 
In a clinical study of 1164 cases of acute MI, Antoniucci et al. reported that the 
presence of well-developed collateral arteries increased the survival rate and decreased 
cardiac events after percutaneous coronary intervention, compared to patients with poorly 
developed collaterals (17).  Significant majority of patients with well –developed collaterals 
were nondiabetic but demonstrated greater incidence of chronic angina, multi vessel disease 
and total chronic occlusion compared to that of patients without collateral arteries (17).  
Another large scale study of 1697 patients with chronic total coronary artery 
occlusion (defined as >50% stenosis in ≥ 1 coronary artery) revealed the importance of the 
collateral circulation in preserving cardiac function despite the presence of coronary artery 
disease. Interestingly, previous myocardial infarction was not reported in 60% of this patient 
population, even though all patients had chronic total coronary artery occlusion. In addition, 
more than 50% of the patients had normal left ventricular function. Together, these 
observations indicate the existence of an efficient collateral circulation in many patients, 
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which serves as an alternative source of blood supply to the myocardium, preventing 
myocardial death (18).  
In addition, survival of patients following percutaneous coronary intervention was 
significantly improved by the presence of coronary collaterals, indicating that coronary 
collaterals not only reduce myocardial death but also improve myocardial recovery following 
revascularization therapy. Wang et al reported survival rates in patients with acute 
myocardial infarction undergoing percutaneous coronary intervention within 12 hours of 
onset, grouped according to the presence of Angiographically evident collateral filling of the 
left anterior descending artery (LAD) (collateral group, n=78) and or absence of collateral 
filling of the LAD (no collateral group, n=111). During the one-year follow up study, the 
collateral group had significantly higher survival rates compared to no collateral group. 
However, there were no differences in the occurrence of reinfarction and stent thrombosis 
between the two groups (19).  
Upstream occlusion is a key requirement for functional collateral development. In 
healthy human hearts, collaterals exist but these small, high-resistance vessels carry little 
flow compared to the more pronounced collateral arteries of patients with atherosclerosis 
(20;21). Severe stenosis has been recognized as a potent stimulator of collateral growth in 
humans (22). Moreover, the degree of occlusion proportionally influences the extent of 
collateral formation. As shown in dogs, only occlusions that develop a significant pressure 
gradient across the collateral pathway are capable of inducing outward remodeling. This 
knowledge has been applied to the development of experimental laboratory animal models to 
study externally induced arteriogenesis, including the arteriovenous fistula(23), surgical 
ligation (24-29), ameroid occlusion (29;30), and repetitive occlusion models (31;32). 
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Similar to the observations in the coronary collateral circulation, peripheral collaterals 
also remodel in response to arterial occlusion (33-35). Peripheral arterial stenosis animal 
models reported similar finding that a significant degree of stenosis is a prerequisite for 
collateral remodeling (36). However, some studies report functional collateral circulation in 
patients without coronary artery occlusion. Among 100 patients with angiographically 
normal coronary arteries (no stenosis), 25% had functional collateral flow to the level that 
there were no signs of MI during a brief experimental coronary occlusion period (37). 
Diversity of arteriogenic responses among different animal species and strains 
Understanding the diversity in collateral development in response to ischemia across 
species, as well as across strains within a particular species, has led to an appreciation of the 
role of genetic factors in arteriogenesis (38;39). Collateral dependent blood flow 
measurements in different species following acute coronary ligation revealed that 
considerable differences in the number of collateral conduits exist across species.  For 
instance, the pig heart is sparse in collaterals to the extent that acute coronary ligation is 
generally lethal and results in widespread infarcted regions (40;41). In contrast, the dog heart 
has abundant epicardial collateral anastomoses, and acute coronary ligation results in a 
relatively smaller infarct size (42). Maxwell et al reported a quantitative comparison of 
coronary collateral circulation in acute myocardial ischemia across eight species as assessed 
by radioactive microspheres. Comparison of microsphere accumulation in ischemic tissue 
normalized to non-ischemic tissue showed that the size of the infarct region was directly 
proportional to the degree of collateral flow. Guinea pigs showed the highest collateral flow 
(which was as high as flow to non-ischemic tissue), followed by dogs and cats. The species 
with low collateral flow (in descending order) were rat, ferret, baboon, rabbit, and pig (43). 
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Other studies are consistent with the finding that subendocardial collateral flow is well-
developed in dogs (44), whereas pigs have poor subepicardial and subendocardial collateral 
flow (45). 
 Interestingly, different mouse strains show diversity in collateral flow capacity and 
the extent of collateral remodeling (39;46;47).  The collateral flow response to acute femoral 
artery ligation clearly differs (in order from greatest to least) between C57BL/6, 129S2/Sv, 
and BALB/c. The number of preexisting collaterals is also high in the C57BL/6 strain, which 
demonstrates complete flow recovery following femoral artery occlusion. Consequently, 
ischemic insult is minimal in C57BL/6(8). The opposite is seen in BALB/c, where the lowest 
number of collaterals, worst recovery, and highest ischemic damage is observed. Similar 
strain differences in the extent of collateral flow increase in response to femoral artery 
occlusion have been seen in rats (48). Although strain differences in arteriogenic capacity are 
not completely understood, they have been attributed to genetic differences in VEGF-A (38) 
and endothelial nitric oxide synthase (eNOS) expression (49) across strains. 
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Figure 1.1: Cumulative survival of 264 patients following acute myocardial infarction, 
grouped according to the presence of coronary collaterals supplying the infarct area. Solid 
line represents patients with angiographically evident collaterals. Dashed line represents 
patients without collaterals (50).    
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Key changes at the cellular level during arteriogenesis 
Structural reorganization of peripheral collaterals begins two to three days after an 
upstream occlusion (10). Several lines of evidence demonstrate that collateral enlargement is 
an active process involving cellular proliferation, rather than a passive vasodilation. Soon 
after upstream occlusion, endothelial cells (ECs) lining collateral vessels acquire an activated 
phenotype characterized by swollen and longitudinal bulges, as opposed to the flat inner 
surface of unchallenged collaterals (51;52).  
 Schaper et al observed DNA synthesis with thymidine labeling in coronary collateral 
arterioles of dogs subjected to progressive stenosis of the left circumflex coronary artery 
(53). The mitosis signal was more pronounced in narrow parts of the vessels and was seen in 
endothelial, medial and adventitial cells, with peak mitotic activity at 3 weeks post occlusion. 
Similar results were reported with BrdU/ TUNEL assay (53). Electron and confocal 
microscopy revealed both proliferating cells and apoptotic cells in narrow regions of the 
vessels, resulting in neointimal formation with luminal expansion. In rabbit hindlimb, a 
distinguishable neointimal layer was evident after 2 weeks, although the extracellular matrix 
was still actively rearranged. Smooth muscle cells of the secretory phenotype were observed 
in the neointima (54). Monocyte infiltration is another key early event, occurring during the 
first 1-2 weeks post-occlusion, and abnormalities in monocyte recruitment inhibit 
arteriogenesis (55). The role of monocytes in arteriogenesis will be discussed in detail later. 
  Vascular smooth muscle cells (SMC) undergo the most drastic changes during 
angiogenesis. In normal coronary arteries, SMC in the media are arranged in a circular and 
very regular structure. This is no longer the case in the growing artery, where the basement 
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membrane disappears. The number of SMC decreases in the media, mainly because of 
migration of SMC to the sub-endothelial layer.  SMC with a contractile phenotype, 
characterized by abundant -smooth muscle actin and scarcity of cellular organelles, switch 
to a secretory phenotype characterized by prominent rough endoplasmic reticulum, Golgi 
apparatus, and mitochondria, while contractile components are reduced (54). Furthermore, 
desmin, a principal intermediate filament protein, disappears in the secretory phenotype (56). 
SMC proliferation is mainly responsible for the outwardly remodeling pattern of collateral 
growth. The thickening of the vessel wall varies across species: approximately 3- fold in 
mice, 10-fold in rabbits, and 20-fold in dogs (57). As collateral growth reaches completion, 
SMC regain the contractile phenotype and are once again arranged in a typical pattern (58). 
Interestingly, SMC proliferation and wall thickening in pathological atherosclerosis results in 
inward remodeling that decreases the luminal diameter (59;60), in contrast to arteriogenesis, 
where outward remodeling of the vessel leads to elevated blood flow (61) to areas where the 
primary route has become obstructed. However, the underlying cause for this bidirectional 
response of blood vessel wall thickening is not clear. It is also important to note that 
arteriogenesis is a controlled process and self-limited in which collateral remodeling extends 
to partially restore blood flow sufficient to avoid tissue damage preserving vital tissues from 
ischemia (62;63). The development process cease and collaterals disappears following 
intervention of occlusion (64).  
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Figure 1.2: A coronary angiograph from a 42-year-old male with a completely occluded 
right coronary artery (65). As a physiological compensatory mechanism, Rentrop grade III 
collateral (large arrowheads) has developed from the non-occluded left anterior descending 
artery (LAD).  Restoration of blood flow through the collateral pathway prevented the 
blocked right coronary from seriously compromising the functional capacity of the heart, as 
reflected by a left ventricular ejection fraction of 60%. LCX, left circumflex coronary artery. 
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Angiogenesis 
 Angiogenesis (proliferation of new blood vessels or capillary formation) is another 
important form of vascular growth by which both embryonic and adult vasculature acts to 
maintain oxygen homeostasis and tissue integrity. Sprouting angiogenesis is initiated by 
vascular leakage and a coordinated loosening of the extracellular matrix (ECM) by EC in 
response to a proangiogenic stimulus such vascular endothelial growth factor (VEGF-A), an 
endothelial cell mitogen. ECs proliferate and migrate toward gradients of VEGF-A, first 
forming immature vessels. These immature vessels eventually form lumens, mature, and 
adapt to the tissue-specific environment (66). As a physiological process, angiogenesis 
establishes a functional circulatory system during embryogenesis. Although it plays a vital 
role both in development and in maintenance of the vasculature, deregulation of angiogenesis 
is associated with many of the leading causes of mortality and morbidity in the modern world 
(67). Therefore, both angiogenic stimulation in ischemic cardiovascular disease and 
angiogenic inhibition in cancer are equally important areas for clinical research. 
 As previously mentioned, arteriogenesis is the outward growth of a mature collateral 
arteriole in response to stenosis or occlusion of a major conductance artery, and is driven by 
hemodynamic factors such as an increase in stretch and/or fluid shear stress on ECs. The 
process has the capacity to restore the blood supply to an extent that adverse ischemic 
damages are minimal. Angiogenesis is new capillary formation as oppose to remodeling of 
preexisting anastomoses and is triggered by different stimuli, with different functional 
consequences (68). 
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 Angiogenesis is mainly triggered by hypoxia, which occurs in many pathological 
conditions such as cancer, stroke and ischemic vascular disease. Defective oxygenation of 
cells leads to activation and increased stability of the transcription factor hypoxia-inducible 
factor (HIF) one and two (69). HIF is a heterodimeric protein with a constitutively expressed 
and stable beta subunit and a hypoxia-induced alpha subunit (70).  Even though cells 
constitutively synthesize the alpha subunit, it degrades rapidly by ubiquitination mediated 
protein degradation under normoxia. Lack of oxygen leads to block alpha subunit being 
ubiquitination there by increased stability of alpha subunit. This results HIF to form its 
transcriptionally active heterodimer to enhance the expression of hypoxia inducible genes 
associated with vascular growth (71). Therefore, HIF functions as a master regulator of 
oxygen homeostasis and its expression leads to an increase of the transcription of numerous 
“hypoxia-sensitive” genes including VEGF-A, VEGFR2, erythropoietin, and nitric oxide 
synthase (72;73).  
A nitric oxide-mediated local increase in vascular diameter is one of the first 
phenomena of ischemia-stimulated angiogenesis which transiently facilitates increased blood 
supply to the tissue (66). Secondly, VEGF-A mediates hyperpermeability of the vessel wall. 
An increase in leakage of plasma proteins is observed, which helps forms a scaffold for EC 
migration after local degradation of the basement membrane of the mother vessel. Elevated 
permeability is achieved mainly via re-organization of adherens junctions proteins such as 
vascular endothelial (VE)-cadherin proteins of adjacent ECs, which form the principal 
permeability barrier throughout the majority of the vasculature. Src kinase signaling also 
appears to be important in VEGF-A dependent increased permeability, via inhibition of 
specific phosphatases (74). This is likely leads to increased tyrosine phosphorylation of VE-
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cadherin, p120 and β-catenin. Phosphorylation-driven conformational changes alter protein-
protein affinities, destabilizing the binding between members of the adherens junction and 
widening the gap between adjacent endothelial cells, promoting enhanced filtration of fluids 
and macromolecules (plasminogen, fibrinogen) from plasma to the interstitial space. It is 
hypothesized that these changes in permeability allow plasma components that promote the 
angiogenic cascade access to the interstitial matrix, where they stimulate the endothelial cell 
proliferative and migratory phenotype.   
Under normal physiological conditions, capillary ECs are quiescent during their 
extended life span. However, angiogenic mitogens promote a switch to the EC proliferative 
phenotype by triggering the switch from the G0 to G1 stage of the cell cycle via signaling 
through the MAPK (ERK1/2, JNK1/2) axis (75). The initial decision of an EC to acquire a 
proliferative phenotype is associated with changes in the genetic and biochemical profile of 
EC which generally are considered to represent activated EC. EC activation refers to both 
functional and morphological alteration in ECs in response to inflammatory cytokines or 
hemodynamic forces.  
Activated ECs enhance the expression and secretion of membrane type 1-matrix 
metalloproteinase (MMP), and plasminogen activators which facilitate the cleavage of 
adhesion proteins and matrix proteins, enabling EC to release contact with the BM (76).This 
change helps EC become exposed to interstitial collagen,  which triggers signaling cascades 
in EC that are responsible for reorganization of  the EC cytoskeleton to form filopodia and/or 
lamellipodia extensions to invade the interstitial matrix. A VEGF-A gradient drives the 
formation of a pioneering tip cell, which demonstrates directional chemotactic movement. 
The tip cell membrane is rich with VEGFR1, VEGFR2 (77) and delta-like ligand 4 (dll4) 
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(78). VEGF-A also induces mitosis of trailing stalk cells located proximally to the tip, 
forming a new vessel sprout. Excessive sprouting is limited by a mechanism by which dll4 
on the tip membrane binds to its receptor, Notch, on adjacent stalk cells, promoting 
controlled development of new capillaries (79). 
 Recruitment of pericytes by EC plays a major role in regulating vascular maturation 
during angiogenesis, as pericytes act as a “turn off” switch for the proteolytic phenotype of 
the tip cell (80). Downregulation of tip cell MMP activity, termination of the EC proliferative 
phenotype, reestablishment of adherens junctions, recruitment of SMC, and generation of a 
BM mark the maturation process of the new vessels. Lumen formation occurs, mainly by 
fusion of intracellular vesicles with the plasma membrane. Vessels then stabilize to fulfill the 
tissue requirements by EC differentiation. 
Arteriogenesis versus angiogenesis 
In the postnatal organism, 2 types of vessel growth exist: angiogenesis, which 
involves the proliferation of capillaries mainly through effects on endothelial cells (EC), and 
arteriogenesis, defined as the development of collateral arteries from preexisting arteriolar 
connections, requiring the proliferation of both EC and smooth muscle cells (SMC). 
Angiogenesis and arteriogenesis are driven by two distinct initial triggers. During normal 
growth and development and in pathological tumor growth, capillary vascular network 
formation is initiated by hypoxia. It is a logical correlation, according to homeostasis 
principles, that O2 stress in tissue should stimulate new capillary formation to restore 
normoxia. Cells respond to decreased O2 tension by upregulating several hypoxia-inducible 
factors and other angiogenic molecules including the VEGF family. VEGF-A is a strong EC 
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mitogen which also increases EC permeability. Orchestration between pro-angiogenic factors 
(VEGF-A, FGF2, PDGF, TGF1, ANGPT1) and inhibitory factors (ddl4, Notch, jagged1) 
that provide negative feedback to prevent pathological angiogenesis is vital for orderly 
vascular growth. 
In contrast, arteriogenesis or remodeling of the collateral circulation can be induced 
independently from hypoxia (6;81). Ito et al. developed a rabbit hind limb femoral artery 
ligation model which allows simultaneous examination of both collateral vessel growth and 
capillary formation (6). In this model, the proximal region (thigh) in which the appearance of 
corkscrew collateral arteries occurs is normoxic, unlike the distal region (calf) where blood 
flow is reduced below the level of tissue demands resulting in hypoxia and capillary 
formation. These authors showed that collateral enlargement was associated with 
histochemical evidence for EC and SMC proliferation and resulted a 6-fold increase in 
collateral conductance, compared to non-ligated control. In contrast, a profound perfusion 
deficiency was observed in the calf region, with no signs of collateral vessel growth but 
extensive capillary sprouting. The reduced perfusion rates in the calf region clearly predict 
the hypoxia, while the several fold higher perfusion rates in thigh region are less likely to 
cause hypoxia.  Therefore, this femoral artery occlusion model clearly demonstrated that 
arteriogenesis and angiogenesis are different in terms of their requirement to trigger by 
hypoxia. 
 Hindlimb ischemia models have been widely used in studying collateral development 
and have been validated extensively. In a separate study, time scale analysis of the mRNA 
expression profile of the rabbit femoral artery ligation induced arteriogenesis model clearly 
demonstrated that collateral artery growth is not associated with an increased expression of 
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VEGF-A (82). Direct measurements of mRNA and protein in growing collateral arteries and 
in skeletal muscle types which show consistent collateral supply failed to demonstrate an 
associated increase in VEGF-A, HIF and LDH-A, showing that molecular signature of 
collateral growth does not show characteristics of hypoxia in contrast to angiogenesis.  
In another study, the femoral artery ligation model was used to assess the relative 
efficiency of collateral development across different mouse strains. Electron paramagnetic 
resonance oximetry, a technique which allows measuring regional pO2, demonstrated in 
C57BL/6 mice that collateralization happened in well-oxygenated tissue. The authors 
concluded that local ischemia is not essential for collateral growth (47). The available 
evidence from femoral artery ligation models supports the idea that hypoxia alone is not 
likely to trigger arteriogenesis. However, in tissues where both types of vascular remodeling 
happen in an adjacent tissue environment, such as in the ischemic myocardium, where spatial 
separation of hypoxic territory and the area of collateral formation is limited, ischemia may 
have an influence on arteriogenesis. Thus, studies to assess the potential effect of hypoxia on 
collateral growth are best done using models other than hindlimb ischemia. 
 Physical forces such as altered shear stress through collateral vessels are considered 
to be the primary stimulus for arteriogenesis (6;10;83-85). When a supply artery is occluded, 
the blood flow is diverted through these preexisting collaterals, which have little or no flow 
under normal conditions. Occlusion in the major artery results in a large pressure difference 
along the collaterals, driving the flow through the collaterals, which originally possess 
narrow luminal diameters, about 30-100 m. Since the blood flow resistance is inversely 
proportional to the fourth power of the vessel diameter, the elevated flow and low vessel 
diameter exerts high fluid shear stress on the collateral wall, activating the endothelium. 
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 The altered physical shear forces on EC cause a marked increase in the expression of 
many genes, including monocyte chemoattractant protein-1 (MCP-1) (86) and endothelial 
surface receptors and adhesion molecules such as selectins, ICAM-1, and VCAM-1 (10) 
which are involved in monocyte tethering, rolling and migration to the adventitial space (53). 
Monocyte adherence and subsequent transformation into macrophages is a pivotal 
event in the growth of collaterals, since monocytes produce various cytokine mediators, 
growth factors and proteases involved in arteriogenesis (10;24;53). Monocyte adherence to 
the growing collaterals was observed at day 3 post-occlusion using electron microscopy and 
immunohistochemistry in the rabbit hindlimb ischemia model and was associated with 
maximum cell proliferation in growing collaterals (24). The role of monocytes in the growth 
of collateral arteries after acute ligation of the femoral artery has been studied in both rabbits 
and mice. Heil and his group (87) reported that an increased circulating concentration of 
blood monocytes stimulates arteriogenesis, whereas collateral growth is diminished with 
reduced monocyte counts. The latter negative phenotype was reversed by injection of 
purified monocytes, demonstrating the concentration-dependent effect of monocytes on 
collateral growth. 
 Furthermore, monocytes accumulated in the area of collateral remodeling showed 
strong positive expression of bFGF and TNF alpha. The importance of TNF alpha in 
collateral formation was further supported by elevated collateral density and peripheral 
conductance in response to externally administered LPS, which is a well-known inducer of 
TNF alpha expression. Monocytes express chemokine receptor 2, which binds to MCP-1 on 
activated EC and initiates a cascade of events by producing a repertoire of cytokines 
including TNF alpha and b-FGF. TNF alpha further augments the monocyte response by 
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upregulating the expression of adhesion molecules on both ECs and monocytes and 
upregulation of granulocyte macrophage colony stimulating factor (GM-CSF). B-FGF is a 
mitogen for both ECs (88) and SMCs (89) and has been shown to potentiate the effect of 
VEGF (90). 
In animal models of peripheral vascular disease, tissue ischemia does not appear to be 
an important controller of arteriogenesis, as the tissue in which the remodeling artery resides 
is not hypoxic. Furthermore, arteriogenesis is not associated with hypoxia-induced gene 
expression pattern or an ischemic metabolic profile. Rather, arteriogenesis is predominantly 
stimulated as a response to local hemodynamic changes. Thus, angiogenesis and 
arteriogenesis are governed by two different signaling pathways (91). In addition to their 
varying dependence on hypoxia, other key differences in signaling have been documented 
between these two processes. For instance, blockage of the nitric oxide synthase pathway has 
a profound inhibitory effect on exercise-induced collateral growth in femoral artery ligated 
rats, but does not prevent exercise-induced capillary proliferation (92). 
Placenta growth factor 
In 1991, Maglione et al isolated and named the placenta growth factor (PLGF) from a 
human placental cDNA library (93). Human PLGF was predicted as a 149 amino-acid-long 
protein displaying 53% sequence identity to the platelet-derived growth factor (PDGF)-like 
domain of VEGF-A. Subsequent gene mapping studies by the same author showed that it is 
located in human chromosome 14q24 (94). It is an N-glycosylated, secretory protein and a 
heterodimer in vivo.  
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PLGF is abundantly expressed in the placenta (95), with the primary site of synthesis 
in trophoblasts (96) which are the cells producing the outer layer of the blastocyst. Although 
it was first isolated from placenta, PLGF is expressed in other tissue types such as vascular 
EC and smooth muscle cells (97), heart, skeletal muscle (98), retina (99) and tumor cells 
(100). 
Isoforms of PLGF  
Pioneer studies revealed that, by alternative splicing of mRNA, the PLGF gene 
produces two different protein isoforms: PLGF131 (PLGF-1) and PLGF152 (PLGF-2). The 
latter carboxyl terminal has a 21 amino acid long insertion enriched with basic amino acids 
(101). The smaller isoform, PLGF-1, has a 20 amino acid signal sequence that is cleaved to 
yield mature PLGF131. PLGF isoforms exist as homodimeric proteins showing different 
binding ability to heparin. PLGF-2 strongly binds to heparin, mainly due to its positively 
charged 21 amino acid insertion, whereas PLGF-1 lacks this insertion and does not bind to 
heparin (102). Mouse genome analysis revealed that there is a single PLGF gene in mice, 
which encodes for a 150 amino-acid protein which has 65% sequence similarity to human 
PLGF-2 (103). 
Subsequent studies discovered two more isoforms of PLGF produced by alternative 
splicing of PLGF mRNA in humans, PLGF-3 (104) and PLGF-4 (105). PLGF-3 was also 
isolated from a human cDNA library prepared from term placenta tissue and consists of 221 
amino acids. Similar to PLGF-1, PLGF-3 does not have 21-amino-acid insertion at the 
carboxyl terminal and therefore is unable to bind to heparin. Mammalian cells transiently 
expressing PLGF-3 secreted the polypeptide as both monomers and homodimers (104). The 
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fourth isomer, PLGF-4, was isolated from human trophoblasts and human umbilical cord 
vein EC, and the sequence was highly similar to PLGF-3 with the addition of the heparin 
binding domain (105). 
Structure of PLGF 
X–ray crystallography of PLGF demonstrated two α-helices and seven β-sheets with a 
cysteine knot (106) structural motif in which two disulfide bridges on β3 and β7 form a loop 
through which a third disulfide bond between two cystenes on β1 and β4 passes (107). Two 
additional disulfide bridges between Cys-59 and Cys-68 hold two PLGF monomers in an 
anti-parallel manner to form a PLGF homodimer (108). 
 The receptor binding specificity of PLGF for VEGF receptors has been tested for 
fms-like tyrosine kinase (Flt-1; VEGFR1) (109) and kinase domain region (KDR; VEGFR2) 
or the murine homologue of VEGFR2, fetal liver kinase-1 (Flk-1) (102;110;111).  These 
tyrosine kinase receptors consist of a signal sequence, a transmembrane domain, an 
extracellular domain with seven immunoglobulin-like domains, and a consensus tyrosine 
kinase sequence. Competitive binding assays using chimeric receptor-IgGs and radiolabeled 
growth factors showed that 
125
I-VEGF-A binding to Flt-1 was greatly reduced by PLGF, 
whereas no competition by PLGF was observed for KDR binding of 
125
I-VEGF-A (102). 
Therefore, PLGF binds to the Flt-1 receptor, but not to the KDR receptor. In contrast, VEGF-
A binds to both Flt and KDR (109;112). X-ray crystallography studies revealed that both 
PLGF and VEGF-A bind to the second of the seven immunoglobulin-like domains of Flt-1 
(108). Flt-1 is essential for early embryonic vascular organization, with gene knockout 
causing death in utero at mid-somite stages (113). Abnormal vascular channel formation is 
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observed in the absence of Flt-1. Endothelial differentiation appeared to be normal, however. 
Flt-1 is expressed in many adult cells including EC (109), vascular SMC (114;115) and 
monocytes (116). 
 Site directed mutagenesis of PLGF revealed that mutations at Asp-72 and Glu-73, 
located in the 3-4 loop, make PLGF unable to bind to the flt-1 receptor and activate 
downstream signaling. Thus, these residues are essential for Flt-1 binding (117). Flt-1 
activation by PLGF homodimers requires receptor dimerization followed by trans-
autophosphorylation of specific tyrosine residues on each Flt-1 cytoplasmic domain (118). 
As shown for other receptor tyrosine kinase receptors, the receptor transactivation is then 
able to transduce the signal to the cell interior by recruiting signaling molecules with 
phosphotyrosine binding domains (119). 
PLGF functions 
 PLGF isoforms have little or no mitogenic activity on EC (100;102;111;120;121). 
Ligand binding to ECs demonstrated that PLGF binds to ECs through Flt-1 with high affinity 
and an uncharacterized low affinity binding was also detected (102). However, in this study 
PLGF binding to bovine adrenal cortex-derived capillary endothelial (ACCE) cells failed to 
induce tyrosine phosphorylation. PLGF failed to induce a mitogenic response in either 
cultured ACCE cells or human umbilical vein endothelial cells (HUVEC).  
 PLGF potentiates the effects of VEGF in vitro and in vivo. Interestingly, when ACCE 
or HUVE cells are co-treated with both VEGF (very low amounts) and PLGF, the mitogenic 
response to the combined growth factor treatment is about 50% higher than to VEGF-A 
treatment alone. Furthermore, this potentiation effect of PLGF is specific to VEGF, but not to 
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other growth factors such as bFGF (102;122). In agreement to the previous observation, the 
VEGF-dependent increase in vascular permeability was potentiated by PLGF in a dose-
dependent manner in vivo. Altogether, these observations indicate that PLGF potentiates the 
biological activity of VEGF (102). 
  Naturally occurring PLGF/VEGF heterodimers have been reported in various human 
tumor cell lines (100;118;121). Heterodimers formed in vitro have increased mitogenic 
activity on EC, a higher degree of VEGFR2 binding and tyrosine phosphorylation, and 
greater promotion of EC chemotaxis, compared to PLGF homodimers. These observations 
support the idea that PLGF may modulate VEGF induced angiogenesis by forming 
PLGF/VEGF heterodimers in cells co-expressing both factors. 
 The femoral artery ligation method has been widely employed to study various 
aspects of arteriogenesis. PLGF treatment after femoral artery ligation in mice stimulates the 
growth and expansion of preexisting collateral arteries and also the precapillary arterioles, as 
a structural adaptation to reduce flow resistance (123). Furthermore, PLGF-boosted collateral 
expansion not only improves hind limb perfusion more than threefold, but also exercises 
tolerance as measured by a swim endurance exercise test. VEGF treatment under the same 
conditions fails to produce the same degree of beneficial structural adaptation and functional 
improvement in the ischemic hind limb (123). 
 PLGF knockout is not lethal in mice and PLGF knockout mice demonstrate normal 
embryonic vascular development (122). In contrast, VEGF is essential for embryonic 
development and loss of even a single allele of VEGF results embryonic lethality (124;125). 
However, PLGF knockout mice exhibit an impaired arteriogenic capacity compared to the 
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wild type in the presence of ischemia, wound healing and cancer, confirming the 
physiological role of PLGF as a mediator of adaptive collateral formation (122). 
Interestingly, this phenotype was reversed significantly by the transplantation of wild type 
bone marrow, demonstrating the importance of bone-marrow derived cells in PLGF-induced 
arteriogenesis (126). 
Although the arteriogenic capacity of PLGF has been established in vitro and in vivo, 
little is known about the mechanisms by which the expression of PLGF is regulated. Since 
PLGF is arteriogenic, shear stress, a key initiator of arteriogenesis, would be a logical 
potential regulator of PLGF expression in vasculature. Indeed, in vitro co-culture studies with 
human coronary artery endothelial cells and human coronary artery vascular smooth muscle 
cells revealed that PLGF mRNA expression is increased in smooth muscle cells by high 
shear stress (physiologically relevant to 60% stenosis) and that PLGF protein levels are also 
increased (Rashdan and Lloyd, submitted) in agreement with this observation. PLGF has 
been shown to be upregulated by mechanical stimulation (127). When bronchial epithelial 
cells are exposed to cyclic stretch, increased levels of PLGF and NO are observed. The 
amount of PLGF produced is directly proportional to the magnitude of the cyclic stretch as 
well as the time length of exposure, (127) indicating that regulation of PLGF is sensitive to 
mechanical stress.   
 Furthermore, human patients with coronary artery disease and chronic total coronary 
occlusion showed higher levels of circulating PLGF in blood samples drawn from the distal 
coronary bed (which is fed by collaterals) (128). Importantly, the release of PLGF appeared 
to be related to increased shear stress, but not to the duration of the occlusion (with which the 
level of bFGF was shown to be correlated).  
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 Studies focusing on hypoxia as an inducer of PLGF expression have  produced 
conflicting results, in that some studies reported hypoxia did not stimulate PLGF expression 
(120) while others did find some evidence of hypoxia mediated upregulation of PLGF 
(99;129). Hypoxia in human choriocarcinoma cells did not alter PLGF mRNA levels, in 
contrast to VEGF, which showed a marked increase in both mRNA and protein (120). 
However, PLGF mRNA levels were about twice the background normoxic control, which 
may indicate a hypoxia induced PLGF mRNA stabilizing effect. However, when neonatal 
mice were exposed to hyperoxia for five days and then transferred to room air (which results 
in ischemic retina), PLGF mRNA was increased in retina. However, in this study VEGF and 
its isoforms were down regulated during hyperoxia (99). This study model represents retinal 
obliteration in immature cornea induced by means of hyperoxia, which may have a different 
pathological influence on PLGF expression as opposed to hypoxia generated as a 
consequence of vascular obstruction. In another report, cardiomyocyte PLGF expression was 
elevated by hypoxia in vitro and human allografts from myocardial ischemia patients. PLGF 
upregulated allografts were positively correlated with reduced ischemic damage suggesting a 
cardio protective effect of PLGF (130). Studies from our laboratory also found PLGF 
elevation by hypoxia in human coronary artery endothelial cells (131). Therefore, majority of 
evidence support hypoxia as a possible inducer for PLGF expression. 
 Unlike VEGF, which has been extensively studied, very little is known about 
signaling pathways by which PLGF exerts its biological function. Comparison of PLGF 
mediated signaling pathways in term trophoblasts and HUVEC showed differential 
downstream kinase activation (132) with common upstream mediators (133). In trophoblasts, 
Flt-1 activation of PLGF induced stress activated kinase, JNK and p38 with little induction of 
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ERK 1/2 signal transduction pathways. In contrast, in HUVEC PLGF induced strong ERK 
1/2 signaling with little activation of JNK and p38 pathways. In addition, Gab2, a member of 
the IRS (insulin receptor substrate)/Gab family of adaptor proteins) and tyrosine phosphatase 
SHP-2 (Src homology 2 - domain containing tyrosine phosphatase) was uniquely upregulated 
in HUVEC. However, Nck and PLC  activation was common in both types of cells. This 
suggested common signaling mediators in upstream signaling mechanism with divergent 
stimulation of various MAPK downstream, possibly influencing differential responses 
according to the cell type (133). 
PLGF as a potential therapeutic agent 
 PLGF administration as a proangiogenic factor may provide a suitable strategy for 
treatment of ischemic injury secondary to vascular obstruction. PLGF gene transfer into 
mouse ear skin induced the formation of large, stable tortuous vessels via arteriogenesis 
(123). PLGF treatment also induces SMC proliferation as indicated by the increased 
thickness of the collateral branches (123). Furthermore, transgenic mice expressing mouse 
PLGF under a constitutively active keratin 14 promoter in skin have a hypervascularized 
phenotype with enlarged and tortuous vessels compared to background control mice (134). 
(134). 
 Despite the extensive knowledge of the physiological and pathological role of VEGF, 
attempts at therapeutic VEGF-A gene transfer in many occasions resulted in inconsistent and 
ineffective preclinical and clinical outcomes. Undesirable side effects such as an 
unorganized, leaky vascular phenotype and hemangioma formation have also been reported 
(123;135-137). For instance, administration of recombinant VEGF protein to induce 
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arteriogenesis in pig myocardium caused severe hypotension resulting in the death of 50% of 
the treated animals (138). In phase 2 human clinical trials employing a VEGF gene therapy 
approach for ischemic vascular disease have been unsuccessful (139;140). Percutaneous 
intramyocardial transfer of a plasmid encoding VEGF-A in patients with severe coronary 
artery disease was unable to produce a significant improvement in perfusion deficits (139). In 
a separate study, intramuscular delivery of an adenoviral vector encoding VEGF-A to the 
lower extremities of patients with peripheral artery disease failed to promote recovery from 
debilitating limb performance associated with disabling intermittent claudication (140). This 
inconsistent and unsatisfactory outcome of VEGF therapy for ischemic diseases suggests that 
further research is required on other potential growth factors to promote arteriogenesis to 
circumvent ischemia. 
 As previously mentioned, monocytes play a vital role in arteriogenesis and monocyte 
infiltration at sites of collateral expansion is a prelude to arteriogenesis. An important finding 
that suggested PLGF as a key mediator in arteriogenesis is its chemoattractant behavior 
towards monocytes (116;123;126;141;142). Interestingly, monocytes express only one type 
of VEGFR1, with which PLGF specifically interacts (116). This finding marks the first 
biological role reported for the VEGFR1 receptor in human monocyte recruitment and 
activation via PLGF. Moreover, PLGF promoted the production of the arteriogenic cytokines 
TNF and monocyte chemoattractant protein (MCP-1) by recruiting monocytes/ 
macrophages (123). Inhibitors of MAPK/MEK and phosphoinositide-3 kinase, but not p38 
kinase, abrogate the effects of PLGF on monocytes suggesting potential downstream signal 
pathways (143). 
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 In vivo evidence also supports the importance of PLGF dependent monocyte 
attraction. The decreased arteriogenic response to femoral artery ligation in PLGF-/- mice 
was rescued by administration of human PLGF, and this recovery was shown to be 
associated with PLGF-induced elevated monocyte population at sites of collateral growth. 
Monocyte depletion by pharmacological methods prior to femoral artery ligation in rabbits 
completely abolished the PLGF dependent collateral expansion. Similarly, PLGF-/- mice 
with hampered arteriogenic ability recovered arteriogenesis upon infusion of exogenous 
PLGF, but exogenous PLGF failed to rescue arteriogenesis under conditions of depleted 
circulating monocyte levels (144). This was further supported by impaired arteriogenesis in 
response to femoral artery occlusion in monocyte/macrophage deficient mice (145). 
Consistent with the previous studies, these mice showed significant monocytophenia and 
demonstrated reduced blood flow perfusion seven days after femoral artery ligation, 
compared to control mice with normal circulating monocyte levels. Furthermore, monocyte 
deficiency related impairment of arteriogenesis was angiographically evident, with narrow 
collaterals and a diminished macrophage population as detected by immunohistology. 
Effect of diabetes on arteriogenesis 
Over 360 million adults are living with diabetes worldwide, and this number is 
projected to rise to over 550 million by 2030. Diabetes caused 4.6 million deaths in 2011, 
and cardiovascular complications are mainly responsible for the high morbidity and mortality 
of diabetes. In fact, more than 50% of diabetics die of cardiovascular complications of 
diabetes, and diabetes is an independent risk factor for cardiovascular disease. In addition, 
related disorders such as peripheral artery disease (PAD) and cerebrovascular disease are also 
complicated by diabetes (146;147). 
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 Diabetes mellitus is one of the major risk factors for atherosclerosis mainly through 
promoting endothelial dysfunction (148) which in turn precedes the development of ischemic 
disease. For instance, diabetes patients without previous myocardial infarction (MI) are at 6 
fold higher risk of MI than are non-diabetics without history of MI (149).  Diabetes is also 
known to complicate the prognosis of coronary and peripheral artery disease, and the patients 
have a less favorable outcome after coronary stenting (150;151) or leg bypass surgery (152), 
and a higher incidence of restenosis (153).  
Diabetes mellitus has been recognized as a negative predictor of collateral formation 
(154-158). Arteriogenesis, a natural adaptive response by outward remodeling of pre-existing 
collateral arteries when the primary pathway of blood supply is blocked, restores the blood 
flow to downstream tissue protecting it from ischemic damage. However, patients with 
coronary and peripheral artery disease demonstrate huge variability in the extent of collateral 
development. The observed variability in formation of functional coronary collateral vessels 
among patients with coronary artery disease reflects the fact that co-occurrence of additional 
disorders may have a role in suppressing the innate vascular response to arterial occlusion. A 
comparative angiographic assessment of the degree of coronary collateralization between 
diabetic patients with coronary artery disease and nondiabetic patients with comparable other 
baseline characteristics revealed a reduced extent of coronary collateral formation in the 
diabetic condition (154). 
The limited ability to develop an effective coronary collateral network in response to 
occlusion in a primary supply artery may contribute to the observed high mortality of 
diabetes-associated coronary artery disease. A direct comparison of the relative effects of 
type 1 and type 2 diabetes on neovascularization following femoral artery ligation revealed 
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that type 2 diabetes more severely reduced collateral dependent blood flow, compared to type 
1 diabetes (159). Therefore, impairments in arteriogenesis associated with type 1 diabetes 
appear to be less severe than those produced by type 2 diabetes.  
 Numerous studies have demonstrated a negative effect of diabetes on arteriogenesis. 
The mechanism by which diabetes inhibits arteriogenesis is largely unknown, however. As 
previously explained, monocyte migration is a key event in arteriogenesis, and several 
studies have attempted to evaluate the effect of diabetes on monocyte migration (160). When 
alloxan-induced diabetic New Zealand White rabbits were subjected to femoral artery 
ligation, they developed a reduced number of collateral vessels, with narrow luminal 
diameter. The vessels delivered less blood compared to collaterals of non-diabetic rabbits. 
Furthermore, when monocytes were collected from these two groups and tested for VEGF-A 
and MCP-1 mediated chemotaxis, the monocyte population from the diabetic rabbits showed 
significantly less migration compared to monocytes from control subjects. Reduced 
migratory response of monocytes from diabetic rabbits was also shown to be specific, as only 
VEGF-A and MCP-1 mediated migration was abrogated. When monocytes were stimulated 
with FormylMetLeuPhe (fMLP) peptide, a known chemoattractant for monocytes, no 
difference was observed between groups for migration.  
 Several other studies, including work on monocytes from diabetic human patients, 
demonstrated the same reduced chemotactic response of diabetic monocytes, indicating one 
negative aspect of diabetes that may explain, at least partly, the compromised arteriogenic 
phenotype in the diabetes disease environment (161). As current knowledge supports the 
notion that monocyte recruitment to growing collaterals is PLGF dependent, it is possible 
that diabetes negatively influences PLGF-dependent monocyte recruitment to sites of 
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arteriogenesis. Although the level of VEGF (162;163), and bFGF (164) has been shown to be  
suppressed and elevated respectively in diabetic cardiac tissue, no studies have evaluated the 
effect of diabetes on baseline expression of PLGF, which is a potent mediator of 
arteriogenesis. Therefore, more studies are needed to characterize the effect of diabetes on 
PLGF expression. This is one of the primary goals of this study. 
 Sudden elevation of blood flow through collateral vessels with narrow lumens causes 
a significant mechanical force on the endothelial lining of these vessels. As discussed above, 
shear stress sensed by the endothelium has been identified as a key initiating stimulus for 
arteriogenesis. Furthermore, endothelial dysfunction is related to the pathology of vascular 
diseases associated with diabetes (165;166). Therefore, impaired shear stress sensing by the 
endothelium may suggest a parallel mechanism of suppressed arteriogenesis in diabetes 
patients. In an experimental porcine model of  left iliac artery ligation, when the right iliac 
artery was infused with glucose to mimic acute hyperglycemia, normal shear stress induced 
vessel dilation was inhibited while acetylcholine mediated vasodilation was preserved (165). 
In contrast, normoglycemic control vessels responded to both shear stress and acetylcholine 
dependent vasodilatation. The authors concluded that hyperglycemia impaired the 
endothelium dependent mechanotransduction of shear stress. 
 Endothelial dysfunction is a complex process, where loss of the optimal balance 
between the production and degradation of mediators of normal function is altered. One such 
pathological imbalance is oxidative stress, in which the normal balance of reactive oxygen 
species (ROS) generation and their neutralization is destroyed. Several studies have 
demonstrated a link between oxidative stress and impaired arteriogenesis (167-169). Indeed, 
these studies demonstrated the redox window concept, which states that optimal ROS 
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concentrations are critical for normal vascular function (169-171). For instance, repetitive 
ischemia (RI) in rat left anterior descending artery stimulated arteriogenesis as measured by 
collateral dependent blood flow (169). However, this phenotype was reversed by 
pharmacological inhibition of either NADPH oxidase, which activates the production of 
superoxide (O2
2-
) radical or specific inhibition of superoxide dismutase, which converts O2
2-
into H2O2.  H2O2 is further metabolized into molecular O2 and water by catalase (167). In 
vitro, VEGF driven human coronary artery EC and SMC proliferation (169) was highly 
sensitive to either increased or decreased ROS. This indicates that optimal ROS levels are 
critical for collateral growth, and that they have a physiological role in cell signaling (172).  
 RI induced arteriogenesis was shown to occur via a mechanism involving p38 kinase, 
as pharmacological inhibition of this signaling enzyme abrogated the arteriogenic response 
(167). In addition, p38 kinase was shown to be activated during normal EC proliferation, and 
this activation of p38 kinase is redox sensitive both in vitro and in vivo (167). Moreover, 
further studies added more candidates to this signaling mechanism, including Akt and Src, 
whose activity was sensitive to the cellular balance of ROS (169). Overall, both antioxidant 
treatment and pathological oxidative stress interfere with the physiological role of ROS in 
arteriogenesis, where the latter condition more resembles the diabetes/metabolic syndrome 
related suppression of collateral formation. 
 Research from our laboratory has demonstrated the signaling role of H2O2 as a 
mediator of intercellular communication between EC and SMC. Shear stress arising from 
increased blood flow through collaterals stimulates EC and triggers the production of various 
soluble mediators that act on underlying SMC. We hypothesize that SMC produce PLGF in 
response to mediators from shear-stimulated EC via H2O2 dependent cell signaling. When 
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EC-conditioned culture medium was added to SMC, there was a ~4.5 fold upregulation of 
PLGF gene expression compared to SMCs that were not exposed to EC-conditioned medium 
(173). This upregulation was determined to be due to increased H2O2 in the EC medium. 
Further studies in our lab demonstrated that externally added, physiologically relevant levels 
of H2O2 increase PLGF gene and protein expression as well as the mRNA half-life (174) of 
PLGF. Therefore EC produced H2O2 acts as a soluble mediator for arteriogenesis. This 
evidence suggests that proper regulation of ROS is vital to normal physiological 
arteriogenesis, and that disruption of the ROS balance can potentially cause impairments in 
arteriogenesis, as seen in diabetes. 
The use of mouse models in diabetes research 
 Diabetes is characterized by absolute lack of insulin production (type 1) or insulin 
resistance and the inability of beta cells to compensate (type 2).  Type 1 and type 2 diabetes 
represent diverse endocrine disorders that affect different bodily systems differently. In 
animal models of type 1 diabetes, lack of insulin production is achieved mainly by chemical 
disruption of the beta cells, leading to hyperglycemia. In contrast, type 2 diabetic animal 
models are mainly generated by naturally occurring genetic variations or genetic 
manipulation, leading to obesity associated insulin resistance.  When selecting an animal 
model to study CVD complications associated with diabetes, it is important to consider the 
aspect of the disease being investigated. For instance, if the primary focus of the study to 
evaluate the effect of hyperglycemia on CVD, a type 1 diabetic model is suitable.  If insulin 
resistance is the central aspect of the study, a type 2 diabetic model is appropriate (175). 
Mouse models of type 1 diabetes 
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Streptozotocin model:  Streptozotocin is administered i.p. or i.v. and accumulates in 
pancreatic beta cells through Glut-2 transporter uptake. Streptozotocin alkylates beta cell 
DNA, which in turn leads to NAD+ depletion (176;177). Subsequent reduction of beta cell 
ATP results in inhibition of insulin production. There are two major dose regimens: a single 
high dose (200 mg/kg) or multiple low doses (50 mg/kg daily for 5 days). One disadvantage 
of the single high dose regimen is that possible regeneration of beta cells can occur, which 
raises the need of appropriate controls for the experiment. Another unfavorable feature of this 
model is that non-targeted toxicity of streptozotocin to other organs can occur. This 
drawback can be partially overcome by using the multiple low-dose regimen (178). 
Depending on the duration and severity of diabetes, these mice are reported to develop 
systolic and diastolic dysfunction when associated with dyslipidemia (179).  Increased fatty 
acid oxidation, reduced glucose oxidation and reduced pyruvate dehydrogenase activity has 
been observed in cardiac tissue of these mice (180). 
Alloxan model: Alloxan is administered at a rate of 40-200 mg/kg, depending on the strain 
and route of administration. Alloxan is rapidly taken up by beta cells. Similar to 
streptozotocin, alloxan preferentially accumulates in pancreatic beta cells through GLUT 2 
glucose transporter uptake. Alloxan is a free radical generator causing DNA fragmentation. 
Alloxan also oxidizes essential thiol groups in proteins, and disturbs intracellular calcium 
homeostasis. The reduced form of alloxan (dialuric acid) is then autoxidized to superoxide, 
hydrogen peroxide and hydroxyl radicals. These hydroxyl radicals induce beta cell death, 
since these cells have a low redox neutralization capacity (181).  Selecting the proper alloxan 
dose is highly important, since it has a narrow diabetogenic dose range, and even slight 
overdosing can cause kidney toxicity.    
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Non-obese diabetic mice:  The spontaneous development of autoimmune disease that 
disrupts pancreatic beta cell insulin production is the mechanism for development of type 1 
diabetes in this rodent model (175). The non-obese diabetic (NOD) mouse is the most 
commonly used autoimmune model for type I diabetes. NOD mice develop insulitis at the 
age of one month, which causes partial beta cell disruption leading to pre-diabetes (182). The 
onset of overt diabetes occurs at around 3-4 months, when 90% of the pancreatic insulin 
production is affected. There is a high gender bias for development of diabetes in NOD mice, 
with diabetes more prevalent in females (60-90%) than males (10-30%). An important 
feature of the disease progression is that NOD mice tend to lose weight and require insulin 
treatment. Furthermore, MHC class 2 in NOD mice and human share high structural 
similarity. Therefore, NOD mice are useful in studying mechanisms of type 1 diabetes (183). 
AKITA mice: AKITA mice were originally derived in Akita, Japan from a spontaneous 
mutation of the insulin 2 gene in the C57BL/6NSIc mouse (184). The mutation causes 
abnormal processing of pro-insulin, which causes accumulation of misfolded protein in the 
ER, leading to ER stress. The onset of insulin-dependent diabetes begins at one month of age 
and is associated with dyslipidemia (185). Homozygotes fail to survive more than three 
months if untreated. This model, combined with LDL receptor deficiency, has been used to 
study type 1 diabetes related macrovascular disease (186) and nephropathy (187). 
Mouse models of type 2 diabetes 
Lep
ob/ob
 mice: The Lep
ob/ob
 genetic model in the C57BL/6 background is characterized by a 
monogenic mutation that leads to leptin deficiency (188). Lack of leptin causes hyperphagia-
related severe obesity.  Significant weight gain is observed early as 2 weeks, and the mice 
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develop hyperglycemia by one month of age.  Dyslipidemia, physical inactivity and 
infertility are characteristic features of this model (189). Insulin release is maintained without 
complete beta cell failure, and animals usually die at around 14 months of age. Lep
ob/ob
 mice 
develop cardiac hypertrophy with subtle impairment of systolic function. It is accepted that 
Lep
ob/ob
 mice recapitulate the metabolic phenotype and cardiac remodeling of obese humans 
with insulin resistance (190). However, the direct contribution of leptin deficiency in CVD 
has not been characterized yet. 
Lepr
db/db 
mice: The Lepr
db/db
 genetic model in the C57BLKS/J background carries an 
autosomal recessive mutation in the leptin receptor (191). Similar to Lep
ob/ob
 mice, excessive 
eating, obesity, hyperinsulinemia and hyperglycemia are observable in these mice starting at 
a very early age.  Lepr
db/db
 mice develop ketosis after a few months of age and have a 
relatively short life span. High levels of serum fatty acids and triglycerides are also observed 
(192). Cardiac hypotrophy and contractile dysfunction is more intense in Lepr
db/db 
mice than 
in Lep
ob/ob
 mice (193). Furthermore, increased fatty acid oxidation and lipid storage 
combined with reduced glucose uptake and oxidation is evident in these mice (194), similar 
to Lep
ob/ob
 mice. Similar to Lep
ob/ob
 mice, the effect of abnormal leptin receptor function on 
the CVD phenotype is incompletely understood.  Interestingly, the gene transcription profile 
of Lepr
db/db 
mice subjected to hindlimb ischemia revealed a different transcript signature, 
compared to the wild-type background strain (195).  
Diet-induced altered glucose homeostasis: The first study reporting the use of high fat fed 
C57BL/6 mice as a model for diabetes was published in 1988 (196). This model allows 
researchers to circumvent the potential effects of altered leptin signaling.  Characteristic 
features of this diet-induced model include obesity, hyperinsulinemia, dyslipidemia and 
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altered glucose homeostasis, in the absence of genetic manipulation. However, 
hyperglycemia and insulin resistance is not as severe in this model as has been observed in 
Lep
ob/ob
 or Lepr
db/db 
mice. Since the major inductive force is caloric excess rather than genetic 
manipulation, the diet-induced model is considered to mimic of the typical path of human 
diabetes progression.  However, in order to observe irreversible metabolic dysfunction and 
impaired cardiac function, the high fat/high sucrose diet consumption needs to be maintained 
for over 20 weeks (197;198). Thus, studies of diet-induced diabetes are lengthy.  Many 
different mouse strains have been used to study diet-induced alterations in glucose 
homeostasis. Care should be taken when selecting the mouse strain, since differential 
susceptibility to diet-induced disease across mouse strains has been reported (199;200). High 
fat and/or high sucrose feeding is often combined with genetic models to generate additive or 
gradient metabolic effects (201).  Prolonged feeding of a high fat diet recapitulates the early 
phases of diabetic cardiomyopathy, in which reduction in contractility, cardiomyocyte 
hypertrophy, cardiac fibrosis, increased fatty acid consumption, reduced glucose oxidation 
and vasoconstriction all occur (202). In summary, high fat/ high sucrose feeding enables the 
researcher to model impaired glucose homeostasis and cardiovascular abnormalities in mice 
without the precipitative effects of genetic manipulation.  Another major advantage of this 
model is that the availability of a wide range of customized diets allows for tailoring of the 
study to recapitulate the metabolic stage of interest. 
Effect of diabetes on PLGF 
Detailed characterization of the effect of diabetes on PLGF is yet to be described.  
However, limited reports in the published literature suggest that diabetes does have effects on 
PLGF. PLGF expression is upregulated during wound healing in epidermal cells, 
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keratinocytes and hyperplastic epidermis where new blood vessels grow (203), and the PLGF 
knockout mouse shows delayed wound healing (122). Similarly, streptozotocin induced 
diabetic mice demonstrate that the normal PLGF upregulation is abolished in diabetic 
wounds, contributing to delayed wound healing (204). Overexpression of PLGF by gene 
transfer rescued wound healing in diabetic animals. This therapeutic effect of PLGF gene 
transfer was associated with enhanced granulation tissue formation, vascularization and 
recruitment of monocytes/macrophages. 
Acute hindlimb ischemia studies between healthy animals and experimentally 
induced diabetic animals revealed differences in PLGF expression. In healthy mice, temporal 
analysis of global gene expression profiles in acute hindlimb ischemia using the microarray 
technique revealed that PLGF mRNA increases ~3.5 fold at day 1 and ~1.75 fold at day three 
post ligation in the skeletal muscle surrounding growing collaterals (205). In a different 
study, vascular repair of acutely ligated hindlimb was impaired in the Lepr
db/db
 type 2
 
diabetic 
mouse, and microarray analysis of gene expression revealed differences in vasculogenic 
molecules. Importantly, PLGF mRNA expression was down regulated at day 14 in these 
diabetic mice, compared to wild type control (206). 
PLGF levels in proliferative diabetic retinopathy were reported to vary in the opposite 
direction of diabetic skeletal muscle and wound tissue. Vitreous fluid PLGF protein levels 
were higher in diabetic patients compared to non-diabetic individuals (207). Similarly, 
elevated PLGF was observed in akita diabetic mice and the PLGF knock out akita diabetic 
mouse did not show adverse signs of diabetic retinopathy such as diabetes induced retinal 
cell death, capillary degeneration. The mechanism of protective effect of PLGF -/- mice was 
associated with inhibition of HIF1 alpha – VEGF signaling (208). 
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In conclusion, it is well established that PLGF plays an important role in 
arteriogenesis and that arteriogenesis is inhibited in type II diabetes. Therefore, we 
hypothesized that regulation of PLGF expression is dysfunctional in type II diabetes and 
contributes to reduced arteriogenic capacity. To test this hypothesis, we assessed PLGF 
expression in cardiac, skeletal muscle, and vascular tissue of mice fed a Western-type diet to 
induce a metabolic phenotype similar to that of humans with type II diabetes determined 
whether PLGF was correlated with key metabolic variables. We further assessed the effect of 
a Western-type diet on the response of PLGF to hindlimb ischemia induced by gradual 
femoral artery occlusion. Lastly, we conducted in vitro studies to characterize cell-specific 
responses of PLGF expression to key metabolic variables. 
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CHAPTER II 
 
 
PLACENTA GROWTH FACTOR EXPRESSION IN MOUSE HEART AND 
PORCINE CORONARY ARTERIES CORRELATES WITH LONG TERM DIET 
INDUCED HYPERLIPIDEMIA AND OXIDATIVE STRESS 
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Abstract 
Arteriogenesis (collateral artery remodeling) is a survival adaptation of the 
vasculature in response to occlusion, minimizing ischemia. Stimulation of arteriogenesis 
would be highly beneficial in diabetics, who are especially prone to develop ischemic 
cardiovascular disease. However, arteriogenesis is suppressed in diabetes by an undefined 
mechanism. Placenta growth factor (PLGF) is a key arteriogenic factor whose expression 
is elevated during myocardial ischemia. Furthermore, PLGF expression is sensitive to 
oxidative stress in vitro, and oxidative stress occurs in diabetes associated hyperglycemia 
and hyperlipidemia. Thus, we hypothesized that decreased PLGF levels might contribute 
to impaired arteriogenesis in diabetes. To test this hypothesis, we studied PLGF 
expression in cardiac tissue of C57BL/6J and ApoE-/- mice fed either a control diet or a 
Western-type diet high in fat, sucrose, and cholesterol for 6 mo (N=6-14/group). Male 
and female mice were studied separately to identify possible gender differences. Mouse 
phenotype was characterized by measuring plasma cholesterol, triglycerides, insulin, 
isoprostane (a biomarker of oxidative stress), and by performing intraperitoneal glucose 
tolerance testing. Cardiac PLGF protein expression was significantly decreased by ~ 40-
50% in all Western diet fed groups, regardless of gender (p< 0.005). This decrease was 
specific to PLGF, as the related factor VEGF-A and VEGFR1 (the PLGF receptor) were 
not affected by diet. To study the mechanism for decreased PLGF expression, we 
performed regression analysis of PLGF protein levels vs metabolic parameters. Total 
cholesterol, triglycerides and isoprostane were well correlated (r
2
>0.75, p<0.001) with 
reduced PLGF protein, while PLGF was poorly correlated with glucose, insulin, and the 
HOMA-IR index. These results provide strong support for our hypothesis that PLGF 
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expression is inhibited by hyperlipidemia and oxidative stress. In order to begin to 
characterize the cellular basis for the overall effects observed in cardiac tissue, we treated 
human coronary artery endothelial cells (HCAEC) with oxidized LDL (Ox-LDL, 50-200 
g/ml), advanced glycation end products (AGE, 300-1000 mg), and H2O2 (0.05-0.3 mM), 
since these factors increase during hyperlipidemia, hyperglycemia, or oxidative stress. 
Interestingly, hyperglycemia-related AGE, but not Ox-LDL or H2O2, significantly 
decreased PLGF protein levels by ~50%   in HCAEC (p<0.05). Further experiments are 
underway to test the effect of these treatments on PLGF expression in cardiomyocytes.  
 
Introduction 
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity 
and mortality in patients with type II diabetes (1-5). Diabetes is an independent risk 
factor for coronary and peripheral artery disease and worsens patient prognosis (6;7). For 
instance, diabetics without previous myocardial infarction (MI) have a risk of infarction 
similar to that of nondiabetics with prior history of MI (8). Metabolic disorders such as 
hyperlipidemia, metabolic syndrome and obesity commonly co-occur with type II 
diabetes, and make the risk of CVD even higher (9). Current treatment strategies (e.g. 
coronary artery bypass grafting, stenting) for CVD are invasive. Diabetes also reduces the 
efficacy of coronary artery bypass grafting and percutaneous revascularization and 
increases the chance of restenosis (10-14). There is, therefore, a critical need for 
alternative treatment regimens for diabetics with ischemic CVD. 
An important physiological mechanism that can protect tissue from ischemia due 
to upstream vascular stenosis is the enlargement of pre-existing collateral arteries, or 
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arteriogenesis (15-19). Arteriogenesis is an adaptive process of structural alteration that 
serves as a bypass mechanism to improve O2 and nutrient supply to affected tissue, 
thereby decreasing the chance of damage due to ischemia. In their unchallenged state, 
collaterals in the heart (20) are elements of the microcirculation, ranging from 30-100 m 
in diameter. Nevertheless, they can remodel into arteries larger than 1 mm in diameter 
when stimulated (21). When an upstream artery is occluded, a pressure gradient across 
the collaterals (linked to an adjacent supply artery) develops. Blood flow is then diverted 
through collaterals, generating high shear stress on the endothelium. This increase in 
shear stress is considered to be one key trigger for arteriogenesis, although other factors 
such as hypoxia may also play a role (22).  
Arteriogenesis mainly depends on locally generated growth factors, vasoactive 
substances and hemodynamic stimuli (23). However, details on the key molecular 
players governing arteriogenesis and their regulation remain obscure, limiting 
therapeutic applications. 
Placenta growth factor (PLGF), a vascular endothelial growth factor (VEGF)-related 
protein, is a key mediator of arteriogenesis (24-26). Although much work has been done 
on VEGF-A, little is known about mechanisms regulating PLGF expression in cardiac 
and vascular tissue. Although PLGF and VEGF-A share more than 50% sequence 
identity, they also show functional diversity. PLGF binds solely to VEGFR1, whereas 
VEGF-A binds to both VEGFR1 and VEGFR2 (27). The physiological effects of PLGF 
and VEGF-A are likewise distinct. PLGF is strongly arteriogenic and is thought to act 
primarily on monocytes (26;28), whereas VEGF-A is more angiogenic and acts mainly 
on endothelial cells (29). PLGF-/- mice exhibit impaired arteriogenic capacity compared 
64 
 
to wild type mice in ischemia, wound healing and cancer, confirming the physiological 
role of PLGF as a mediator of collateral formation (24). Furthermore, administration of 
PLGF following experimental vascular ligation significantly improves the arteriogenic 
response in mice and rabbits (25;26). Clinically, increased expression of PLGF following 
acute myocardial infarction predicts improved patient outcome, as assessed by increased 
left ventricular ejection fraction (30). Hence, pharmacological modulation of PLGF 
expression or signaling offers a potential therapeutic strategy to compensate for 
atherosclerotic occlusion by promoting the development of an efficient collateral 
circulation (31).  
PLGF was first discovered in placenta, but is also expressed in skeletal muscle, 
heart, lung, thyroid, adipose tissue, tumors, and adult vasculature (24;32-34). In vessels, 
PLGF is expressed by both endothelial cells (EC) and smooth muscle cells (SMC). 
Previous studies from our lab showed that PLGF expression can be induced in SMC by 
H2O2, an important vascular signaling molecule produced by EC (25;35). PLGF 
expression is increased in collaterals following upstream ligation (36), suggesting that 
shear stress may be an important regulator of PLGF. Patients with ischemic CVD have 
significant variability in collateral formation, reflecting the fact that co-occurrence of 
additional disorders may suppress arteriogenesis. Importantly, diabetes and/or metabolic 
syndrome are negative predictors of collateral formation (37-43). Limited ability to 
develop an effective coronary collateral network in response to occlusion may contribute 
to the increased risk of MI in type 2 diabetics. The mechanism by which diabetes inhibits 
arteriogenesis is largely unknown. However, a direct comparison of the relative effects 
of type 1 and type 2 diabetes on peripheral collateralization in mice revealed that type 2 
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diabetes was more inhibitory than type 1 diabetes (44;45). Obesity and associated 
hyperlipidemia were also shown to be negatively associated with poor collateral growth 
(46). This finding suggests that factors associated with type II diabetes (hyperglycemia, 
hyperlipidemia, and hypercholesterolemia) may contribute to the suppression of 
arteriogenesis in type 2 diabetics. Indeed, mouse studies indicate that hyperlipidemia can 
significantly reduce collateral growth, and that the impairment is cholesterol dependent 
(44;47). During hyperlipidemia, low-density-lipoprotein (LDL) can be converted to 
oxidized LDL, which suppresses vascular remodeling by downregulating growth factor 
expression and increases the risk of atherogenesis by inducing inflammatory molecule 
production (48-50). Hyperglycemia can also negatively affect the collateral growth 
process, as shown by a reduction in arteriogenesis in an alloxan induced hyperglycemic 
diabetic rabbit (51). Persistent hyperglycemia leads to the generation of advanced 
glycation end products (AGE), which are formed by glycation of proteins in the presence 
of high glucose or aldehyde. Increased levels of AGE are considered to be a major 
contributor to impaired vascular growth in diabetic patients, as restoration of collateral 
growth was observed after inhibiting AGE formation (52). 
 Arteriogenesis is regulated by the interaction of growth factors generated locally 
in the ischemic myocardium in a temporal specific manner (53;54). Studies in chronic 
totally coronary occluded patients identified several growth factors that were elevated, 
including PLGF, basic fibroblast growth factor, macrophage chemoattractant protein-1, 
and transforming growth factor beta, and suggested that these factors could be induced 
by shear (55). Impaired growth factor signaling is considered to be one mechanism for 
poor collateral growth in diabetes and metabolic syndrome. However, the effect of these 
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conditions on PLGF regulation in the cardiovascular system has not been studied in 
detail. Therefore, the goal of this study was to identify metabolic parameters influencing 
PLGF expression in the cardiovascular system, and to identify the mechanism(s) by 
which type II diabetes-associated metabolic dysfunction modulates PLGF expression and 
signaling. 
We have previously shown that reactive oxygen species (ROS) stimulate PLGF 
expression at low, physiological levels (35;56). However, a hallmark of the diabetic 
vasculature is oxidative stress, in which the normal balance of ROS generation and 
neutralization is lost. Several studies have demonstrated a link between oxidative stress 
and impaired arteriogenesis (57-59). Indeed, these studies led to the “redox window” 
concept, which states that optimal ROS concentrations are critical for arteriogenesis 
(58;60;61). We therefore hypothesize that PLGF is subject to the same redox window, 
with low ROS concentrations enhancing PLGF expression and arteriogenesis, whereas 
chronic oxidative stress inhibits PLGF expression and arteriogenesis.  
Materials and Methods 
Animals: C57BL/6J and ApoE
-/-
 mice were either fed a Western-type diet or a control 
diet. The diet regimen was started when mice were 6-8 weeks of age and was continued 
for 24 weeks.  Male and female mice were studied separately. Therefore, we studied 8 
groups: C57BL/6J males fed the control diet (n=9), C57BL/6J females fed the control 
diet (n=8), C57BL/6J males fed the Western diet (n=14), C57BL/6J females fed the 
Western diet (n=8), ApoE
-/-
 males fed the control diet (n=6), ApoE
-/-
 females fed the 
control diet (n=6), ApoE
-/-
 males fed the Western diet (n=6), and ApoE
-/-
 females fed the 
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Western diet (n=6). All mice had access to food and water ad libitum and were housed in 
a temperature controlled facility with a 12 hour dark-light cycle. This study was 
approved by the Institutional Animal Care and Use Committee at Oklahoma State 
University. 
Diets: The Western diet (TD 88137, Harlan) supplied 42% kcal from anhydrous milk fat 
and cholesterol, 42.7% kcal from carbohydrate, and 15.2% kcal from protein. The 
control diet (TD120336) supplied 13% kcal from fat, 67.9% from carbohydrate, and 
19.2% from protein. The Western diet also has three times more sucrose by weight, 
compared to the control diet. The source of the relatively high carbohydrate content in 
the control diet is corn starch and maltodextrin, which are not readily available sources 
of sugar. Therefore, the Western diet used in this study is characterized by both high fat 
and high sucrose. 
Metabolic phenotyping of the experimental groups: Body weight of each mouse was 
recorded weekly. Fasting (6 h) blood samples were obtained from all mice at the end of 
24 week- diet regime for metabolic measurements. Glucose homeostasis was assessed by 
intraperitoneal glucose tolerance testing under fasting (6h) conditions in all mice just 
prior to sacrifice. 
Cholesterol and triglycerides: Total plasma cholesterol was determined using the 
Amplex Red cholesterol assay (Molecular Probes). Total plasma triglycerides were 
measured using a triglyceride determination kit (Sigma). 
Glucose and insulin: Intraperitoneal glucose tolerance testing (IPGTT) was performed 
on 6 h fasted, non-anesthetized mice by administering a 1g/kg ip D-glucose bolus (~30 
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mg/mouse in 300L of water). Venous blood (0.05 mL/mouse/time point; total, 0.25 
mL) was drawn from the facial vein for measurement of glucose and insulin at 0, 15, 30, 
60, and 120 min. Plasma glucose levels were measured using a portable glucose meter 
(Life Scan, Inc.). Insulin was measured using a rat/mouse insulin ELISA kit (EMD 
Millipore, Germany). 
Oxidative stress: Plasma 8-isoprostane was measured as a biomarker for oxidative stress 
using a competitive enzyme immunoassay (Cayman Chemical) according to the 
manufacturer’s protocol. 
Tissue isolation: After 24 weeks of the diet, mice were anesthetized with 5% isoflurane 
for ~5 min. After confirming a completely anesthetized state by applying mild pressure 
to the toes, the thoracic cavity was opened and the heart and aorta were excised. One 
third of the heart tissue (a longitudinal section, including both left atrium and the left 
ventricular region) was immediately immersed in liquid nitrogen and stored at -80C. 
Heart tissues were homogenized in 1 mL of lysis buffer containing protease inhibitors 
(phenylmethylsulfonyl fluoride, sodium orthovanadate, leupeptin, benzamidine 
hydrochloride, aprotinin, and pepstatin A). Three one-minute homogenizations were 
done using a Bio-Gen Pro200 homogenizer (PRO Scientific).  The homogenates were 
centrifuged at 700g for 5 minutes and the supernatants were transferred to clean 
microcentrifuge tubes and stored at -80C. 
Assessment of PLGF, VEGF, MCP-1 and VEGFR1 protein levels: PLGF, VEGF-A 
and VEGFR1 were quantified using ELISA (Mouse PLGF-2, VEGF-A, VEGFR-1 
Quantikine ELISAs, R&D Systems). All samples were assayed in duplicate. Data were 
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normalized to total protein concentration, as determined by BCA assay (Pierce). All 
assay plates were read using a Biotek Synergy HT plate reader. 
Real time PCR for gene expression analysis: Total RNA was isolated from the 
thoracic aorta and from cardiac tissue using RNeasy mini columns (Qiagen) following 
the manufacturer’s directions. Following removal of genomic DNA from 1 g of total 
RNA, reverse transcription was carried out using the QuantiTect reverse transcription kit 
(Qiagen). Real time PCR was performed on an ABI 7500 Fast instrument (Applied 
Biosystems) using PerfeCTa SYBR Green FastMix, Low ROX (Quanta Biosystems). 
The relative abundance of PLGF, VEGF, VEGFR1, NOX2, NOX4 and HO1 mRNA was 
determined using the comparative Ct method with target gene expression normalized 
to β-actin. Primer sequences are listed in table 1. 
Large animal model: Archived porcine coronary artery samples from three separate 
studies (one in Yucatan miniature swine and two in Ossabaw swine) were used in this 
project (Lloyd PG and Sturek M, unpublished). The original animal studies were 
conducted at the University of Missouri (Columbia, MO) and at Indiana University 
School of Medicine (Indianapolis, IN). Detailed descriptions of the study protocols and 
characterization of the animals’ metabolic phenotype has been previously reported 
(62;63). Pigs were divided into control (N=16 total) and high fat (N=20 total) groups. 
Pigs in the high fat groups were fed diets containing up to 78% kcal from fat for up to 55 
wk. Control pigs received standard minipig diets. PLGF gene expression was assessed in 
archived frozen samples of right coronary artery and left anterior descending coronary 
artery. Similar PLGF gene expression results were found in each study. Thus, the results 
were combined for further analysis.  
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RNA isolation and RT-PCR: Porcine artery samples were powdered with a metal pestle 
in liquid nitrogen. The frozen powder was then transferred to tubes containing Trizol 
reagent (Invitrogen, Carlsbad, CA). Total RNA was then isolated according to 
manufacturer’s protocol. RNA was treated with Turbo DNA Free (Ambion) to remove 
contaminating genomic DNA according to manufacturer’s instructions and reverse 
transcribed into cDNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). 
Real-time quantitative PCR was performed on an ABI 7500 (Applied Biosystems, Foster 
City, CA) instrument. PCR was performed using TaqMan Universal Master Mix 
(Applied Biosystems, Foster City, CA). PLGF mRNA was detected with TaqMan probe 
chemistry and was normalized to the signal of 18s rRNA. All primers were custom-
synthesized by Invitrogen (Carlsbad, CA). PCR reactions were run in triplicate for 40 
cycles. 
Cell culture: Cell culture experiments were performed by Farzana Rouf. Human 
coronary artery endothelial cells (HCAEC) were purchased from Lonza (Walkersville, 
MD). Cells were grown to 85% confluence in 12 well plates at 37ºC in a humidified 
incubator containing 5% CO2. HCAEC were maintained in endothelial cell basal medium 
(EBM) supplemented with EGM-2 MV SingleQuot growth factors (Lonza) and used at 
passage 6 for all experiments. Equal numbers of cells (~25000 cells/cm
2
) were seeded on 
each well of the 12 well plates. The medium of the cells were refreshed the day after the 
cells were subcultured.  
Advanced Glycation End Product (AGE) preparation: AGE was prepared through the 
glycation of bovine serum albumin (BSA) in the presence of D-(+) glucose or DL-
glyceraldehyde. To make glucose derived AGE, 50 mg/mL BSA (Sigma-Aldrich, St. 
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Louis, MO) was incubated in the presence of 45 mg/mL D-(+) glucose (Sigma-Aldrich) 
in phosphate buffered saline (PBS, pH 7.4). The solution temperature was maintained at 
37˚C for 8 weeks to fully glycate the albumin and to prepare irreversibly formed AGE. 
As a control, 50 mg/mL BSA was also incubated in PBS in the absence of D-(+) glucose 
for 8 weeks at 37˚C. Glyceraldehyde derived AGE was prepared by incubating 25 mg/mL 
BSA with 20 mM DL-glyceraldehyde (Sigma-Aldrich) in PBS at 37˚C for 1 week. After 
the incubation period, both the control and glucose- or glyceraldehyde-glycated samples 
were dialyzed in fresh PBS at 4˚C every 2 hours for a total of 4 changes. The 
glyceraldehyde derived AGE was centrifuged at 3,000 rpm for 30 min in Amicon 
concentrator tubes (Millipore, Billerica, MA) to concentrate the AGE solution. Total 
protein concentration in the control and AGE preparations was quantified using the BCA 
assay (Pierce, Rockford, IL).  BSA and AGE samples were determined to be endotoxin 
free by testing with the LAL chromogenic Endotoxin Quantitation Kit (Life Technologies 
Corporation, Grand Island, NY).  
Treatment of cells: HCAEC were serum starved in 2% serum media for 24 hours after 
reaching 85% confluence. Cells were then exposed to different treatment conditions for 
24 hours. To study the effects of different metabolic parameters (hyperlipidemia, 
hyperglycemia, oxidative stress) associated with diabetes, cells were treated with 
different concentrations of oxidized LDL (Ox-LDL, 50, 100, and 150 µg/mL), AGE 
(glucose or glyceraldehyde derived, 300, 500, 750, and 1000 µg/mL), and hydrogen 
peroxide (H2O2, 0.05, 0.1, and 0.3 mM). Treatments were directly added to the cell 
medium. Cell medium was collected 4, 8, and 24 hours post-treatment in fresh tubes 
containing protease inhibitors for quantification of PLGF protein. Ox-LDL was 
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purchased from Alfa Aesar (Ward Hill, MA), and H2O2 was purchased from vWR 
International (Houston, TX). 
ELISA: PLGF production by endothelial cells was quantified using a commercially 
available ELISA development kit (PLGF DuoSet, R&D Systems, McKinley Place, MN). 
Cell medium were added to microtiter plates coated with a PLGF capture antibody 
(prepared overnight) and PLGF present in the samples was quantified following 
manufacturer’s instructions. In brief, the microtiter plates were first blocked with BSA 
(1%, RT, 1 h). Samples and PLGF protein standards were then added (RT, 2 h) followed 
by detection antibody (RT, 2 h), streptavidin-HRP (RT, 20 min, in the dark), substrate 
solution (RT, 20 min, in the dark). The reaction was then stopped using stop solution 
(provided in the ELISA kit) and absorbance was measured using a BioTek Synergy HT 
Multi-mode Plate Reader (BioTek Instruments, Winooski, VT) at 450 nm wavelength. 
Total protein in the samples was measured using the BCA assay at 562 nm wavelength. 
Statistical analyses 
 Differences in mouse metabolic phenotype and mouse protein and mRNA 
expression were analyzed by 3-way ANOVA followed by post-hoc testing using SAS 
software. Values are mean ± SEM. * Diet effect by strain/gender; † strain effect by 
gender/diet; ‡ gender effect by strain/diet. The effects of different treatment conditions on 
endothelial cell PLGF and protein secretion were assessed using one-way ANOVA 
followed by Student-Newman-Keuls post hoc method for multiple comparisons. Primer 
of Biostatistics software (Version 4.02, McGraw Hill) was used for this purpose. In order 
to identify possible relationships between metabolic parameters and PLGF expression, 
linear regression and correlation analysis was performed. PLGF gene expression between 
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control and high fat fed pigs were analyzed by t-test using SigmaStat software. All 
differences were considered significant at p<0.05.  
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Table1.1 Primers used for gene expression analysis using real time PCR.  
Primer Sequence 5’ to 3’  
Pig PLGF forward GGAGACGGTCAATGTCACCAT 
Pig PLGF reverse GAGAATGTCAGCTCCACGTAGGA 
Probe for pig PLGF mRNA CAGCTCCTGAAGATCCGCTCTGGG 
Mouse PLGF forward  CTGCTGGGAACAACTCAAACAGA 
Mouse PLGF reverse GCGACCCCACACTTCGTT 
VEGF forward CCCTGGCTTTACTGCTGTACCT 
VEGF reverse CTTGATCACTTCATGGGACTTCTG 
VEGFR1 forward TGCGAAGCCACCGTCAA 
VEGFR1 reverse CTCGGCGGGCGTATTTG 
HO-1 Forward CAACATTGAGCTGTTTGAGGAGC 
HO-1 reverse ATCTTGCACCAGGCTAGCAG 
NOX2 forward CACACCGCCATCCACACAAT 
NOX2 reverse GTCACCGATGTCAGAGAGAGC 
NOX4 Forward TGCCCCAGTGTATCAGCATTAG 
NOX4 reverse CCGGAATCGTTCTGTCCAGTC 
β-actin forward AGTTCGCCATGGATGACGAT 
β-actin reverse TGCCGGAGCCGTTGTC 
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Results 
In order to induce diverse metabolic characteristics associated with diabetes and 
to determine their effects on PLGF and related proteins, C57BL/6J and ApoE
-/-
 mice 
were fed a Western diet for 6 months. C57BL/6J mice fed the Western diet showed 
profound hyperglycemia, hyperinsulinemia, a high HOMA-IR index, and obesity, 
consistent with published results (64-68), whereas the effects of the diet on these 
parameters were less pronounced in the ApoE
-/-
 strain. We observed significantly 
elevated fasting blood glucose in the C57BL/6J Western diet groups (both male and 
female) from as early as week 3-4 onwards. In contrast, the ApoE
-/-
 Western diet fed 
groups did not demonstrate any impairment in fasting blood glucose until week 13, after 
which it was inconsistently elevated (data not shown). Fasting glucose levels were 
elevated among all the Western diet fed groups (p<0.05) by week 23 (data not shown). 
Glucose clearance as measured by IPGTT (Figure 2.1) and presented as area under the 
curve (Figure 2.2) indicated that both male and female C57BL/6J mice fed the Western 
diet had impaired glucose tolerance (WD fed C57BL/6J males, 39959 ± 742 vs CD fed 
C57BL/6J males, 26852 ± 1126; WD fed C57BL/6J females, 44731 ± 2317 vs CD fed 
C57BL/6J females, 23003 ± 890, p<0.01). From all the Western diet fed groups 
C57BL/6J strain demonstrated highest glucose intolerance (p< 0.0001). In contrast, only 
male ApoE
-/-
 mice fed the Western diet had slightly but significantly elevated glucose 
intolerance (WD fed ApoE
-/-
 males, 29876 ± 1161 vs CD fed ApoE
-/-
 males, 23524 ± 
1344, P<0.01), whereas female WD fed ApoE
-/- 
mice were not glucose intolerant. 
Therefore, IPGTT results confirmed that feeding of the Western diet disrupted glucose 
homeostasis. However, significant differences were noted for both sex (in ApoE
-/-
) and  
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Figure 2.1: IPGTT in C57BL/6 mice (above) and ApoE-/- mice (below). *, p<0.05 for Western diet vs 
control diet group of same strain/gender at the same time point. 
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Figure 2.2: Area under the curve calculated from IPGTT in C57BL/6 mice and ApoE-/- 
mice fed with a control diet and a Western diet for six months. 
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Figure 2.4: Feeding of a Western diet increased plasma cholesterol in all the 
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Figure 2.6: Plasma 8-isoprostane was measured as a biomarker for oxidative stress. 
Western diet fed mice showed increased oxidative stress, compared to control diet 
fed groups 
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strain. C57BL/6J males, regardless of diet, had elevated plasma glucose compared to 
ApoE
-/-
 males on the same diet (data not shown, p<0.05).  
All Western diet fed groups (both strains and sexes) were hyperinsulinemic 
(Figure 2.3, p<0.0001), in agreement with other published data (65;69). A significant 
(p<0.0001) strain difference existed, with Western diet fed ApoE
-/-
 mice of both sexes 
showing less hyperinsulinemia than their C57BL/6J counterparts.  
Among all the Western diet fed groups, ApoE
-/-
 mice were significantly less obese 
than C57BL/6J mice, similar to other reports (65;70-72).  
Feeding of a Western diet increased plasma cholesterol (Figure 2.4) in all groups 
relative to their matched strain/sex group on the control diet (p<0.001). However, 
significant effects of both sex (p<0.001) and strain (p<0.0001) were observed. The 
Western diet increased cholesterol in both male (338.30 ± 10.92 mg/dL) and female 
C57BL/6J mice (260.09 ± 19.26 mg/dL) relative to control diet fed male (104.94 ± 8.43 
mg/dL) and female (77.61 ± 9.70 mg/dL) C57BL/6 mice, with a relatively greater effect 
in males. No sex differences were observed in the ApoE
-/-
 strain. Cholesterol levels were 
sharply increased (by up to 4-5 fold) in all ApoE
-/-
 groups regardless of diet and sex 
when compared to the corresponding C57BL/6J groups (p<0.0001; ApoE
-/-
 male control, 
604.13 ± 18.97 mg/dL; ApoE
-/-
 female control, 614.20 ± 9.27 mg/dL; ApoE
-/-
 male WD, 
1207.00 ± 16.70 mg/dL; ApoE
-/-
 female WD, 1242.73 ± 18.24 mg/dL). These findings 
are in agreement with those shown by others (65;72-74).  
Feeding of a Western diet elevated triglyceride levels in both male and female 
ApoE
-/-
 mice relative to control diet fed ApoE
-/-
 mice (p<0.001), but had no effect in 
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C57BL/6J mice of either sex (Figure 2.5). Female ApoE
-/-
 mice had higher triglyceride 
levels than male ApoE
-/-
 mice on either diet (p<0.01). There was a clear strain difference, 
with all ApoE
-/-
 groups showing significantly higher triglyceride levels than the 
corresponding C57BL/6J groups (p<0.05). 
These metabolic data demonstrate that the Western diet induced different 
metabolic phenotypes, which mainly varied according to mouse strain. C57BL/6J mice 
fed a Western diet (C57-WD) were hyperglycemic, hyperinsulinemic, and 
hypercholesterolemic, while ApoE
-/-
 mice fed the Western diet (ApoE-WD) were 
extremely hyperlipidemic and hyperinsulinemic. ApoE
-/-
 mice receiving the control diet 
(ApoE-CD) were moderately hyperlipidemic, whereas C57BL/6J mice fed the control 
diet (C57-CD) were considered to be normoglycemic and normolipidemic and represent 
the controls for this study. 
 In order to characterize the oxidative stress levels associated with each of these 
metabolic phenotypes, we measured plasma 8-isoprostane, which widely used as an 
indicator of oxidative stress. The Western diet significantly increased 8-isoprostane levels 
across both strains and sexes (Figure 2.6, p<0.001) as previously reported (75-78). There 
was a significant strain effect, with all ApoE
-/-
 mice demonstrating greater levels of 
oxidative stress than the corresponding C57BL/6J groups (p<0.05). A significant effect of 
sex on the response to the Western diet was seen in both strains. Interestingly, however, 
the effect varied in opposite directions by strain, with Western diet fed female C57BL/6J 
mice demonstrating lower 8-isoprostane levels than the corresponding male group, 
whereas Western diet fed female ApoE
-/-
 mice had greater levels of oxidative stress than 
did the matched male group (p<0.01). 
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After characterizing the metabolic phenotypes of the mouse groups, we analyzed 
PLGF protein expression to determine whether baseline (unstimulated) PLGF levels are 
affected by metabolic phenotype. The Western diet significantly decreased PLGF protein 
in cardiac tissue by ~40-50% in both C57BL/6J and ApoE
-/-
 mice (p<0.001), with no sex 
differences (Figure 2.7). There was a significant effect of strain to further decrease PLGF 
levels by ~40-50% in ApoE
-/-
 mice in both the control and Western diet fed groups, 
relative to the same C57BL/6J groups. Since the most striking differences between the 
two strains were the higher cholesterol, triglyceride, and oxidative stress levels in ApoE
-/-
 
mice compared to C57BL/6J, our data suggest that these factors may act to inhibit PLGF 
expression.  
In order to further investigate possible mechanisms behind the decreased PLGF 
levels in our mouse models of metabolic dysfunction, we performed Pearson correlation 
analysis of each individual animal’s PLGF protein level with its plasma cholesterol, 
isoprostane, triglyceride, glucose, insulin and HOMA-IR values. This analysis revealed 
that cardiac PLGF levels were strongly and inversely correlated with plasma cholesterol, 
isoprostane, and triglyceride levels (r
2
 = 0.88, 0.89, and 0.76, p<0.0001 respectively). 
However, plasma insulin, glucose and HOMA-IR were only weakly correlated with 
cardiac PLGF levels (r
2
 = 0.43, 0.39, and 0.45, p<0.001) respectively).  
In contrast to the marked effects of the Western diet on PLGF, expression of the 
related protein VEGF-A (Figure 2.8) and the PLGF receptor VEGFR1 (Figure 2.9) was 
not affected by diet. ApoE
-/-
 males fed the control diet expressed slightly less VEGF-A 
than the corresponding C57BL/6J males (p<0.05), while all ApoE-/- groups expressed 
less VEGFR1 than did the matched C57BL/6J groups (p<0.01). This latter finding is  
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interesting, since it suggests that PLGF signaling in the ApoE
-/-
 strain may be impaired at 
the level of the receptor as well as the ligand. The lack of effect of the Western diet on 
VEGF-A levels in cardiac tissue indicates that the effect of the diet on PLGF is specific. 
We next assessed PLGF expression in the aorta to determine whether a similar 
pattern of response to a Western diet occurs in this tissue as it does in cardiac tissue. 
Interestingly, however, the aorta demonstrated the opposite diet effect, with increased 
PLGF mRNA levels in both C57BL/6J and ApoE
-/-
 mice fed the Western diet (Figure 
2.10, p<0.05). Similarly, an opposite strain effect was observed in aorta relative to 
cardiac tissue, with ApoE
-/-
 mice having higher aortic PLGF levels than C57BL/6J mice 
(p<0.05). No effect of sex on aortic PLGF expression levels was observed. In addition to 
its beneficial role in arteriogenesis, PLGF is also known to play a pathological role in the 
development of atherosclerosis (79) (80) (81); thus, the increased expression of PLGF in 
aorta of mice fed a Western diet is a particularly interesting finding. 
Both VEGF-A and VEGFR1 mRNA levels were increased in aorta by the 
Western diet, although only in the ApoE
-/-
 strain (Figures 2.11 and 2.12; p<0.05 for both 
proteins). A strain difference also existed for VEGF-A expression in aorta, with ApoE-
WD having higher expression than C57-WD (p<0.05). Strain differences in VEGFR1 
levels were also seen for ApoE
-/-
 males vs C57BL/6J males (p<0.05). No gender 
differences were detected. 
Other studies in our lab have demonstrated that a signaling cascade involving 
Nox4 and heme oxygenase 1 contributes to regulation of PLGF (Rashdan and Lloyd, in 
preparation). In order to determine whether the effect of the Western diet on PLGF were 
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associated with alterations in the expression of these factors, we measured the relative 
abundance of Nox2, Nox4 and heme oxygenase 1 mRNA in cardiac tissue. No clear 
pattern of altered expression of these genes corresponding to our PLGF results could be 
identified (Figure 2.13). 
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Figure 2.10: Western diet fed groups had elevated PLGF gene expression in 
aorta. 
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PLGF expression in porcine models of hyperlipidemia 
 Coronary artery PLGF gene expression was reduced to a similar extent in 
all three studies by a high fat diet (to 47  17, 55  13, and 67  17% of the same-study 
control group). Thus, the data were combined for further analysis. Overall, PLGF gene 
expression in coronary arteries of high fat fed animals (N=20) was reduced to 52 ± 8% 
of the level in control animals (N=16) (Figure 2.14). Linear regression analysis was 
performed between PLGF mRNA levels and metabolic end points (plasma cholesterol, 
triglycerides, LDL and peak glucose value from glucose tolerance test). This analysis 
revealed that porcine coronary artery PLGF gene expression was strongly and inversely 
correlated to plasma cholesterol (r
2
=0.475, p<0.05) than any other parameter in 
consistent with mouse cardiac PLGF protein expression.  
The tissues examined in this study consist of multiple cell types (cardiac tissue: 
cardiac myocytes, endothelial cells, smooth muscle cells, and fibroblasts; aorta: 
endothelial cells and smooth muscle cells). It is unknown which of these cell types 
contributes to the alterations in PLGF expression which we observed in the mouse 
models of metabolic dysfunction. Our previous studies have shown that endothelial cells 
are a significant source of PLGF. Therefore, we next tested the effect of specific 
molecules associated with hyperglycemia, hypercholesterolemia, and oxidative stress 
(advanced glycation end products, AGE; oxidized LDL, Ox-LDL; and hydrogen 
peroxide, H2O2) on PLGF protein production by cultured HCAEC. Three different doses 
of each compound were tested across three exposure times (4, 8 and 24 h). Surprisingly, 
neither Ox-LDL nor H2O2 affected PLGF expression in HCAEC at the doses and times 
tested (Figure 14). However, AGE treatment produced a dose-dependent inhibition of 
97 
 
PLGF production in HCAEC at the 24 h time point (p<0.05). Further studies are 
underway to test the effects of these compounds on PLGF expression in other cell types. 
Discussion 
Diabetes is a negative predictor of arteriogenesis; however, the mechanism of 
inhibition is undefined. The central role of PLGF as a mediator of arteriogenesis led us to 
hypothesize that regulation of PLGF expression may be dysfunctional in type II diabetes. 
To test this hypothesis, we modeled type II diabetes-related metabolic abnormalities in 
two mouse strains fed either a control diet or a Western diet for six months. After 
characterizing the metabolic phenotypes, we assessed the level of PLGF in cardiac 
tissue. The related protein VEGF-A was also studied for comparison, along with 
VEGFR1. We found that a Western diet induces significant metabolic abnormalities and 
consistently decreases cardiac PLGF protein expression without affecting VEGF-A 
levels. Genetically-based metabolic dysfunction (in the ApoE
-/-
 mice fed the control diet) 
also reduced PLGF protein levels and this affect was additive to the effect of the diet. 
Further analysis showed that cardiac PLGF protein levels were strongly and negatively 
correlated with plasma cholesterol and triglyceride levels, and with markers of oxidative 
stress. Interestingly, PLGF inhibition in a cholesterol dependent manner was conserved 
in porcine coronary arteries suggesting hyperlipidemia a common route of PLGF 
inhibition in cardiovascular system. 
Diabetes associated oxidative stress is known to be the root cause for 
microvasculature and macrovascular defects of diabetes. Excess food intake along with 
sedentary life style results greater influx of glucose and fatty acids in to cellular catabolic 
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reactions. This leads to the generation of excess ROS, particularly through the 
mitochondrial electron-transport chain (82). ROS synthesis via AGE signaling also 
greatly contributes to excess oxidative stress in diabetes (83). In addition, hyperglycemia 
mediated elevation of circulatory inflammatory markers; TNF-, IL-6(84), are known to 
initiate sequence of additional mechanisms for ROS generation by liver (85).  
The redox window hypothesis of arteriogenesis states that an optimal 
physiological redox balance is critical for arteriogenesis, and that imbalance to either 
side inhibits arteriogenesis (86). Arteriogenesis involves redox sensitive signaling; Akt, 
Src in repetitive ischemia model and both overt oxidative stress and antioxidant 
treatments inhibit the signaling mediators resulting poor arteriogenesis (58). Diabetic 
hyperglycemia and consequential overt reactive oxidative species formation have been 
directly linked to growth factor abnormalities in microvascular complications including 
arteriogenesis.  This is in line with our finding that inhibition of PLGF, a key 
arteriogenic factor is highly correlated with ROS. 
Several studies have demonstrated that elevated cholesterol levels have an 
inhibitory effect on arteriogenesis (87;88). Hypercholesterolemic low-density lipoprotein 
receptor -/- and ApoB-48 -/- mice demonstrated down regulated FGF receptor 1, HIF1a, 
vascular cell adhesion molecule -1 along with reduced monocyte recruitment (89). 
Hyperlipidemia in high fat fed athymic rats also shown to reduce collateral remodeling 
via endothelial dysfunction and defective NO signaling (90) which is essential for 
successful arteriogenesis (91). Antioxidant treatment improved the reduced arteriogenesis 
in hypercholesterolemia.   
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 Another line of evidence demonstrated hypercholesterolemia mediated sparse 
arteriogenic response in hypercholesterolemic rabbit and ApoE-/- mice (47). This is in 
accordance with our finding that highest inhibition of PLGF occurred in ApoE-WD 
group along with high negative correlation of PLGF and plasma total cholesterol in our 
study. Altogether, previous findings that support reduced arteriogenesis by impaired 
ROS generation and hypercholesterolemia represent the major link to PLGF inhibition in 
our study. Therefore, our results, PLGF inhibition by Western diet provide a mechanistic 
basis for reduced arteriogenesis found in previous studies. 
Interestingly, the effect of the Western diet on PLGF expression in aorta trended 
in the opposite direction relative to cardiac tissue, with an increase in PLGF observed in 
aorta of Western diet fed mice. This may indicate tissue and/or cell-type specific 
responses to the diet. This finding is consistent with the previously reported pro-
atherogenic role of PLGF. PLGF has been shown to be elevated in atherosclerotic lesions 
of hypercholesterolemic mice and rabbits (79) similarly to what we observed in our mice 
models. Indeed, ApoE
-/-
 mice develop severe atherosclerosis in the thoracic aorta 
regardless of diet. Increased PLGF expression in the vascular wall may contribute to this 
effect. The mechanism for increased PLGF expression in aorta in response to a Western 
diet is an important area for future research, as is the basis for the apparently differing 
regulation of PLGF between cardiac and vascular tissue. It remains to be determined 
whether increased aortic PLGF reflects increased synthesis of PLGF by vascular cells, 
decreased PLGF degradation, or increased sequestration of PLGF in the vascular 
extracellular matrix. 
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Although our study is the first to examine the effect of Western-diet induced 
metabolic dysfunction on PLGF expression in cardiac tissue, other groups have reported 
decreased PLGF expression in other tissue types during diabetes. PLGF was shown to be 
decreased in wounds of diabetic mice relative to healthy mice, and this decrease was 
associated with impaired wound healing secondary to reduced neovascularization. When 
this PLGF deficit was overcome by PLGF adenoviral gene therapy, wound healing was 
improved (92).  In another study, reduced collateralization in respond to hindlimb 
ischemia in diabetic mice was overcome by exogenous PLGF infusion (93). Diabetes 
also shown to cause reduced PLGF expression in rat placenta (94). All these studies were 
performed in streptozotocin induced diabetes in mice which represents type 1 diabetes. 
Our finding that Western diet induced metabolic dysfunction reduces PLGF 
expression in cardiac tissue suggests that coronary collateral development would be 
diminished in these mice, compared to mice expressing normal levels of PLGF.  This 
observation is consistent with the reduced arteriogenic capacity seen in human type II 
diabetes patients. We hypothesize that the inhibition of coronary arteriogenesis in type II 
diabetes may be due to reduced PLGF expression in diabetic cardiac tissue, leading to 
greater vulnerability of diabetic patients to life threatening MI. PLGF has been shown to 
be elevated during MI, possibly as a compensatory mechanism to acute occlusion, and 
PLGF treatment prior to experimental MI resulted larger vessel size and reduced 
ischemic damage in mice (95;96). However, these studies were performed in young 
healthy animals, which do not accurately represent the clinical population, where most 
MI patients are elderly and many have co-occurring diabetes or metabolic syndrome. 
Therefore, our study design and outcomes are highly relevant to the human clinical 
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situation and provide important considerations for therapeutic developments aimed at 
preventing MI by enhancing collateral artery growth. 
Vascular related growth factor deficiency has been linked to reduced collateral 
growth and single growth factor supplementation has produced mixed results in clinical 
diabetes (Reviewed in (97)). Therefore, knowledge on the expression and the regulation 
of key arteriogenic growth factors in diabetic back ground has a high demand. To our 
knowledge, the effect of type II diabetes-associated metabolic abnormalities on 
cardiovascular PLGF levels has not previously been reported. Our findings from multiple 
animal species suggests that PLGF may be one of several key growth factors that are 
abnormally expressed in diabetes, making PLGF and/or its downstream signaling 
pathways potential therapeutic targets for enhancing collateralization in diabetic heart. 
Our in vitro findings with HCAEC treated with AGE, Ox-LDL and H2O2 
somewhat surprisingly showed that AGE, but not Ox-LDL or H2O2, dose-dependently 
decreased PLGF expression. This finding is in contrast to our results showing that 
cardiac PLGF is best correlated with plasma oxidative stress and cholesterol. There are 
several possible explanations for this disparity. First, there may be species differences 
between mouse and human underlying this effect. Second, it is possible that PLGF is 
regulated differently in the various cell types found in cardiac tissue. Third, it may be 
that endothelial cells are not the primary source of PLGF in cardiac tissue as a whole, 
and that another cell type is largely responsible for the effects we observed in cardiac 
tissue. Studies are ongoing in cardiac myocytes to determine what contribution this cell 
type makes to overall cardiac PLGF expression and whether PLGF regulation differs in 
this cell type as compared to EC.  
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In summary, we have provided the first demonstration that Western diet-induced 
metabolic abnormalities decrease PLGF mRNA and protein levels in mouse heart and 
porcine coronary arteries in a manner consistent with the type II diabetes associated 
impairment of arteriogenesis which has previously been reported. Hypercholesterolemia, 
hypertriglyceridemia, and oxidative stress appear to play a role in this inhibition, 
although the mechanism remains to be further defined.  Interestingly, we found clear 
tissue-dependent differences in the effect of the Western diet on PLGF expression, with 
aortas of Western diet fed mice expressing higher levels of PLGF protein, consistent 
with the known pro-atherogenic effect of PLGF in the vascular wall. Studies to 
characterize cell-specific mechanisms controlling PLGF levels will provide a basis for 
development of therapeutic methods to normalize PLGF expression and enhance 
arteriogenesis in the diabetic heart and may also suggest ways in which PLGF expression 
could be inhibited in tissues in which it has a pathological role.   
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CHAPTER III 
 
 
PLACENTA GROWTH FACTOR EXPRESSION IN MOUSE SKELETAL 
MUSCLE CORRELATES WITH LONG TERM DIET INDUCED 
HYPERINSULINEMIA 
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Abstract  
Arteriogenesis (collateral artery remodeling) is a vital adaptation of the 
vasculature in response to peripheral artery disease (PAD) which serves to improve O2 
and nutrient delivery to distal tissue, thereby decreasing risk of tissue damage due to 
ischemia. Stimulation of arteriogenesis would be highly beneficial in diabetics, who are 
especially prone to develop critical limb ischemia and limb loss. However, arteriogenesis 
is suppressed in diabetes by an undefined mechanism. Placenta growth factor (PLGF) is a 
key arteriogenic factor whose expression is sensitive to oxidative stress in vitro, and 
oxidative stress occurs in diabetes associated hyperglycemia and hyperlipidemia. Thus, 
we hypothesized that decreased PLGF levels might contribute to impaired arteriogenesis 
in diabetes. To test this hypothesis, we utilized three mouse models of long term (6 mo) 
diet-induced metabolic dysfunction: hyperglycemic + hyperlipidemic (Western diet fed 
C57BL/6J; n=21), hyperlipidemic (control diet fed ApoE
-/-
, n=12) and extremely 
hyperlipidemic (Western diet fed ApoE
-/-
, n=12). A normoglycemic + normolipidemic 
control group (control diet fed C57BL/6J, n=13) was also studied. Both males and 
females were studied to identify gender differences. Quadriceps femoris (thigh) and 
gastrocnemius/plantaris/soleus (GPS; calf) muscles were isolated and assayed separately 
for arteriogenic markers. During hindlimb ischemia, arteriogenesis occurs in the 
quadriceps, whereas vascular growth in the GPS is primarily angiogenesis. Mouse 
metabolic phenotype was confirmed by measuring plasma cholesterol, insulin, and 
isoprostane (biomarker for oxidative stress), performing intraperitoneal glucose tolerance 
testing, and tracking body weight. Quadriceps femoris muscle PLGF protein was 
significantly decreased in all Western diet fed groups, except C57BL/6J females (p< 
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0.01). VEGF-A protein levels were also affected by diet, but in a strain dependent 
manner. Interestingly, the Western diet increased PLGF in C57BL/6J (p<0.0001) but 
decreased it in ApoE
-/-
 (p<0.001). A notable gender response was seen for VEGFR1, 
which was elevated only in females by the Western diet (p<0.05). To study the 
mechanism for decreased PLGF expression in the Western diet groups, we performed 
regression analysis of PLGF protein levels vs metabolic parameters. PLGF was best 
correlated with insulin (r
2
=0.66, P<0.0001), in contrast to our results from cardiac tissue, 
in which PLGF was best correlated to total cholesterol and isoprostane. In the GPS 
muscle group, PLGF and VEGF-A expression was generally reduced by the Western diet 
(p<0.05). In contrast to our findings in quadriceps, VEGFR1 was decreased in ApoE
-/-
 
males by the Western diet (p<0.05). Regression analysis of PLGF protein vs metabolic 
variables in the GPS muscle group yielded similar results as were seen in quadriceps.    
We conclude that PLGF protein is decreased in the mouse quadriceps and GPS 
muscles by a Western diet, and that this decrease is inversely correlated with insulin. Our 
previous results in cardiac tissue identified hyperlipidemia and oxidative stress as 
possible mediators of PLGF inhibition in diabetes. It is possible that plasma isoprostane 
does not accurately reflect the level of oxidative stress within skeletal muscle. 
Alternatively, regulation of PLGF may differ between cardiac and skeletal muscle.                      
 
Introduction 
Over 21 million people are diabetic and approximately 40% of them have PAD in 
the United States (1;2). Atherosclerosis reduces the blood flow and perfusion pressure in 
diabetic PAD, leaving tissue at risk of ischemia. Adverse outcomes of PAD with 
underlying diabetes include critical limb ischemia, foot ulcers, and limb amputation. 
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Revascularization surgery is not an option for many patients, due to impaired wound 
healing ability (3).  
The compensatory physiological response to gradual arterial occlusion is 
arteriogenesis, in which remodeling of preexisting collateral arteries results in a natural 
bypass of the occlusion, minimizing downstream ischemia (4;5). However, arteriogenesis 
is impaired in diabetes by a mechanism that is yet to be fully defined (6). Successful 
arteriogenesis requires a coordinated response involving sensing of signals of reduced 
blood flow, recruitment of circulating cells, and the expression of a variety of growth 
factors in a temporally specific manner (7;8). Growth factor abnormalities, altered 
monocyte function (9-11), and impaired shear stress signaling (12;13) have all been 
linked to poor arteriogenesis in diabetes (14). Levels of multiple growth factors have 
been reported to be altered in diabetes, including VEGF-A (10;15), bFGF-2(14;16), HGF 
(17), and GM-CSF (18). However, attempts to overcome reduced arteriogenesis by 
targeting single growth factors have had limited success (19). Development of efficient 
therapies to overcome the adverse effects of diabetes on arteriogenesis is hampered by 
the lack of knowledge regarding the mechanism(s) by which diabetes affects the behavior 
of key arteriogenic growth factors.  
Placenta growth factor is a key arteriogenic growth factor which induces 
arteriogenesis primarily through a monocyte-mediated mechanism (20). PLGF 
overexpression induces formation of large stable vessels (21) whereas PLGF inhibition 
leads to poor collateral growth (22). PLGF infusion at the site of vessel occlusion has 
been shown to be more effective than VEGF-A at inducing arteriogenesis in animal 
models of PAD (20;23). Similarly, decreased PLGF expression is implicated in impaired 
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wound healing in diabetes, and administration of a PLGF adenoviral construct improves 
wound healing by increasing microvasculature in the wound (24). However, mechanisms 
regulating PLGF expression in skeletal muscle, where arteriogenesis is highly important, 
have not been characterized yet, nor has the effect of diabetes on skeletal muscle PLGF 
expression been examined to our knowledge.  We hypothesized that PLGF levels would 
be decreased in skeletal muscle tissue under metabolic conditions associated with type II 
diabetes. To test this hypothesis, we examined the expression of PLGF, the related 
protein VEGF-A and the PLGF receptor VEGFR1 in skeletal muscle of mice exhibiting 
varying degrees of metabolic dysfunction produced by feeding of a Western diet. Similar 
to what others have reported for diabetic wounds, we found that PLGF protein levels are 
decreased in skeletal muscle by a Western diet. These results suggest type II diabetes 
associated metabolic dysfunction may result in PLGF deficiency in diabetic human 
patients, impairing their ability to undergo arteriogenesis. Exploration of the mechanistic 
basis of Western diet-induced PLGF inhibition may suggest novel therapeutic strategies 
to improve patient outcomes in diabetics with PAD.    
Materials and Methods 
 
Animals: C57BL/6J and ApoE
-/-
 mice were either fed a Western-type diet or a control 
diet. The diet regimen was started when mice were 6-8 weeks of age and was continued 
for 24 weeks.  Male and female mice were studied separately. Therefore, we studied 8 
groups: C57BL/6J males fed the control diet (n=9), C57BL/6J females fed the control 
diet (n=8), C57BL/6J males fed the Western diet (n=14), C57BL/6J females fed the 
Western diet (n=8), ApoE
-/-
 males fed the control diet (n=6), ApoE
-/-
 females fed the 
control diet (n=6), ApoE
-/-
 males fed the Western diet (n=6), and ApoE
-/-
 females fed the 
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Western diet (n=6). All mice had access to food and water ad libitum and were housed in 
a temperature controlled facility with a 12 hour dark-light cycle. This study was 
approved by the Institutional Animal Care and Use Committee at Oklahoma State 
University. 
Diets: The Western diet (TD 88137, Harlan) supplied 42% kcal from anhydrous milk fat 
and cholesterol, 42.7% kcal from carbohydrate, and 15.2% kcal from protein. The 
control diet (TD120336) supplied 13% kcal from fat, 67.9% from carbohydrate, and 
19.2% from protein. The Western diet also has three times more sucrose by weight, 
compared to the control diet. The source of the relatively high carbohydrate content in 
the control diet is corn starch and maltodextrin, which are not readily available sources 
of sugar. Therefore, the Western diet used in this study is characterized by both high fat 
and high sucrose. 
Metabolic phenotyping of the experimental groups: Body weight of each mouse was 
recorded weekly. Fasting (6 h) blood samples were obtained from all mice at the end of 
24 week- diet regime for metabolic measurements. Glucose homeostasis was assessed by 
intraperitoneal glucose tolerance testing under fasting (6h) conditions in all mice just 
prior to sacrifice. 
Cholesterol and triglycerides: Total plasma cholesterol was determined using the 
Amplex Red cholesterol assay (Molecular Probes). Total plasma triglycerides were 
measured using a triglyceride determination kit (Sigma). 
Glucose and insulin: Intraperitoneal glucose tolerance testing (IPGTT) was performed 
on 6 h fasted, non-anesthetized mice by administering a 1g/kg ip D-glucose bolus (~30 
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mg/mouse in 300L of water). Venous blood (0.05 mL/mouse/time point; total, 0.25 
mL) was drawn from the facial vein for measurement of glucose and insulin at 0, 15, 30, 
60, and 120 min. Plasma glucose levels were measured using a portable glucose meter 
(Life Scan, Inc.). Insulin was measured using a rat/mouse insulin ELISA kit (EMD 
Millipore, Germany). 
Oxidative stress: Plasma 8-isoprostane was measured as a biomarker for oxidative stress 
using a competitive enzyme immunoassay (Cayman Chemical) according to the 
manufacturer’s protocol. 
Tissue isolation: After 24 weeks of the diet program, mice were euthanized by excision 
of the heart under deep isoflurane anesthesia. Two sets of skeletal muscles were isolated 
from the hindlimb: the quadriceps femoris muscle (from the thigh) and the 
gastrocnemius/plantaris/soleus muscle group (from the calf). Tissues were immediately 
immersed in liquid nitrogen and stored at -80C until use. Muscle tissue was 
homogenized in 1 mL of lysis buffer containing protease inhibitors (PMSF, sodium 
orthovanadate, leupeptin, benzamidine hydrochloride, aprotinin, and pepstatin A). Three 
one minute homogenizations were done at speed 5 using a Bio-Gen Pro200 homogenizer 
(PRO Scientific).The homogenates were centrifuged at 700 x g for 5 minutes, and the 
supernatant was transferred to a clean microcentrifuge tube. 
Assessment of PLGF, VEGF and VEGFR1 protein levels: PLGF, VEGF-A and 
VEGFR1 protein were quantified by ELISA (Mouse PLGF-2, VEGF-A, and VEGFR-1 
Quantikine ELISAs, R&D Systems). All samples were assayed in duplicate. Data were 
normalized to total protein concentration, as determined by BCA assay (Pierce). All assay 
plates were read using a Biotek Synergy HT plate reader. 
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Results 
In order to induce diverse metabolic characteristics associated with diabetes and 
to determine their effects on PLGF and related proteins, C57BL/6J and ApoE
-/-
 mice 
were fed a Western diet for 6 months. C57BL/6J mice fed the Western diet showed 
profound hyperglycemia, hyperinsulinemia, a high HOMA-IR index, and obesity, 
consistent with published results (25-29), whereas the effects of the diet on these 
parameters were less pronounced in the ApoE
-/-
 strain (See table 3.1 for metabolic data). 
We observed significantly elevated fasting blood glucose levels in the C57BL/6J 
Western diet groups (both male and female) from as early as week 3-4 onwards. In 
contrast, the ApoE
-/-
 Western diet fed groups did not demonstrate any impairment in 
fasting blood glucose until week 13, after which it was inconsistently elevated (data not 
shown). Fasting glucose levels were elevated among all the Western diet fed groups 
(p<0.05) by week 23 (data not shown). Glucose clearance as measured by IPGTT and 
presented as area under the curve indicated that both male and female C57BL/6J mice 
fed the Western diet had impaired glucose tolerance (WD fed C57BL/6J males, 39959 ± 
742 vs CD fed C57BL/6J males, 26852 ± 1126; WD fed C57BL/6J females, 44731 ± 
2317 vs CD fed C57BL/6J females, 23003 ± 890, p<0.01). From all the Western diet fed 
groups C57BL/6J strain demonstrated highest glucose intolerance (p< 0.0001) as 
depicted by AUC of IPGTT. In contrast, only male ApoE
-/-
 mice fed the Western diet 
had slightly but significantly elevated glucose intolerance (WD fed ApoE
-/-
 males, 29876 
± 1161 vs CD fed ApoE
-/-
 males, 23524 ± 1344, P<0.01), whereas female WD fed ApoE
-
/- 
mice were not glucose intolerant. Therefore, IPGTT results confirmed that feeding of 
the Western diet disrupted glucose homeostasis. However, significant differences were 
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noted for both sex (in ApoE
-/-
) and strain. C57BL/6J males, regardless of diet, had 
elevated plasma glucose compared to ApoE
-/-
 males on the same diet (data not shown, 
p<0.05).  
All Western diet fed groups (both strains and sexes) were hyperinsulinemic 
(p<0.0001), in agreement with other published data (26;30). A significant (p<0.0001) 
strain difference existed, with Western diet fed ApoE
-/-
 mice of both sexes showing less 
hyperinsulinemia than their C57BL/6J counterparts.  
Among all the Western diet fed groups, ApoE
-/-
 mice were significantly less obese 
than C57BL/6J mice, similar to other reports (26;31-33).  
Feeding of a Western diet increased plasma cholesterol in all groups relative to 
their matched strain/sex group on the control diet (p<0.001). However, significant effects 
of both sex (p<0.001) and strain (p<0.0001) were observed. The Western diet increased 
cholesterol in both male (338.30 ± 10.92 mg/dL) and female C57BL/6J mice (260.09 ± 
19.26 mg/dL) relative to control diet fed male (104.94 ± 8.43 mg/dL) and female (77.61 
± 9.70 mg/dL) C57BL/6 mice, with a relatively greater effect in males. No sex 
differences were observed in the ApoE
-/-
 strain. Cholesterol levels were sharply increased 
(by up to 4-5 fold) in all ApoE
-/-
 groups regardless of diet and sex when compared to the 
corresponding C57BL/6J groups (p<0.0001; ApoE
-/-
 male control, 604.13 ± 18.97 
mg/dL; ApoE
-/-
 female control, 614.20 ± 9.27 mg/dL; ApoE
-/-
 male WD, 1207.00 ± 
16.70 mg/dL; ApoE
-/-
 female WD, 1242.73 ± 18.24 mg/dL). These findings are in 
agreement with those shown by others (26;33-35).  
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Feeding of a Western diet elevated triglyceride levels in both male and female 
ApoE
-/-
 mice relative to control diet fed ApoE
-/-
 mice (p<0.001), but had no effect in 
C57BL/6J mice of either sex. Female ApoE
-/-
 mice had higher triglyceride levels than 
male ApoE
-/-
 mice on either diet (p<0.01). There was a clear strain difference, with all 
ApoE
-/-
 groups showing significantly higher triglyceride levels than the corresponding 
C57BL/6J groups (p<0.05). 
These metabolic data demonstrate that the Western diet induced different 
metabolic phenotypes, which mainly varied according to mouse strain. C57BL/6J mice 
fed a Western diet (C57-WD) were hyperglycemic, hyperinsulinemic, and 
hypercholesterolemic, while ApoE
-/-
 mice fed the Western diet (ApoE-WD) were 
extremely hyperlipidemic and hyperinsulinemic. ApoE
-/-
 mice receiving the control diet 
(ApoE-CD) were moderately hyperlipidemic, whereas C57BL/6J mice fed the control 
diet (C57-CD) were considered to be normoglycemic and normolipidemic and represent 
the controls for this study. 
 In order to characterize the oxidative stress levels associated with each of these 
metabolic phenotypes, we measured plasma 8-isoprostane, which widely used as an 
indicator of oxidative stress. The Western diet significantly increased 8-isoprostane levels 
across both strains and sexes (p<0.001) as previously reported (36-39). There was a 
significant strain effect, with all ApoE
-/-
 mice demonstrating greater levels of oxidative 
stress than the corresponding C57BL/6J groups (p<0.05). A significant effect of sex on 
the response to the Western diet was seen in both strains. Interestingly, however, the 
effect varied in opposite directions by strain, with WD fed female C57BL/6J mice 
demonstrating lower 8-isoprostane levels than the corresponding male group, whereas 
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WD fed female ApoE
-/-
 mice had greater levels of oxidative stress than did the matched 
male group (p<0.01). 
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Table 3.1:  Summary of the key metabolic data  
 C57BL6/J ApoE-/-  
 Male Female Male Female P value 
 Normal High fat Normal High fat Normal High fat Normal High fat  
Total 
cholesterol 
(mg/dL) 
104.94 ± 
8.43† 
338.30 ± 
10.92*†‡ 
77.61 ± 
9.70† 
260.09 ± 
19.26*†‡ 
614.20 ± 
9.27† 
1207.00 ± 
16.70*† 
604.13 ± 
18.97† 
1242.73 ± 
18.24*† 
*†‡<.000
1 
Plasma 
isoprostane 
(pg/mL) 
84.17 ± 
10.90† 
298.40 ± 
13.09*†‡ 
60.90 ± 
5.85† 
194.93 ± 
15.20*†‡ 
275.13 ± 
21.39† 
492.70 ± 
17.58*†‡ 
302.88 ± 
26.73† 
574.28 ± 
50.10*†‡ 
*†<.0001 
‡<.05 
Plasma 
triglycerides 
(mg/dL) 
94.38 ± 
9.40† 
92.75 ± 
10.74† 
103.81 ± 
11.23† 
133.79 ± 
12.27† 
204.72 ± 
35.96†‡ 
581.72 ± 
15.94*†‡ 
365.31 ± 
18.57†‡ 
733.31 ± 
85.90*†‡ 
*<.0001 
†<.05 
‡<.01 
Fasting 
glucose wk0 
(mg/dL) 
137.33 ± 
10.64 
136.60 ± 
6.72 
117.50 ± 
6.62* 
121.43 ± 
7.60 
135.83 ± 
5.06 
136.67 ± 
10.11 
125.33 ± 
4.14 
128.67 ± 
7.20 
‡<.05 
*†NS 
Fasting 
glucose wk23 
(mg/dL) 
131.67 ± 
3.00† 
193.80 ± 
3.63*† 
121.00 ± 
2.23† 
194.71 ± 
5.09* 
155.17 ± 
4.83† 
175.33 ± 
4.94*† 
164.50 ± 
4.09† 
181.67 ± 
6.24 
*†<.05 
‡NS 
Plasma insulin 
(ng/mL) 
1.36 ± 
0.49 
7.33 ± 
0.43*† 
1.61 ± 
0.38 
6.93 ± 
0.78*† 
0.54 ± 
0.02 
5.54 ± 
0.45*† 
0.79 ± 
0.06 
5.15 ± 
0.33*† 
*<.0001 
†<.001 
‡NS 
Area under the 
curve  
26852 ± 
1126‡ 
39959 ± 
742*†‡ 
23003 ± 
890‡ 
44731 ± 
2317*†‡ 
23524 ± 
1344 
29876 ± 
1161*† 
24654 ± 
1078 
27245 ± 
2806† 
*<.01 
†<.0001 
‡<.05 
HOMA-IR 
index 
10.74 ± 
1.01 
60.31 ± 
1.81* 
10.29 ± 
1.17 
65.40 ± 
7.94*† 
4.51 ± 
0.22 
53.28 ± 
4.34* 
4.50 ± 
0.30 
42.66 ± 
4.92*† 
*†<.0001 
‡NS 
Values are mean ± SEM. * Diet effect by strain/gender; † strain effect by gender/diet; ‡ gender 
effect by strain/diet (3-way ANOVA followed by post-hoc testing using SAS software. Analysis 
performed by Dr. Mark Payton, Professor & Head, Dept. of Statistics, Oklahoma State University). 
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Growth factor expression in quadriceps femoris muscle 
We found that PLGF protein was significantly decreased by the Western diet in 
the quadriceps femoris muscle (p<0.001), except in C57-WD females (Figure 3.1). The 
magnitude of the reduction was similar to what we previously observed in cardiac 
muscle. Interestingly, the Western diet had a clear strain-dependent effect on VEGF-A 
protein levels in quadriceps femoris muscle (Figure 3.2). VEGF-A was increased by the 
Western diet in the C57BL/6J strain (p<0.0001), but decreased in the ApoE
-/-
 strain 
(p<0.0001). No gender differences in the response of VEGF-A to the Western diet were 
detected. However, a clear gender-dependent difference in the response of VEGFR1 to 
the Western diet was observed in quadriceps muscle (Figure 3.3), with the females of 
both strains showing a diet-dependent increase in VEGFR1 protein (p<0.05). A strain-
dependent difference in VEGFR1 expression in quadriceps was also noted, with overall 
higher expression levels in ApoE
-/-
 females vs C57BL/6J females (p<0.05). 
In order to understand the possible mechanism(s) behind the Western-diet induced 
reduction of PLGF in quadriceps femoris muscle, where arteriogenesis is possible due to 
the presence of pre-existing collaterals, we performed Pearson correlation analysis of 
each individual animal’s PLGF protein level with its plasma cholesterol, isoprostane, 
triglyceride, glucose, insulin, HOMA-IR, and AUC values. The analysis revealed that 
quadriceps muscle PLGF levels were highly negatively correlated with plasma insulin 
and the HOMA-IR index (r
2
=0.66 and 0.65, p<0.0001) respectively. Furthermore, there 
was a weaker but still significant negative correlation of PLGF with fasting glucose 
(r
2
=0.35, p<0.05). However, plasma cholesterol, isoprostane, and triglycerides were not 
significantly correlated with quadriceps muscle PLGF levels. These findings are in 
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contrast to our results from cardiac tissue, in which PLGF was best correlated with 
plasma cholesterol and isoprostane. The basis for this tissue-specific difference remains 
to be determined. 
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Growth factor expression in the GPS muscle group 
PLGF expression in the GPS muscle group was generally reduced by the Western 
diet, but the effect tended to be less than what we previously observed in cardiac and 
quadriceps femoris tissue, and only reached statistical significance in C57BL/6J males 
and ApoE
-/- 
females (p<0.05) when compared to their respective control diet fed animals 
(Figure 3.4). A strain difference was observed in control diet fed females, with ApoE
-/- 
females showing elevated PLGF protein levels compared to C57BL/6J females 
(p<0.0001). A gender difference was evident in the ApoE
-/- 
strain, with females having 
elevated PLGF levels compared to males (p<0.0001). 
VEGF-A protein expression in the GPS muscle group was decreased by the 
Western diet regardless of strain and gender (p<0.05). These results are in contrast to the 
opposing strain-dependent effects of the Western diet on VEGF-A expression in the 
quadriceps femoris muscle (Figure 3.5). Similar to what we observed for PLGF in the 
GPS group, a strain difference was observed for VEGF-A in control diet fed females, 
with ApoE
-/- 
females showing elevated VEGF-A protein levels compared to C57BL/6J 
females (p<0.05). VEGF-A levels in the GPS also varied significantly with gender in the 
ApoE
-/- 
strain, with ApoE
-/- 
females expressing significantly higher VEGF-A levels 
compared to ApoE
-/- 
males (p<0.05). 
Western diet-dependent effects to decrease VEGFR1 expression in the GPS were 
only seen in ApoE
-/- 
males (Figure 3.6). Strain-dependent differences in GPS VEGFR1 
expression regardless of diet treatment were also observed, with ApoE
-/- 
mice generally 
showing lower expression compared to C57BL/6J mice (p<0.001). Gender effects on 
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VEGFR1 expression were seen in the ApoE
-/- 
strain, with lower VEGFR1 levels in 
females than in males on either diet (p<0.05). 
  Pearson correlation analysis was performed to compare each individual animal’s 
PLGF protein level with its plasma cholesterol, isoprostane, triglyceride, glucose, insulin, 
HOMA-IR index, and AUC values. Interestingly, similar to our observations for PLGF in 
quadriceps, PLGF levels in the GPS were also best correlated with indices of 
hyperglycemia such as plasma insulin (r
2
=0.52, p<0.001), HOMAIR (r
2
=0.51, p<0.001), 
and fasting glucose (r
2
=0.32, p<0.05). However, also similar to our findings in the 
quadriceps, but in contrast to results from cardiac tissue, PLGF was not significantly 
correlated with plasma cholesterol, isoprostane, or triglycerides in the GPS muscle group. 
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Discussion 
The primary goal of this study was to investigate the effect of diabetes related 
metabolic dysfunction on the expression and regulation of PLGF and related growth 
factors and receptors in skeletal muscle tissues, particularly those in which vascular 
remodeling occurs in peripheral artery disease. Long term feeding of a Western diet is a 
physiologically relevant model for human type II diabetes and studying its associated 
cardiovascular complications including PAD (25;40). Here we demonstrate that 
C57BL/6J mice develop significant hyperglycemia, hyperinsulinemia and 
hypercholesterolemia on a Western diet, whereas ApoE
-/-
 mice develop extreme 
hyperlipidemia. Even when consuming a control diet, ApoE
-/-
 mice developed 
significantly higher levels of hyperlipidemia than C57BL/6J mice. By studying two 
strains of mice with varying genetic susceptibility to diet-induced metabolic dysfunction, 
we were able to study PLGF expression under a wide range of metabolic phenotypes. In 
humans, PAD most commonly occurs in older patients with type II diabetes or other 
metabolic abnormalities; however, most animal studies aimed at characterizing signal 
pathways mediating collateral growth in the periphery have utilized young animals with a 
normal metabolic profile. Therefore, our results are more relevant to the typical clinical 
setting of human PAD.  
We previously demonstrated that PLGF is reduced by a Western diet in cardiac 
tissue in a hyperlipidemia- and oxidative stress-associated manner, in agreement with the 
known inhibitory effect of type II diabetes on arteriogenesis. We therefore hypothesized 
that a similar inhibition may occur in skeletal muscle and contribute to reduced 
arteriogenesis in diabetic PAD. 
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PLGF was decreased in skeletal muscle from the quadriceps and GPS by a 
Western diet, similar to our findings in cardiac tissue. The Western diet had a greater 
inhibitory effect on PLGF expression in the quadriceps muscle than the GPS group, in 
agreement with the fact that arteriogenesis (which is regulated by PLGF) is the 
predominant type of vascular remodeling in the quadriceps in response to occlusion, 
whereas angiogenesis (which is primarily regulated by VEGF-A) is the main type of 
remodeling in skeletal muscle of the distal limb. Contrary to our results in cardiac tissue, 
the metabolic variable which showed the strongest statistical correlation to PLGF protein 
level in skeletal muscle was plasma insulin, as opposed to plasma cholesterol and 
oxidative stress for the heart. The basis for this observation remains to be determined. It 
is possible that changes in plasma oxidative markers do not accurately represent the 
muscle tissue redox balance as shown by others (41). Therefore, a stronger correlation of 
skeletal muscle PLGF levels might be obtained if a direct comparison to skeletal muscle 
oxidative stress was made. It is also possible that PLGF is differentially regulated in 
cardiac muscle vs skeletal muscle. Lastly, the PLGF expression which we observed in 
whole cardiac and muscle tissues may arise from different cell types. Further studies are 
needed to better characterize differences in PLGF expression and regulation between 
cardiac and skeletal muscle tissues. 
Elevated levels of VEGF-A in skeletal muscle of high fat diet fed mice have been 
previously reported. The elevated VEGF-A observed was attributed to high fat diet 
induced increased fatty acid oxidation, resulting in high oxygen demand in skeletal 
muscles and capillaries resulting hypoxic environment (42). Our results were somewhat 
different. Although the Western diet did increase VEGF-A levels in the quadriceps 
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muscle of C57BL/6J mice, it decreased VEGF-A in the quadriceps muscle of ApoE-/- 
mice and in the GPS muscle group of both mouse strains. The strain dependent difference 
in the quadriceps muscle was quite striking. The mechanism behind this difference, as 
well as its functional significance to the collateral remodeling process, is an important 
area for future study. 
The effect of a Western diet on VEGFR1 expression in skeletal muscle varied 
between quadriceps and the GPS group. The Western diet increased VEGFR1 in 
quadriceps of female mice of both strains, but reduced it in male and female ApoE
-/-
 
mice. VEGFR1 levels were unaffected by the diet in the remaining experimental groups. 
One previous report shows that reduced VEGFR1 in diabetic tibialis anterior muscle (43). 
It remains to be determined whether the differences we observed between the quadriceps 
muscle and the GPS group relate to muscle fiber type, the predominant form of vascular 
remodeling that occurs in each muscle (arteriogenesis in quadriceps vs angiogenesis in 
GPS), or other factors. 
Although we observed a few gender-related differences, overall PLGF expression 
in skeletal muscle of female mice was similar to that in male mice. This finding is of 
interest due to the predominant role of PLGF in placental development and suggests that 
PLGF is equally important in mediating non-reproductive related vascular remodeling in 
both males and females.  
In summary, this study focused on the effect of a Western diet on baseline 
(unstimulated) PLGF, VEGF-A, and VEGFR1 expression. We show that PLGF levels in 
skeletal muscle are generally reduced by a Western diet, suggesting that dysfunctional 
PLGF expression could contribute to impaired peripheral arteriogenesis in type II 
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diabetes. PLGF expression has been demonstrated to increase significantly above 
baseline in rat hindlimb following induction of experimental PAD (44). Therefore, the 
next question to be addressed is whether PLGF is normally upregulated in skeletal 
muscle of Western diet fed mice by the physiological stimulus of vascular occlusion, or 
whether the inhibitory effect of the Western diet on baseline PLGF expression also 
applies to upregulation of PLGF. Normalization of PLGF expression in skeletal muscle 
could potentially rescue impaired peripheral arteriogenesis in type II diabetes. Thus, our 
results have important clinical implications. 
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CHAPTER IV 
 
 
A WESTERN DIET DECREASES AND DELAYS PLACENTA GROWTH 
FACTOR UPREGULATION IN RESPONSE TO FEMORAL ARTERY 
LIGATION IN MICE 
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Abstract 
Arteriogenesis (collateral remodeling) preserves blood flow distal to occlusions, 
ameliorating ischemic tissue damage in peripheral artery disease (PAD). Stimulation of 
arteriogenesis would be highly beneficial in diabetics, who are especially prone to 
develop PAD. However, arteriogenesis is reduced in diabetes by an undefined 
mechanism. Placenta growth factor (PLGF) is a key arteriogenic factor that induces the 
formation of large, stable vessels. PLGF is known to be upregulated following arterial 
occlusion, and PLGF therapy improves arteriogenesis. However, whether PLGF 
regulatory mechanisms function normally in diabetic peripheral tissues in response to 
occlusion is unknown. We previously showed that baseline PLGF protein levels are 
significantly decreased in mouse hindlimb skeletal muscle by a Western-type diet in a 
hyperinsulinemia-associated manner. Thus, we hypothesized that upregulation of PLGF 
in response to the physiological stimulus of upstream vascular occlusion may also be 
impaired by feeding of a Western diet. We hypothesized that both basal and stimulated 
PLGF expression might be abnormal by Western diet induced metabolic dysfunction, 
potentially contributing to impaired arteriogenesis in diabetic PAD. To test this 
hypothesis, we utilized three mouse models of long term (6 mo) diet-induced metabolic 
dysfunction: hyperlipidemic + hyperglycemic + hyperinsulinemic (Western diet fed 
C57BL/6J, C57-WD; n=58), very hyperlipidemic (control diet fed ApoE
-/-
,
 
ApoE-CD; 
n=42) and extremely hyperlipidemic + hyperinsulinemic (Western diet fed ApoE
-/- 
, 
ApoE-WD; n=45). A normolipidemic + normoglycemic + normoinsulinemic control 
group (control diet fed C57BL/6J, C57-CD; n=52) was also studied. After 24 weeks on 
the diet, animals were subjected to gradual femoral artery occlusion by placement of an 
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ameroid constrictor. Sham control animals (Total n= 20) were also studied. Hindlimb 
skeletal muscle was collected 3-28 days post-surgery (dps) for measurement of PLGF and 
related arteriogenic proteins. Flow recovery at 21dps was measured (n=4/group) by 
infusion of fluorescent microspheres. Mouse metabolic phenotype was confirmed by 
measuring relevant plasma parameters. PLGF was sharply elevated in skeletal muscle of 
CONT mice in response to femoral artery occlusion, peaking around 10 dps. PLGF 
upregulation by occlusion was both decreased and delayed in C57-WD group (p<0.05). 
Even more strikingly, the response to PLGF to occlusion was completely abolished in 
ApoE-CD and ApoE-WD groups. We conclude that metabolic dysfunction induced by a 
Western-type diet inhibits PLGF upregulation by the physiological stimulus of occlusion, 
in addition to reducing baseline PLGF levels as we previously described. Impaired PLGF 
regulation may therefore contribute to the poor arteriogenic response in diabetes. 
 
Introduction 
Peripheral artery disease is a major cause of morbidity and mortality in the US. 
Current treatment strategies include life style changes and pharmacological interventions 
aimed at controlling the metabolic conditions that promote atherosclerosis. However, 
these strategies are not optimally effective, and ~40% of patients with critical limb 
ischemia will eventually need limb amputations (approximately 150,000/year) (1). 
 Type II diabetes is a major predictor for development of PAD. Diabetic patients 
are five times more likely to have undergone limb amputation compared to nondiabetic 
patients (2). Furthermore, diabetic PAD patients have a poorer response to 
revascularization therapies (vascular reconstruction, stent placement or angioplasty), 
compared to non-diabetic PAD patients (3). Arteriogenesis is an innate mechanism by 
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which the vasculature can remodel to naturally bypass blood vessel occlusion. Since 
arteriogenesis results in an increase in blood flow capacity to the tissue, it is a more 
efficient mechanism of countering PAD-induced tissue ischemia than angiogenesis, 
which can decrease the diffusion distance for O2 but does not alter overall blood flow to 
the tissue (4;5). However, aging and metabolic conditions that promote PAD also tend to 
inhibit arteriogenesis (6;7). 
Type II diabetes and associated hyperlipidemia are the worst negative predictors 
of arteriogenesis (8-10). The mechanism of this inhibition is unclear, but oxidative stress, 
endothelial dysfunction, and abnormal growth factor signaling have all been implicated. 
Normalization of diabetes-associated abnormal arteriogenic growth factor signaling has 
long been regarded as a potential target for new PAD therapies (11). However, despite 
the promising arteriogenic and angiogenic effects of VEGF-A and FGF in preclinical 
studies, translation of these findings to clinical application has been disappointing (12-
17). One explanation for the lack of success for such therapies is that multiple growth 
factors and cytokines are involved in orchestrating arteriogenesis, and supplying a single 
factor may not be sufficient, especially since multiple factors may be dysfunctional in 
diabetic PAD (18). Therefore, there is a critical need for knowledge of how additional 
growth factor and cytokine targets are altered in diabetes. Another major consideration is 
that the growth factors that have been tested for therapeutic benefit in PAD (e.g. VEGF-
A) are either primarily angiogenic or have a mixed angiogenic/arteriogenic action, when 
the process that should be targeted to optimally improve tissue blood flow is 
arteriogenesis. 
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Placenta growth factor is a key arteriogenic growth factor. PLGF knockout mice 
show impaired arteriogenesis (19), while overexpression (20) or localized infusion of 
PLGF has positive arteriogenic effects through a monocyte-mediated mechanism. MCP-
1, another important monocyte chemoattractant, is also arteriogenic in animal models of 
PAD; however, MCP-1 has a systemic atherogenic effect, limiting its potential 
therapeutic use (21).   
PLGF has been recognized as a promising therapeutic cytokine target for 
compromised vascular remodeling in PAD (22). However, detailed characterization of 
PLGF expression and regulation in diabetic PAD has not yet been reported. PLGF 
treatment has shown consistent positive outcomes when administered to animals with 
experimental PAD. However, these studies have used healthy young animals in which 
acute hindlimb ischemia is induced; whereas clinical PAD patients are often elderly and 
suffer from underlying diabetes, and occlusion occurs gradually over a period of years. 
Therefore, one goal of this study was to study the regulation of PLGF in a more clinically 
relevant model system.  
We characterized the temporal expression patterns of PLGF, VEGF-A, VEGFR1, 
and MCP-1 in mouse hindlimb skeletal muscle in response to gradual arterial occlusion. 
We sought to determine the detailed temporal expression profile of PLGF in response to 
gradual femoral artery occlusion, and to test whether that response is altered by a 
Western diet. The use of acute femoral artery ligation in healthy animals, as done in most 
studies of experimental PAD, does not accurately mimic the human clinical presentation 
of PAD. Therefore, we combined a Western diet-induced phenotype of Type II-diabetes 
associated metabolic dysfunction with gradual femoral artery occlusion, to more 
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accurately mimic the typical clinical scenario of PAD. The knowledge gained as a result 
of this study will reveal possible mechanisms contributing to the poor prognosis of PAD 
in diabetic patients and may provide potential therapeutic avenues. 
Materials and Methods 
Animals: C57BL/6J and ApoE
-/-
 mice were either fed a Western-type diet or a control 
diet. The diet regimen was started when mice were 6-8 weeks of age and was continued 
for 24 weeks.  Male and female mice were pooled together in each group. Therefore, we 
studied 4 groups: C57BL/6J fed control diet, n=52 (C57-CD), C57BL/6J fed Western 
diet, n=58 (C57-WD), ApoE-/- fed control diet, n=42 (ApoE-CD), ApoE-/- fed Western 
diet, n=45 (ApoE-WD). All mice had access to food and water ad libitum and were 
housed in a temperature controlled facility with a 12 hour dark-light cycle. This study 
was approved by the Institutional Animal Care and Use Committee at Oklahoma State 
University. 
Diets: The Western diet (TD 88137, Harlan) supplied 42% kcal from anhydrous milk fat 
and cholesterol, 42.7% kcal from carbohydrate, and 15.2% kcal from protein. The 
control diet (TD120336) supplied 13% kcal from fat, 67.9% from carbohydrate, and 
19.2% from protein. The Western diet also has three times more sucrose by weight, 
compared to the control diet. The source of the relatively high carbohydrate content in 
the control diet is corn starch and maltodextrin, which are not readily available sources 
of sugar. Therefore, the Western diet used in this study is characterized by both high fat 
and high sucrose. 
Metabolic phenotyping of the experimental groups: Body weight of each mouse was 
recorded weekly. Fasting (6 h) blood samples were obtained from all mice at the end of 
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24 week- diet regime for metabolic measurements. Glucose homeostasis was assessed by 
intraperitoneal glucose tolerance testing under fasting (6h) conditions in all mice just 
prior to sacrifice. 
Cholesterol and triglycerides: Total plasma cholesterol was determined using the 
Amplex Red cholesterol assay (Molecular Probes). Total plasma triglycerides were 
measured using a triglyceride determination kit (Sigma). 
Glucose and insulin: Intraperitoneal glucose tolerance testing (IPGTT) was performed 
on 6 h fasted, non-anesthetized mice by administering a 1g/kg ip D-glucose bolus (~30 
ime point; total, 0.25 
mL) was drawn from the facial vein for measurement of glucose and insulin at 0, 15, 30, 
60, and 120 min. Plasma glucose levels were measured using a portable glucose meter 
(Life Scan, Inc.). Insulin was measured using a rat/mouse insulin ELISA kit (EMD 
Millipore, Germany). 
Oxidative stress: Plasma 8-isoprostane was measured as a biomarker for oxidative stress 
using a competitive enzyme immunoassay (Cayman Chemical) according to the 
manufacturer’s protocol. 
Femoral artery occlusion: After 24 weeks of the diet program, mice were subjected to 
gradual femoral artery occlusion by placement of an ameroid constrictor (0.25 mm 
inner/0.5 mm outer diameter, Research instruments SW, Figure 4.8a). Mice were 
anesthetized using continuous 2% isoflurane by inhalation. The hair over the thigh was 
shaved and the area was disinfected with Betadine.  A one-to-two centimeter incision was 
made in the medial aspect of the thigh, and the femoral artery and vein were exposed. 
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The vein, artery and nerve were isolated from each other by blunt dissection under a 
surgical microscope (Olympus1X70 inverted microscope) (Figure 4.8b). An ameroid 
constrictor was placed around the femoral artery to produce gradual (~7-10 d) occlusion 
(Figure 4.8c). The skin was then closed with 3M VetBond (3M Animal Care Products) 
tissue adhesive and wound clips, and the incision site treated topically with 2% lidocaine 
ointment and bacitracin/polymyxin/neomycin antibiotic ointment. The right (unoperated) 
limb served as a paired control. Mice were returned to cages for recovery and closely 
observed for signs of discomfort or altered limb function. Wound clips were removed 7 d 
post-surgery if still present. Mice were returned to the same diet until the skeletal muscle 
tissue was harvested at 3, 5, 7, 10, 14, 21 or 28 days post ligation (dps; n=4-7/time point).  
Sham operation: In a different set of mice, a sham surgery was performed 
(n=4/group/time point). The vessels were exposed and isolated as above, except for 
placing the ameroid constrictor on the femoral artery, and then the wound was closed as 
above. The right limb served as a paired control for these animals as well.  
Tissue isolation: At the above mentioned time points, mice were euthanized by excision 
of the heart under deep isoflurane anesthesia, and the quadriceps femoris, biceps femoris 
and adductor muscles were isolated from the occluded and non-occluded leg separately. 
Tissues were homogenized in 1 mL of lysis buffer containing protease inhibitors 
(phenylmethylsulfonyl fluoride, sodium orthovanadate, leupeptin, benzamidine 
hydrochloride, aprotinin, and pepstatin A). Three one-minute homogenizations were 
done using a Bio-Gen Pro200 homogenizer (PRO Scientific).  The homogenates were 
centrifuged at 700g for 5 minutes and the supernatants were transferred to clean 
microcentrifuge tubes and stored at -80C. 
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Blood flow assessment following femoral artery occlusion: In a different set of mice, 
femoral artery occlusion was performed as described in the previous section. Hindlimb 
adductor muscle blood flow was assessed at 21dps (n=6/group) by infusion of 
fluorescent microspheres. Under isoflurane anesthesia, a PE-10 catheter was inserted into 
the right carotid artery proximal to the aortic bifurcation.  Catheters were filled with 
saline containing 100 IU/mL heparin and 1g/L adenosine. Fluorescent microspheres (Red 
– orange, Excitation/Emission at 565/580 nm, 15 m diameter, 5 x 10^5 microspheres, 
Molecular Probes) was infused through the carotid catheter in a rate of 100 L/5 second. 
Three minutes after microsphere infusion, mice were euthanized under 5% isoflurane as 
above. Hindlimb thigh skeletal muscles (adductor, quadriceps and biceps femoris) were 
collected from each hindlimb separately for analysis of the accumulation of 
microspheres. Kidneys were also collected to verify even distribution of microspheres to 
both sides of the body. 
Tissue samples were weighed, and then digested in 5 mL of 2.3M ethanolic KOH 
with 0.5% Tween 80 overnight in a shaker bath at 60°C. The samples were centrifuged at 
2000g for 20 min, and the supernatant was removed. The tissue pellet was resuspended 
twice in distilled water with 0.5% Tween 80 and centrifuged, and the supernatant was 
discarded. The pellet was then resuspended in methanol, centrifuged, and decanted. The 
remaining methanol was removed by evaporative drying. The remaining microsphere 
residue was dissolved in 2 mL of 2-ethoxyethylacetate and fluorescence was measured by 
flow cytometry (Accuri C6; BD) using the recommended extinction and emission 
frequencies for microsphere fluorescence. Mean fluorescence counts from the occluded 
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and non-occluded leg were normalized to tissue weight and used to calculate the ratio of 
flow recovery due to arteriogenesis.  
Assessment of PLGF, VEGF, MCP-1 and VEGFR1 protein levels: PLGF, VEGF-A, 
VEGFR1 and MCP-1 protein were quantified using ELISA (Quantikine, R&D Systems). 
All samples were assayed in duplicate. Protein levels in the occluded leg were normalized 
to the non-occluded leg in order to calculate a ratio for each factor. Data were also 
normalized to total protein concentration, as determined by BCA assay (Pierce). All assay 
plates were read using a Biotek Synergy HT plate reader. 
Results 
In order to induce diverse metabolic characteristics associated with diabetes and 
to determine their effects on PLGF and related proteins, C57BL/6J and ApoE
-/-
 mice 
were fed a Western diet for 6 months. C57BL/6J mice fed the Western diet showed 
profound hyperglycemia, hyperinsulinemia, a high HOMA-IR index, and obesity, 
consistent with published results (23-27), whereas the effects of the diet on these 
parameters were less pronounced in the ApoE
-/-
 strain. We previously observed 
significantly elevated fasting blood glucose levels in the C57BL/6J Western diet groups 
from as early as week 3-4 onwards. In contrast, the ApoE
-/-
 Western diet fed groups did 
not demonstrate any impairment in fasting blood glucose until week 13, after which it 
was inconsistently elevated (data not shown). Fasting glucose levels were elevated 
among all the Western diet fed groups (p<0.05) by week 23 (data not shown). Glucose 
clearance as measured by IPGTT (Figure 4.1) and presented as area under the curve 
(Figure 4.2) indicated that C57BL/6J mice fed the Western diet had impaired glucose 
tolerance (WD fed C57BL/6J, 49950 ± 595 vs CD fed C57BL/6J, 31658 ± 754; WD, 
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p<0.01). From all the Western diet fed groups C57BL/6J strain demonstrated highest 
glucose intolerance (p< 0.001). In contrast, ApoE
-/-
 mice fed the Western diet had 
slightly but significantly elevated glucose intolerance (WD fed ApoE
-/-
 , 33136 ± 626 vs 
CD fed ApoE
-/-
, 29096 ± 591, P<0.01). Therefore, IPGTT results confirmed that feeding 
of the Western diet disrupted glucose homeostasis. However, significant differences 
were noted for strain. 
All Western diet fed groups (both strains) were hyperinsulinemic (Figure 4.3, 
p<0.0001), in agreement with other published data (24;28). A significant (p<0.0001) 
strain difference existed, with Western diet fed ApoE
-/-
 mice showing less 
hyperinsulinemia than their C57BL/6J counterparts.  
Among all the Western diet fed groups, ApoE
-/-
 mice were significantly less obese 
than C57BL/6J mice, similar to other reports (24;29-31).  
Feeding of a Western diet increased plasma cholesterol (Figure 4.4) in all groups 
relative to their matched group on the control diet (p<0.001). However, significant 
effects of strain (p<0.0001) were observed. The Western diet increased cholesterol in 
C57BL/6J mice (282.32 ± 10.04 mg/dL) relative to control diet fed male (100.28 ± 4.44).  
Cholesterol levels were sharply increased (~4 fold) in all ApoE
-/-
 groups regardless of 
diet when compared to the corresponding C57BL/6J groups (p<0.0001; ApoE
-/-
 CD, 
547.49 ± 23.76 mg/dL; ApoE
-/-
 WD, 1104.58 ± 38.98 mg/dL). These findings are in 
agreement with those shown by others (24;31-33).  
Feeding of a Western diet elevated triglyceride levels in both male and female 
ApoE
-/-
 mice relative to control diet fed ApoE
-/-
 mice (p<0.001), but had no effect in 
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C57BL/6J mice (Figure 4.5). There was a clear strain difference, with ApoE
-/-
 showing 
significantly higher triglyceride levels than C57BL/6J groups (p<0.05). 
These metabolic data demonstrate that the Western diet induced different 
metabolic phenotypes, which mainly varied according to mouse strain. C57BL/6J mice 
fed a Western diet (C57-WD) were hyperglycemic, hyperinsulinemic, and 
hypercholesterolemic, while ApoE
-/-
 mice fed the Western diet (ApoE-WD) were 
extremely hyperlipidemic and hyperinsulinemic. ApoE
-/-
 mice receiving the control diet 
(ApoE-CD) were moderately hyperlipidemic, whereas C57BL/6J mice fed the control 
diet (C57-CD) were considered to be normoglycemic and normolipidemic and represent 
the controls for this study. 
 In order to characterize the oxidative stress levels associated with each of these 
metabolic phenotypes, we measured plasma 8-isoprostane, which widely used as an 
indicator of oxidative stress. The Western diet significantly increased 8-isoprostane levels 
across both strains (Figure 4.6, p<0.001) as previously reported (34-37). There was a 
significant strain effect, with all ApoE
-/-
 mice demonstrating greater levels of oxidative 
stress than C57BL/6J groups (p<0.05).  
 
 
 
 
 
 
 
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: IPGTT in C57BL/6 mice (above) and ApoE-/- mice (below). *, p<0.05 for 
Western diet vs control diet group of same strain at the same time point. 
0
100
200
300
400
500
0 30 60 90 120
B
lo
o
d
 g
lu
c
o
s
e
 m
g
/d
L
 
C57BL/6J 
ApoE
-/-
 
0
100
200
300
400
500
600
0 30 60 90 120
B
lo
o
d
 g
lu
c
o
s
e
 m
g
/d
L
 
Control diet
Western diet
* * * 
* 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
15000
30000
45000
60000
A
U
C
 
 C57BL/6J          ApoE-/- 
* 
* † 
 Figure 4.2: Area under the curve calculated from IPGTT in C57BL/6 mice and ApoE-/- 
mice fed with a control diet and a Western diet for six months. 
* p<0.01 for diet by strain 
† p<0.001 for strain by diet 
White bars: Control diet 
Black bars: Western diet 
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Figure 4.3: Feeding of a Western diet for 6 months increased plasma insulin in both 
strains. 
* p<0.01 for diet by strain 
† p<0.0001 for strain by diet 
White bars: Control diet 
Black bars: Western diet 
158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
100
200
300
400
500
600
P
la
s
m
a
 t
ry
g
ly
c
e
ri
d
e
s
 m
g
/d
L
 
 C57BL/6J           ApoE-/- 
* p<0.001for diet by strain 
† p<0.001 for strain by diet 
* † 
† 
Figure 4.5: Western diet fed ApoE
-/-
 mice had elevated plasma triglycerides 
compared to the low fat fed ApoE 
-/-
 mice, as well as all C57BL/6J groups 
White bars: Control diet 
Black bars: Western diet 
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Figure 4.6: Plasma 8-isoprostane was measured as a biomarker for oxidative 
stress. Western diet fed mice showed increased oxidative stress, compared to 
control diet fed groups 
White bars: Control diet 
Black bars: Western diet 
* p<0.001 for diet by strain 
† p<0.05 for strain by diet 
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Figure 4.7: Body weights of Western diet fed mice were higher compared to control 
fed mice at 24
th
 week. ApoE-/- Western diet fed animals were less obese compared to 
C57BL/6J fed with same diet.  
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Effect of a Western diet on PLGF, VEGF-A, VEGFR1 and MCP-1 levels following 
ameroid constrictor placement 
After 6 months of the diet program, mice were subjected to gradual left femoral 
artery occlusion by placement of an ameroid constrictor, and the arteriogenic process was 
allowed to proceed for up to 28 dps. Analysis of blood perfusion measurements at 21-28 
days following femoral artery occlusion reported almost complete flow recovery in mice 
hindlimb (38;39). In order to study the temporal expression pattern of the arteriogenic 
growth factor response in tissue in which arteriogenesis is occurring, we harvested thigh 
skeletal muscle from both limbs at 3, 5, 7, 10, 14, 21, or 28 days after ameroid placement 
and measured the protein levels. Data are presented as the ratio of each protein between 
the left (occluded) limb and the right (non-occluded) limb, which served as a paired 
control. 
PLGF expression was significantly elevated beginning 3-10 dps in C57-CD and 
returned towards control levels thereafter (Figure 4.9). The peak PLGF expression was 
elevated ~2.5-fold in the occluded limb relative to the non-occluded limb at 10 dps. Sham 
operated animals failed to upregulate PLGF at 7 and 10 dps, confirming that the PLGF 
response is due to occlusion and not a nonspecific surgical effect (Figure 4.10). Critically, 
the upregulation of PLGF by occlusion was both delayed and reduced in magnitude in 
C57-WD, where peak expression was only ~1.5 fold of the level in the non-occluded 
limb and did not occur until up to 21 dps. Sham operated C57-WD animals also did not 
show any upregulation of PLGF indicating no effect due to surgery (Figure 4.11). Most 
interestingly, occlusion induced upregulation of PLGF was completely absent in the 
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ApoE
-/-
 groups during all the time points tested, indicating that the greater the degree of 
metabolic dysfunction, the more PLGF is suppressed. 
Since 7 and 10 dps were the time points at which PLGF expression was most 
sharply difference between the three metabolic dysfunction groups, compared to heathy 
control mice, we performed Pearson correlation analysis for PLGF protein levels at these 
two time points with the metabolic parameters of the same animal. The oxidative stress 
biomarker 8-isoprostane (r=0.72, p<0.005), along with insulin (r=0.51, p<0.05), showed 
the strongest inverse correlation with PLGF, whereas no significant correlations were 
found between PLGF and total cholesterol, triglycerides, or fasting glucose at 10 dps. 
Similar trend was observed at 7 dps (see Appendix for SAS output).  
VEGF-A was also upregulated in C57-CD animals by femoral occlusion, reaching 
a peak expression of ~4-fold higher than the non-occluded limb at 14 dps. Similarly to 
what we observed for PLGF, this response was reduced or absent in the metabolic 
dysfunction groups (Figure 4.12). Sham operated animals did not show any response of 
VEGF-A to the procedure (Figure 4.13). 
VEGFR1 expression in C57-CD animals began increasing 10 days after ameroid 
placement (p<0.0001) and continued to increase until the conclusion of the study at 21 d. 
However, this increase in VEGFR1 failed to occur in the C57-WD group or either of the 
ApoE
-/-
 groups (Figure 14). From sham operated C57-CD animals at 7 and 10 dps only 
10 dps was significantly different from the femoral artery occluded animals (Figure 4.15). 
MCP-1 was elevated up to 30-fold as early as 3 dps in C57BL/6J mice (both CD 
and WD fed, p<0.0001), but not in either ApoE
-/-
 group (Figure 4.16).  MCP-1 levels in 
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sham operated animals failed to demonstrate significant elevation of MCP-1 levels 
(Figure 4.17 and 4.18). 
When consider the PLGF level variation in operated leg and non-operated leg 
individually, non-operated leg tissue PLGF level stays unchanged from 3-28 dpl whereas 
operated leg PLGF level fluctuate with time. The same observation is true for VEGF-A, 
VEGFR1 and MCP-1 indicating that temporal regulation of these markers are solely due 
to the arterial occlusion (See appendix for  the graphs that only includes protein levels 
from the operated leg. occlusion)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.75
1.25
1.75
2.25
2.75
0 5 10 15 20 25 30
P
L
G
F
  
ra
ti
o
,O
p
e
ra
te
d
 l
e
g
/u
n
o
p
e
ra
te
d
 l
e
g
 
Days post surgery 
C57BL/6J Control diet
C57BL/6J Western diet
ApoE-/- Control diet
ApoE-/- Western diet
Figure 4.9: Effect of Western diet on the upregulation of PLGF in femoral artery occluded 
mice. Control diet fed C57BL/6J animals showed increased PLGF levels at 7 and 10 dps. 
*, p<0.001 for Western diet vs control diet group of same strain at the same time point.  
* 
* 
* 
* p<0.001 for diet by strain 
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White bars:  Femoral artery ligated 
Black bars: Sham operated 
* p<0.005 for ligated vs sham 
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  Day 7                                   Day 10 
Figure 4.10: Control diet fed C57BL/6J sham operated animals failed to demonstrate 
occlusion associated PLGF induction at 7 and 10 dps compared to femoral artery 
occluded animals from same stain/diet/dps. 
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C57BL/6J Western diet, PLGF protein  
White bars:  Femoral artery ligated 
Black bars: Sham operated 
* p<0.05 for ligated vs sham 
   Day 21 
* 
Figure 4.11: Western diet fed C57BL/6J sham operated animals failed to 
demonstrate occlusion associated PLGF induction at 21 dps compared to femoral 
artery occluded animals from same stain/diet/dps. 
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Figure 4.12: Effect of Western diet on the upregulation of VEGF in femoral artery occluded 
mice. Control diet fed C57BL/6J animals showed increased VEGF levels at 14 dps. *, 
p<0.0001 for Western diet vs control diet group of same strain at the same time point. 
* p<0.0001 for diet by strain 
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Figure 4.13: Control diet fed C57BL/6J sham operated animals failed to demonstrate 
occlusion associated VEGF-A induction at 14 dps compared to femoral artery 
occluded animals from same stain/diet/dps. 
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Figure 4.14: Effect of Western diet on the upregulation of VEGFR1 in femoral artery 
occluded mice. Control diet fed C57BL/6J animals showed increased VEGFR1 
levels from 10 dps onwards. *, p<0.001 for Western diet vs control diet group of 
same strain at the same time point. 
† 
* p<0.0001 for diet by strain 
† p< 0.0001 strain by diet 
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White bars:  Femoral artery ligated 
Black bars: Sham operated 
C57BL/6J control diet, VEGFR1 
* 
* p<0.01 for ligated vs sham 
Figure 4.15: Control diet fed C57BL/6J sham operated animals failed to 
demonstrate occlusion associated VEGFR1 induction at 7 and 10 dps compared 
to femoral artery occluded animals from same stain/diet/dps. 
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Figure 4.16: Effect of Western diet on the upregulation of MCP-1 in femoral 
artery occluded mice. Control diet fed C57BL/6J animals showed increased 
MCP-1 levels from 10 dps onwards. *, p<0.0001 for Western diet vs control 
diet group of same strain at the same time point. 
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* p<0.0001 for diet by 
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   p=NS for strain by diet 
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Figure 4.17: Control diet fed C57BL/6J sham operated animals failed to demonstrate 
occlusion associated MCP-1 induction at 3 dps compared to femoral artery occluded 
animals from same stain/diet/dps. 
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Figure 4.18: Western diet C57BL/6J sham operated animals failed to 
demonstrate occlusion associated MCP-1 induction at 3 dps compared 
to femoral artery occluded animals from same stain/diet/dps. 
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Figure 4.19: Impaired recovery of perfusion of G-P-S muscle at 21 dps 
in Western diet fed C57BL/6J and all ApoE-/- mice regardless of the diet 
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Recovery of perfusion following femoral artery occlusion  
To study the effect of metabolic conditions on blood flow recovery in response to 
femoral artery occlusion, mice fed with respective diets for 24 weeks were subjected to 
unilateral femoral artery occlusion as described above. The degree of perfusion to G-P-S 
muscle was measured in both operated and unoperated limbs using fluorescence 
microsphere method and calculated the ratio. The ratio is higher and gets closer to 1 if the 
perfusion of the operated leg is well recovered due to strong collateral remodeling.  Even 
distribution of microsphere in each side of the body was ensured by comparing the 
fluorescence accumulation among kidneys. Data were discarded if the kidney readings 
demonstrated < 10% variation coefficient. C57-WD, ApoE-CD and ApoE-WD showed 
reduced perfusion recovery compared to C57-CD (0.8  0.03). However, statistically 
significant impaired perfusion was observed only in ApoE-/- mice regardless of the type 
of diet; ApoE-CD (0.65  0.01, p<0.01) and ApoE-WD (0.41 0.06, p<0.001). C57-WD 
demonstrated reduced perfusion recovery (0.66  0.01, p= 0.077) which may reach 
statistical significance with increased number of samples. 
 
Discussion 
Type II diabetes promotes the pathogenesis of PAD. At the same time, however, 
the majority of diabetic PAD patients have limited ability to compensate for vascular 
occlusion via physiological survival mechanisms such as arteriogenesis. Therefore, these 
patients are at high risk for deleterious outcomes of PAD. Diabetes is a negative predictor 
of arteriogenesis with an undefined mechanism. In an attempt to gain insights into the 
mechanism by which diabetes inhibits arteriogenesis, we modeled Type II diabetes-
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related metabolic abnormalities in two mouse strains fed either a control diet or a 
Western diet for six months. In order to better mimic clinical PAD, we performed gradual 
femoral artery occlusion in these animals. We then characterized the temporal expression 
pattern of arteriogenic growth factors in skeletal muscle in the thigh region, where 
arteriogenesis primarily occurs in this model. Coordinated temporal regulation of 
arteriogenic growth factors is essential in order for arteriogenesis to proceed. Here we 
present data showing that the normal response of PLGF, VEGF-A, VEGFR1, and MCP-
1to vascular occlusion is hampered by Western diet-induced metabolic abnormalities in 
mice. 
Gradual femoral artery occlusion using ameroid constrictors is novel in small 
animals and is a superior model system in which to study arteriogenesis compared to 
acute ligation, which often includes excision of the femoral artery and all of its branches, 
resulting in sudden severe ischemia (40). The method has been mainly limited to larger 
animal models due to technical difficulty in implementing it in small animals (41-43). We 
assessed the growth factor response in the thigh region because this is the primary site at 
which arteriogenesis occurs in hindlimb ischemia. The thigh region contains pre-existing 
collateral roots in the medial thigh, quadriceps femoris and biceps femoris muscles (44). 
Furthermore, we believe that the use of long term Western diet feeding to induce 
metabolic abnormalities is more physiologically relevant than use of pancreatic toxins 
(which mimic Type I diabetes) or genetic models of Type II diabetes, where diverse 
transcript signature profiles have been reported (45) according to the specific genetic 
background. Therefore, the outcomes of this study are highly relevant to the clinical 
pathology of PAD. 
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Chronic occlusion of the femoral artery alters the pressure gradient across 
preexisting collateral roots, leading to an increase in shear stress through these small 
vessels. Existing evidence suggests that increased shear stress is a key trigger for these 
small collaterals to undergo arteriogenesis to become functional arteries. The ameroid 
constrictors that we used to occlude the femoral artery in this study are known to close 
and thereby create maximum shear stress in collaterals by 7 dps. Other studies in our 
laboratory have revealed that PLGF is sensitive to shear stress, and increases with 
increasing shear stress in vitro (Rashdan and Lloyd, submitted). Therefore, the elevated 
PLGF expression we observed one week following ameroid placement in our model is 
consistent with other results from our laboratory. 
Although a detailed investigation of the effect of experimental PAD on PLGF 
expression has not been conducted prior to this study to our knowledge, previous reports 
which studied genomic expression profiles using microarrays suggested that PLGF is an 
early responding growth factor in an acute femoral artery occlusion model, consistent 
with our findings (46;47).  
Regional shear stress changes secondary to femoral artery occlusion have been 
studied using laser trans-illumination techniques (48). Shear stress dependent regulation 
of vascular growth factor expression has been studied for many factors including VEGF 
(49;50), PLGF (51), PDGF (52;53), and FGF (54). However, compelling evidence 
suggest that hypercholesterolemia alters shear stress sensing (55;56). Our finding that 
PLGF expression negatively correlates with hypercholesterolemia (r = - 0.45, p =0.07) is 
therefore consistent with potentially altered shear stress responses due to differential 
degrees of hypercholesterolemia in C57-WD, ApoE-CD and ApoE-WD.  
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VEGF-A expression is also elevated in C57-CD. However, it was delayed 
compared to PLGF. Previous studies which measured HIF-1 alpha, a hypoxia inducible 
transcription factor which is a key regulator of VEGF-A expression, showed that HIF-1 
was not activated in adductor muscles at early time points after femoral artery ligation 
(46). It agreement with this result, is well accepted that the thigh region does not become 
hypoxic following femoral artery occlusion.  This lack of hypoxia-inducible gene 
expression could partly explain the delayed response of VEGF-A compared to PLGF in 
our model. However, it contradicts other reported findings showing that VEGF-A is not 
induced in adductor muscles of a rabbit hindlimb ischemia model (57). As we reported in 
chapter 3, basal VEGF-A expression was increased in the C57-WD group, as previously 
reported by others (58). However, VEGF signaling was shown to be reduced as detected 
by reduced activation of key signaling intermediators in diabetes despite elevated protein 
levels (59).     
Reduced PLGF expression in diabetes has previously been reported in diabetic 
wounds in mice and is associated with impaired wound healing due to reduced 
neovascularization, which can be reversed by PLGF supplementation (60).  In another 
study, reduced collateralization in respond to hindlimb ischemia in diabetic mice was 
overcome by PLGF infusion (61). Both these studies were performed in streptozotocin 
treated mice, which represents type 1 diabetes. Growth factor deficiency has been linked 
to reduced collateral growth in and single growth factor supplementation has produced 
mixed results in clinical studies, reviewed in (62). 
The role of MCP-1 in ischemia induced arteriogenesis has been widely studied 
and known to be associated with attraction and localization of monocytes to the sites of 
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arteriogenesis (17) (63). Skeletal muscles of insulin receptor deficient mice elevated 
MCP-1 gene expression along with other inflammatory markers (64).  Humans with type 
2 diabetes and high fat fed mice have elevated circulating MCP-1(65). Elevated MCP-1 
levels in diabetes were attributed to increased baseline inflammatory state. This is 
accordance with C57-WD groups showing sharp upregulation of MCP-1 following 
ameroid placement similar to C57-CD. However, MCP-1 treatment increased collateral 
remodeling response which otherwise depressed in diabetic hindlimb ischemia models 
(17). Further, experiments are needed to determine the effect of increased MCP-1 on 
arteriogenesis of C57-WD.  
Arteriogenesis is a vital source for perfusion recovery in response to femoral 
artery ligation and takes up to 2-4 weeks depending on the animal model and the type of 
surgical occlusion. Higher perfusion recovery in normal C57BL/6J mice have been 
previously reported while ApoE -/- demonstrated worst perfusion recovery attributed to 
hypercholesterolemia (66). In our study ApoE-CD and ApoE-WD demonstrated 
hypercholesterolemia associated impaired growth factor response of PLGF, VEGF, 
VEGFR1 and MCP-1 which further explains the mechanism of inhibited arteriogenesis 
and thereby reduced flow recovery.  
 In contrast to hypercholesterolemia, impaired glucose tolerance (as seen in C57-
WD) considered least inhibitory for perfusion recovery following hindlimb ischemia 
(67). This is in accordance with our findings that C57-WD animals showing least affected 
perfusion recovery. The observation can be explained in part by our finding that C57-WD 
animals demonstrating partially reduced and delayed PLGF protein expression while 
intact MCP-1 response to femoral artery occlusion.      
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Our experiments shows that diet induced metabolic derangements negatively 
affect PLGF protein induction in the presence of gradual narrowing of femoral artery. 
Perfusion recovery was impaired in all the metabolic groups with abnormal PLGF 
response to femoral artery occlusion. To our knowledge, in depth assessment of the 
temporal regulation of PLGF levels in response to gradual femoral occlusion in diabetic 
conditions has not been reported previously. Our findings show that PLGF is abnormally 
regulated in the setting of Western diet induced metabolic dysfunction, suggesting that 
impaired PLGF production may contribute to the limited ability of diabetics with PAD to 
undergo arteriogenesis. 
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Chapter 2 and 3 
Analyses of variance were conducted on the end point data.  The program 
arranged these in groups by how the data were missing, so the order of the 
response variables is a bit different from what was on the spreadsheet.  For 
each response variable, I’ve printed out the ANOVA table.  Note that ordinarily 
we look at interactions to determine whether to analyze simple effects or main 
effects.  More than half the time, it appears that simple effects are the 
proper analysis (enough interactions significant), therefore I analyzed simple 
effects for all response variables in an effort to remain consistent.                                     
 
                               Class Level Information 
 
                      Class         Levels    Values 
 
                      Strain             2    ApoE-/- C57BL/6J 
 
                      Gender             2    F M 
 
                      Diet               2    HF LF 
 
 
 
Dependent Variable: Chol 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     7493907.347     7493907.347    5713.32    
<.0001 
 Gender                       1        5736.524        5736.524       4.37    
0.0411 
 Strain*Gender                1       15478.558       15478.558      11.80    
0.0011 
 Diet                         1     2439412.702     2439412.702    1859.80    
<.0001 
 Strain*Diet                  1      598000.074      598000.074     455.91    
<.0001 
 Gender*Diet                  1          23.222          23.222       0.02    
0.8946 
 Strain*Gender*Diet           1        8403.724        8403.724       6.41    
0.0143 
 
                                   
 
Dependent Variable: Isopro8 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     910951.8122     910951.8122     287.09    
<.0001 
 Gender                       1        272.3414        272.3414       0.09    
0.7706 
 Strain*Gender                1      50103.0656      50103.0656      15.79    
0.0002 
 Diet                         1     630181.3185     630181.3185     198.61    
<.0001 
 Strain*Diet                  1      17798.9767      17798.9767       5.61    
0.0214 
 Gender*Diet                  1        625.2371        625.2371       0.20    
0.6589 
 Strain*Gender*Diet           1      16152.2839      16152.2839       5.09    
0.0281 
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Dependent Variable: Glucose0 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1        27.70842        27.70842       0.06    
0.8151 
 Gender                       1      1793.35951      1793.35951       3.57    
0.0640 
 Strain*Gender                1      1740.84910      1740.84910       3.47    
0.0679 
 Diet                         1     19470.31277     19470.31277      38.78    
<.0001 
 Strain*Diet                  1       296.83674       296.83674       0.59    
0.4452 
 Gender*Diet                  1      1002.02404      1002.02404       2.00    
0.1634 
 Strain*Gender*Diet           1      1744.61887      1744.61887       3.48    
0.0676 
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Dependent Variable: Glucose15 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1      26411.7433      26411.7433       5.58    
0.0217 
 Gender                       1         74.0925         74.0925       0.02    
0.9009 
 Strain*Gender                1        676.0365        676.0365       0.14    
0.7069 
 Diet                         1     189854.6474     189854.6474      40.12    
<.0001 
 Strain*Diet                  1     147492.5343     147492.5343      31.17    
<.0001 
 Gender*Diet                  1       2473.2149       2473.2149       0.52    
0.4728 
 Strain*Gender*Diet           1         79.1641         79.1641       0.02    
0.8976 
 
                                   
 
Dependent Variable: Glucose30 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1      87749.2928      87749.2928      28.49    
<.0001 
 Gender                       1       1815.6722       1815.6722       0.59    
0.4459 
 Strain*Gender                1        610.5719        610.5719       0.20    
0.6579 
 Diet                         1     268534.8540     268534.8540      87.20    
<.0001 
 Strain*Diet                  1      27279.8568      27279.8568       8.86    
0.0043 
 Gender*Diet                  1       1125.6268       1125.6268       0.37    
0.5480 
 Strain*Gender*Diet           1      19413.8618      19413.8618       6.30    
0.0150 
 
                                   
 
Dependent Variable: Glucose60 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     205139.6845     205139.6845      70.35    
<.0001 
 Gender                       1       1550.1136       1550.1136       0.53    
0.4690 
 Strain*Gender                1        856.0077        856.0077       0.29    
0.5901 
 Diet                         1     322438.9577     322438.9577     110.57    
<.0001 
 Strain*Diet                  1     120567.4633     120567.4633      41.34    
<.0001 
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 Gender*Diet                  1        285.7787        285.7787       0.10    
0.7554 
 Strain*Gender*Diet           1      44773.3002      44773.3002      15.35    
0.0002 
 
                                   
 
Dependent Variable: Glucose120 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     164625.9383     164625.9383      53.50    
<.0001 
 Gender                       1       1077.4021       1077.4021       0.35    
0.5565 
 Strain*Gender                1      16091.2283      16091.2283       5.23    
0.0261 
 Diet                         1     237831.1830     237831.1830      77.28    
<.0001 
 Strain*Diet                  1     139445.6629     139445.6629      45.31    
<.0001 
 Gender*Diet                  1      28549.5091      28549.5091       9.28    
0.0036 
 Strain*Gender*Diet           1      31003.2212      31003.2212      10.07    
0.0025 
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Dependent Variable: AUC 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1       768911981       768911981      50.21    
<.0001 
 Gender                       1          300063          300063       0.02    
0.8892 
 Strain*Gender                1         5280489         5280489       0.34    
0.5595 
 Diet                         1      1723096927      1723096927     112.51    
<.0001 
 Strain*Diet                  1       602746639       602746639      39.36    
<.0001 
 Gender*Diet                  1        21229323        21229323       1.39    
0.2441 
 Strain*Gender*Diet           1       137859634       137859634       9.00    
0.0040 
 
                                   
 
Dependent Variable: HOMAIR 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1      1570.64506      1570.64506      18.06    
<.0001 
 Gender                       1        32.29587        32.29587       0.37    
0.5448 
 Strain*Gender                1       209.61547       209.61547       2.41    
0.1263 
 Diet                         1     33005.61337     33005.61337     379.53    
<.0001 
 Strain*Diet                  1       283.19051       283.19051       3.26    
0.0766 
 Gender*Diet                  1        23.02020        23.02020       0.26    
0.6090 
 Strain*Gender*Diet           1       234.43498       234.43498       2.70    
0.1063 
 
                                   
 
Dependent Variable: PLGFHeart 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     6071.644971     6071.644971     339.68    
<.0001 
 Gender                       1        0.000151        0.000151       0.00    
0.9977 
 Strain*Gender                1       13.310404       13.310404       0.74    
0.3919 
 Diet                         1     5272.125335     5272.125335     294.95    
<.0001 
 Strain*Diet                  1       19.387357       19.387357       1.08    
0.3022 
 Gender*Diet                  1        7.356431        7.356431       0.41    
0.5238 
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 Strain*Gender*Diet           1        3.935696        3.935696       0.22    
0.6408 
 
 
 
Dependent Variable: PLGFMT 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1      661.537373      661.537373      17.07    
0.0001 
 Gender                       1       86.001192       86.001192       2.22    
0.1420 
 Strain*Gender                1       69.528523       69.528523       1.79    
0.1860 
 Diet                         1     2279.109316     2279.109316      58.80    
<.0001 
 Strain*Diet                  1      263.592029      263.592029       6.80    
0.0117 
 Gender*Diet                  1      183.582693      183.582693       4.74    
0.0338 
 Strain*Gender*Diet           1        6.550808        6.550808       0.17    
0.6826 
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Dependent Variable: VEGFHeart 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     38519.87626     38519.87626       6.12    
0.0165 
 Gender                       1      2996.30731      2996.30731       0.48    
0.4931 
 Strain*Gender                1      1829.04804      1829.04804       0.29    
0.5920 
 Diet                         1      5177.60821      5177.60821       0.82    
0.3684 
 Strain*Diet                  1      2833.59446      2833.59446       0.45    
0.5051 
 Gender*Diet                  1         4.35101         4.35101       0.00    
0.9791 
 Strain*Gender*Diet           1     12960.62614     12960.62614       2.06    
0.1570 
 
 
Here are the least square means for each response variable for every 
combination of strain, gender and diet.  
                                  
                                               Isopro8       Glucose0      
Glucose15 
Strain     Gender   Diet    Chol LSMEAN         LSMEAN         LSMEAN         
LSMEAN 
 
ApoE-/-    F        HF       1242.73333     574.283333     158.000000     
379.666667 
ApoE-/-    F        LF        604.13333     302.883333     119.333333     
350.583333 
ApoE-/-    M        HF       1207.00000     492.700000     138.500000     
373.333333 
ApoE-/-    M        LF        614.20000     275.133333      94.500000     
375.166667 
C57BL/6J   F        HF        260.08571     194.928571     154.857143     
528.285714 
C57BL/6J   F        LF         77.61250      60.900000     103.250000     
301.375000 
C57BL/6J   M        HF        338.30000     298.400000     135.333333     
512.933333 
C57BL/6J   M        LF        104.94444      84.166667     122.444444     
307.555556 
 
                              Glucose30      Glucose60     Glucose120 
Strain     Gender   Diet         LSMEAN         LSMEAN         LSMEAN     AUC 
LSMEAN 
 
ApoE-/-    F        HF       388.666667     288.666667     151.833333     
27245.0000 
ApoE-/-    F        LF       341.166667     281.833333     123.583333     
24654.3750 
ApoE-/-    M        HF       452.000000     337.333333     178.500000     
29876.2500 
ApoE-/-    M        LF       313.333333     227.833333     146.500000     
23523.7500 
C57BL/6J   F        HF       553.571429     563.142857     437.142857     
44731.0714 
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C57BL/6J   F        LF       345.500000     261.625000     119.125000     
23002.5000 
C57BL/6J   M        HF       530.400000     484.800000     304.066667     
39959.0000 
C57BL/6J   M        LF       378.111111     303.777778     168.000000     
26851.6667 
 
                                 HOMAIR      PLGFHeart         PLGFMT      
VEGFHeart 
Strain     Gender   Diet         LSMEAN         LSMEAN         LSMEAN         
LSMEAN 
 
ApoE-/-    F        HF       42.6581733     12.5100353     20.8402415     
369.950258 
ApoE-/-    F        LF        4.4961977     31.7318010     34.8106831     
404.353942 
ApoE-/-    M        HF       53.2760010     14.7069360     18.1892269     
425.125895 
ApoE-/-    M        LF        4.5098664     31.4522967     37.9549114     
400.595953 
C57BL/6J   F        HF       65.3989540     33.3790243     16.8157298     
448.956047 
C57BL/6J   F        LF       10.2888841     53.8765289     20.8750461     
451.396646 
C57BL/6J   M        HF       60.3079949     32.6059043     17.2121057     
421.545644 
C57BL/6J   M        LF       10.7419053     52.7192948     29.7660119     
485.119786 
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Here are the tests of simple effects.  As an example, the p-value of 0.0931 
refers to the comparison of cholesterol means of the two genders (M v. F) for 
strain = ApoE-/- and diet = HF.  There are four comparisons of gender, one for 
each combination of strain and diet.  Note that the only comparison that was 
significant was the C57BL/6J and the HF combination. 
 
                                   
 
              Strain*Gender*Diet Effect Sliced by Strain*Diet for Chol 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1     3830.613333     3830.613333       2.92    
0.0931 
   ApoE-/-     LF           1      304.013333      304.013333       0.23    
0.6321 
   C57BL/6J    HF           1           29197           29197      22.26    
<.0001 
   C57BL/6J    LF           1     3163.913734     3163.913734       2.41    
0.1261 
 
 
Here are the comparisons of diet (HF v. LF) for each combination of strain and 
gender: 
 
             Strain*Gender*Diet Effect Sliced by Strain*Gender for Chol 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1         1223430         1223430     932.74    
<.0001 
  ApoE-/-     M              1         1054236         1054236     803.74    
<.0001 
  C57BL/6J    F              1          124307          124307      94.77    
<.0001 
  C57BL/6J    M              1          306308          306308     233.53    
<.0001 
 
 
Here are the comparisons of strain for each combination of diet and gender: 
 
              Strain*Gender*Diet Effect Sliced by Gender*Diet for Chol 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1         3119619         3119619    2378.38    
<.0001 
    F         LF           1          950483          950483     724.64    
<.0001 
    M         HF           1         3234170         3234170    2465.72    
<.0001 
    M         LF           1          933628          933628     711.79    
<.0001 
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             Strain*Gender*Diet Effect Sliced by Strain*Diet for Isopro8 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1           19968           19968       6.29    
0.0151 
   ApoE-/-     LF           1     2310.187500     2310.187500       0.73    
0.3972 
   C57BL/6J    HF           1           51098           51098      16.10    
0.0002 
   C57BL/6J    LF           1     2292.724706     2292.724706       0.72    
0.3990 
 
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for Isopro8 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1          220974          220974      69.64    
<.0001 
  ApoE-/-     M              1          142006          142006      44.75    
<.0001 
  C57BL/6J    F              1           67064           67064      21.14    
<.0001 
  C57BL/6J    M              1          258165          258165      81.36    
<.0001 
 
 
                                   
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for Isopro8 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          464940          464940     146.53    
<.0001 
    F         LF           1          200763          200763      63.27    
<.0001 
    M         HF           1          161796          161796      50.99    
<.0001 
    M         LF           1          131286          131286      41.38    
<.0001 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for Glucose0 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1     1140.750000     1140.750000       2.27    
0.1374 
   ApoE-/-     LF           1     1850.083333     1850.083333       3.69    
0.0601 
   C57BL/6J    HF           1     1819.264069     1819.264069       3.62    
0.0622 
   C57BL/6J    LF           1     1560.395425     1560.395425       3.11    
0.0835 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for Glucose0 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     4485.333333     4485.333333       8.93    
0.0042 
  ApoE-/-     M              1     5808.000000     5808.000000      11.57    
0.0013 
  C57BL/6J    F              1     9942.976190     9942.976190      19.81    
<.0001 
  C57BL/6J    M              1      934.444444      934.444444       1.86    
0.1780 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for Glucose0 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1       31.912088       31.912088       0.06    
0.8019 
    F         LF           1      886.880952      886.880952       1.77    
0.1893 
    M         HF           1       42.976190       42.976190       0.09    
0.7709 
    M         LF           1     2811.211111     2811.211111       5.60    
0.0215 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for Glucose15 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1      120.333333      120.333333       0.03    
0.8739 
   ApoE-/-     LF           1     1813.020833     1813.020833       0.38    
0.5385 
   C57BL/6J    HF           1     1124.910823     1124.910823       0.24    
0.6278 
   C57BL/6J    LF           1      161.785131      161.785131       0.03    
0.8540 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for Glucose15 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     2537.520833     2537.520833       0.54    
0.4671 
  ApoE-/-     M              1       10.083333       10.083333       0.00    
0.9633 
  C57BL/6J    F              1          192224          192224      40.62    
<.0001 
  C57BL/6J    M              1          237263          237263      50.14    
<.0001 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for Glucose15 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1           71360           71360      15.08    
0.0003 
    F         LF           1     8302.148810     8302.148810       1.75    
0.1908 
    M         HF           1           83521           83521      17.65    
<.0001 
    M         LF           1           16457           16457       3.48    
0.0675 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for Glucose30 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1           12033           12033       3.91    
0.0531 
   ApoE-/-     LF           1     2324.083333     2324.083333       0.75    
0.3888 
   C57BL/6J    HF           1     2562.549351     2562.549351       0.83    
0.3657 
   C57BL/6J    LF           1     4504.169935     4504.169935       1.46    
0.2317 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for Glucose30 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     6768.750000     6768.750000       2.20    
0.1439 
  ApoE-/-     M              1           57685           57685      18.73    
<.0001 
  C57BL/6J    F              1          161630          161630      52.48    
<.0001 
  C57BL/6J    M              1          130454          130454      42.36    
<.0001 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for Glucose30 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1           87856           87856      28.53    
<.0001 
    F         LF           1       64.380952       64.380952       0.02    
0.8856 
    M         HF           1           26342           26342       8.55    
0.0050 
    M         LF           1           15106           15106       4.91    
0.0309 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for Glucose60 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1     7105.333333     7105.333333       2.44    
0.1243 
   ApoE-/-     LF           1     8748.000000     8748.000000       3.00    
0.0889 
   C57BL/6J    HF           1           29293           29293      10.05    
0.0025 
   C57BL/6J    LF           1     7525.510621     7525.510621       2.58    
0.1139 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for Glucose60 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1      140.083333      140.083333       0.05    
0.8273 
  ApoE-/-     M              1           35971           35971      12.33    
0.0009 
  C57BL/6J    F              1          339409          339409     116.39    
<.0001 
  C57BL/6J    M              1          184326          184326      63.21    
<.0001 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for Glucose60 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          243397          243397      83.46    
<.0001 
    F         LF           1     1400.148810     1400.148810       0.48    
0.4913 
    M         HF           1           93199           93199      31.96    
<.0001 
    M         LF           1           20763           20763       7.12    
0.0100 
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           Strain*Gender*Diet Effect Sliced by Strain*Diet for Glucose120 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1     2133.333333     2133.333333       0.69    
0.4087 
   ApoE-/-     LF           1     1575.520833     1575.520833       0.51    
0.4773 
   C57BL/6J    HF           1           84522           84522      27.47    
<.0001 
   C57BL/6J    LF           1           10117           10117       3.29    
0.0753 
 
 
                                   
                                  
 
          Strain*Gender*Diet Effect Sliced by Strain*Gender for Glucose120 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     2394.187500     2394.187500       0.78    
0.3816 
  ApoE-/-     M              1     3072.000000     3072.000000       1.00    
0.3221 
  C57BL/6J    F              1          377572          377572     122.69    
<.0001 
  C57BL/6J    M              1          104142          104142      33.84    
<.0001 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Gender*Diet for Glucose120 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          262990          262990      85.46    
<.0001 
    F         LF           1       68.148810       68.148810       0.02    
0.8822 
    M         HF           1           67573           67573      21.96    
<.0001 
    M         LF           1     1664.100000     1664.100000       0.54    
0.4652 
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               Strain*Gender*Diet Effect Sliced by Strain*Diet for AUC 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1        20770430        20770430       1.36    
0.2492 
   ApoE-/-     LF           1         3834939         3834939       0.25    
0.6188 
   C57BL/6J    HF           1       108687723       108687723       7.10    
0.0101 
   C57BL/6J    LF           1        62750474        62750474       4.10    
0.0478 
 
 
                                   
                                  
 
              Strain*Gender*Diet Effect Sliced by Strain*Gender for AUC 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1        20134014        20134014       1.31    
0.2565 
  ApoE-/-     M              1       121062769       121062769       7.91    
0.0068 
  C57BL/6J    F              1      1762621714      1762621714     115.10    
<.0001 
  C57BL/6J    M              1       966387303       966387303      63.10    
<.0001 
 
 
                                   
                                  
 
               Strain*Gender*Diet Effect Sliced by Gender*Diet for AUC 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1       987848704       987848704      64.50    
<.0001 
    F         LF           1         9355512         9355512       0.61    
0.4378 
    M         HF           1       435693632       435693632      28.45    
<.0001 
    M         LF           1        39870106        39870106       2.60    
0.1124 
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             Strain*Gender*Diet Effect Sliced by Strain*Diet for HOMAIR 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1      338.214793      338.214793       3.89    
0.0536 
   ApoE-/-     LF           1        0.000560        0.000560       0.00    
0.9980 
   C57BL/6J    HF           1      123.698900      123.698900       1.42    
0.2381 
   C57BL/6J    LF           1        0.869202        0.869202       0.01    
0.9207 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for HOMAIR 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     4369.009150     4369.009150      50.24    
<.0001 
  ApoE-/-     M              1     7134.407647     7134.407647      82.04    
<.0001 
  C57BL/6J    F              1           11339           11339     130.38    
<.0001 
  C57BL/6J    M              1           13819           13819     158.91    
<.0001 
 
 
                                   
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for HOMAIR 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1     1670.770029     1670.770029      19.21    
<.0001 
    F         LF           1      115.046455      115.046455       1.32    
0.2550 
    M         HF           1      211.924019      211.924019       2.44    
0.1242 
    M         LF           1      139.817911      139.817911       1.61    
0.2101 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for PLGFHeart 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1       14.479118       14.479118       0.81    
0.3720 
   ApoE-/-     LF           1        0.234368        0.234368       0.01    
0.9093 
   C57BL/6J    HF           1        2.852729        2.852729       0.16    
0.6911 
   C57BL/6J    LF           1        5.671867        5.671867       0.32    
0.5755 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for PLGFHeart 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     1108.428828     1108.428828      62.01    
<.0001 
  ApoE-/-     M              1      841.221315      841.221315      47.06    
<.0001 
  C57BL/6J    F              1     1568.551395     1568.551395      87.75    
<.0001 
  C57BL/6J    M              1     2275.585190     2275.585190     127.31    
<.0001 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for PLGFHeart 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1     1407.047495     1407.047495      78.72    
<.0001 
    F         LF           1     1681.333625     1681.333625      94.06    
<.0001 
    M         HF           1     1373.027422     1373.027422      76.82    
<.0001 
    M         LF           1     1628.226748     1628.226748      91.09    
<.0001 
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             Strain*Gender*Diet Effect Sliced by Strain*Diet for PLGFMT 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1       21.083636       21.083636       0.54    
0.4639 
   ApoE-/-     LF           1       29.658515       29.658515       0.77    
0.3855 
   C57BL/6J    HF           1        0.749862        0.749862       0.02    
0.8899 
   C57BL/6J    LF           1      334.796916      334.796916       8.64    
0.0048 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for PLGFMT 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1      585.519718      585.519718      15.11    
0.0003 
  ApoE-/-     M              1     1172.046859     1172.046859      30.24    
<.0001 
  C57BL/6J    F              1       61.518049       61.518049       1.59    
0.2130 
  C57BL/6J    M              1      886.503149      886.503149      22.87    
<.0001 
 
 
                                   
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for PLGFMT 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1       52.327782       52.327782       1.35    
0.2503 
    F         LF           1      665.835357      665.835357      17.18    
0.0001 
    M         HF           1        4.091853        4.091853       0.11    
0.7465 
    M         LF           1      241.409075      241.409075       6.23    
0.0156 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFHeart 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1     9133.052806     9133.052806       1.45    
0.2335 
   ApoE-/-     LF           1       42.367440       42.367440       0.01    
0.9349 
   C57BL/6J    HF           1     3585.894102     3585.894102       0.57    
0.4536 
   C57BL/6J    LF           1     4816.588916     4816.588916       0.77    
0.3855 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFHeart 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     3550.840474     3550.840474       0.56    
0.4558 
  ApoE-/-     M              1     1805.154119     1805.154119       0.29    
0.5945 
  C57BL/6J    F              1       22.237682       22.237682       0.00    
0.9528 
  C57BL/6J    M              1           22734           22734       3.61    
0.0626 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFHeart 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1           20166           20166       3.20    
0.0790 
    F         LF           1     7587.483453     7587.483453       1.21    
0.2770 
    M         HF           1       54.935116       54.935116       0.01    
0.9259 
    M         LF           1           25719           25719       4.09    
0.0481 
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Here the analysis is performed for some of the response variable that had 
missing values and the program performed the analysis in an order determined by 
data structure. 
 
Dependent Variable: Triglyc 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     1279517.781     1279517.781     325.81    
<.0001 
 Gender                       1       78903.211       78903.211      20.09    
<.0001 
 Strain*Gender                1       41093.181       41093.181      10.46    
0.0028 
 Diet                         1      358849.712      358849.712      91.38    
<.0001 
 Strain*Diet                  1      308158.210      308158.210      78.47    
<.0001 
 Gender*Diet                  1         306.298         306.298       0.08    
0.7818 
 Strain*Gender*Diet           1         989.463         989.463       0.25    
0.6191 
 
                                 
 
                                                        Triglyc 
                     Strain      Gender    Diet          LSMEAN 
 
                     ApoE-/-     F         HF        733.305000 
                     ApoE-/-     F         LF        365.305000 
                     ApoE-/-     M         HF        581.723750 
                     ApoE-/-     M         LF        204.716250 
                     C57BL/6J    F         HF        133.787667 
                     C57BL/6J    F         LF        103.811500 
                     C57BL/6J    M         HF         92.753500 
                     C57BL/6J    M         LF         94.379000 
 
 
  
211 
 
 
 
             Strain*Gender*Diet Effect Sliced by Strain*Diet for Triglyc 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1           45954           45954      11.70    
0.0017 
   ApoE-/-     LF           1           51577           51577      13.13    
0.0010 
   C57BL/6J    HF           1     5051.408502     5051.408502       1.29    
0.2652 
   C57BL/6J    LF           1      266.916169      266.916169       0.07    
0.7960 
 
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for Triglyc 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1          270848          270848      68.97    
<.0001 
  ApoE-/-     M              1          284269          284269      72.38    
<.0001 
  C57BL/6J    F              1     2695.711704     2695.711704       0.69    
0.4135 
  C57BL/6J    M              1        7.926751        7.926751       0.00    
0.9644 
 
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for Triglyc 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          862610          862610     219.65    
<.0001 
    F         LF           1          164109          164109      41.79    
<.0001 
    M         HF           1          573821          573821     146.11    
<.0001 
    M         LF           1           29218           29218       7.44    
0.0103 
  
212 
 
 
Dependent Variable: Insulin 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1      24.1665693      24.1665693      28.80    
<.0001 
 Gender                       1       0.0805987       0.0805987       0.10    
0.7578 
 Strain*Gender                1       0.0000966       0.0000966       0.00    
0.9915 
 Diet                         1     381.5973755     381.5973755     454.71    
<.0001 
 Strain*Diet                  1       3.3044508       3.3044508       3.94    
0.0523 
 Gender*Diet                  1       1.4860639       1.4860639       1.77    
0.1889 
 Strain*Gender*Diet           1       0.0000332       0.0000332       0.00    
0.9950 
 
 
                                                        Insulin 
                     Strain      Gender    Diet          LSMEAN 
 
                     ApoE-/-     F         HF        5.15116667 
                     ApoE-/-     F         LF        0.79050000 
                     ApoE-/-     M         HF        5.54416667 
                     ApoE-/-     M         LF        0.54233333 
                     C57BL/6J    F         HF        6.92629714 
                     C57BL/6J    F         LF        1.60803875 
                     C57BL/6J    M         HF        7.32753571 
                     C57BL/6J    M         LF        1.36202333 
 
 
 
             Strain*Gender*Diet Effect Sliced by Strain*Diet for Insulin 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1        0.463347        0.463347       0.55    
0.4607 
   ApoE-/-     LF           1        0.184760        0.184760       0.22    
0.6408 
   C57BL/6J    HF           1        0.751298        0.751298       0.90    
0.3483 
   C57BL/6J    LF           1        0.256335        0.256335       0.31    
0.5828 
 
 
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for Insulin 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1       57.046241       57.046241      67.98    
<.0001 
  ApoE-/-     M              1       75.055010       75.055010      89.44    
<.0001 
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  C57BL/6J    F              1      105.593123      105.593123     125.82    
<.0001 
  C57BL/6J    M              1      194.956721      194.956721     232.31    
<.0001 
 
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for Insulin 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1       10.180439       10.180439      12.13    
0.0010 
    F         LF           1        2.291553        2.291553       2.73    
0.1042 
    M         HF           1       13.357702       13.357702      15.92    
0.0002 
    M         LF           1        2.418810        2.418810       2.88    
0.0953 
 
 
                                   
 
Dependent Variable: PLGFGPS 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1       84.245441       84.245441       2.33    
0.1353 
 Gender                       1      105.860103      105.860103       2.93    
0.0954 
 Strain*Gender                1      241.365591      241.365591       6.68    
0.0138 
 Diet                         1     1455.789675     1455.789675      40.28    
<.0001 
 Strain*Diet                  1      114.114857      114.114857       3.16    
0.0838 
 Gender*Diet                  1      153.239749      153.239749       4.24    
0.0466 
 Strain*Gender*Diet           1      506.100276      506.100276      14.00    
0.0006 
 
 
 
Dependent Variable: VEGFGPS 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     1719.821577     1719.821577      10.26    
0.0028 
 Gender                       1     1614.628254     1614.628254       9.63    
0.0037 
 Strain*Gender                1      822.862242      822.862242       4.91    
0.0330 
 Diet                         1     4217.998697     4217.998697      25.16    
<.0001 
 Strain*Diet                  1        1.634335        1.634335       0.01    
0.9219 
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 Gender*Diet                  1       56.068177       56.068177       0.33    
0.5666 
 Strain*Gender*Diet           1       18.736558       18.736558       0.11    
0.7400 
 
 
 
                                                PLGFGPS         VEGFGPS 
             Strain      Gender    Diet          LSMEAN          LSMEAN 
 
             ApoE-/-     F         HF        11.3269904      53.0742181 
             ApoE-/-     F         LF        36.5279239      76.5676629 
             ApoE-/-     M         HF        14.0516715      35.8994214 
             ApoE-/-     M         LF        18.2546669      52.2784252 
             C57BL/6J    F         HF        13.8751880      33.6422992 
             C57BL/6J    F         LF        19.0996409      53.7598915 
             C57BL/6J    M         HF        12.4089562      31.1323589 
             C57BL/6J    M         LF        23.7250521      49.3478044 
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             Strain*Gender*Diet Effect Sliced by Strain*Diet for PLGFGPS 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1       20.246965       20.246965       0.56    
0.4589 
   ApoE-/-     LF           1      801.388614      801.388614      22.17    
<.0001 
   C57BL/6J    HF           1        6.449507        6.449507       0.18    
0.6752 
   C57BL/6J    LF           1       64.183284       64.183284       1.78    
0.1908 
 
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for PLGFGPS 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     1411.304549     1411.304549      39.04    
<.0001 
  ApoE-/-     M              1       52.995509       52.995509       1.47    
0.2336 
  C57BL/6J    F              1       81.884727       81.884727       2.27    
0.1408 
  C57BL/6J    M              1      384.162080      384.162080      10.63    
0.0024 
 
 
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for PLGFGPS 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1       17.709029       17.709029       0.49    
0.4883 
    F         LF           1      728.988111      728.988111      20.17    
<.0001 
    M         HF           1        8.095541        8.095541       0.22    
0.6388 
    M         LF           1       89.775343       89.775343       2.48    
0.1235 
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             Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFGPS 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1      804.473569      804.473569       4.80    
0.0349 
   ApoE-/-     LF           1     1415.920960     1415.920960       8.45    
0.0061 
   C57BL/6J    HF           1       18.899400       18.899400       0.11    
0.7389 
   C57BL/6J    LF           1       58.399539       58.399539       0.35    
0.5586 
 
 
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFGPS 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     1226.537662     1226.537662       7.32    
0.0103 
  ApoE-/-     M              1      804.815297      804.815297       4.80    
0.0348 
  C57BL/6J    F              1     1214.152571     1214.152571       7.24    
0.0106 
  C57BL/6J    M              1      995.407361      995.407361       5.94    
0.0198 
 
 
                                  
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFGPS 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1     1029.816750     1029.816750       6.14    
0.0179 
    F         LF           1     1248.466644     1248.466644       7.45    
0.0097 
    M         HF           1       68.174654       68.174654       0.41    
0.5276 
    M         LF           1       25.765615       25.765615       0.15    
0.6973 
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Dependent Variable: VEGFMT 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     10252.71548     10252.71548      74.95    
<.0001 
 Gender                       1       462.76395       462.76395       3.38    
0.0714 
 Strain*Gender                1         8.27591         8.27591       0.06    
0.8066 
 Diet                         1       672.18880       672.18880       4.91    
0.0309 
 Strain*Diet                  1     15815.90631     15815.90631     115.63    
<.0001 
 Gender*Diet                  1       282.42701       282.42701       2.06    
0.1565 
 Strain*Gender*Diet           1         2.91187         2.91187       0.02    
0.8845 
 
 
                                                         VEGFMT 
                     Strain      Gender    Diet          LSMEAN 
 
                     ApoE-/-     F         HF        55.0435995 
                     ApoE-/-     F         LF        90.4380726 
                     ApoE-/-     M         HF        45.1709166 
                     ApoE-/-     M         LF        90.4053364 
                     C57BL/6J    F         HF        61.8675642 
                     C57BL/6J    F         LF        31.3213305 
                     C57BL/6J    M         HF        51.3727788 
                     C57BL/6J    M         LF        28.8524134 
 
 
 
             Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFMT 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1      292.409606      292.409606       2.14    
0.1495 
   ApoE-/-     LF           1        0.003215        0.003215       0.00    
0.9961 
   C57BL/6J    HF           1      525.670664      525.670664       3.84    
0.0551 
   C57BL/6J    LF           1       24.001235       24.001235       0.18    
0.6770 
 
                                  
 
            Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFMT 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     3758.306175     3758.306175      27.48    
<.0001 
  ApoE-/-     M              1     6138.458220     6138.458220      44.88    
<.0001 
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  C57BL/6J    F              1     3265.753372     3265.753372      23.88    
<.0001 
  C57BL/6J    M              1     2852.813580     2852.813580      20.86    
<.0001 
 
                                
 
             Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFMT 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1      150.445596      150.445596       1.10    
0.2990 
    F         LF           1           11291           11291      82.54    
<.0001 
    M         HF           1      164.841837      164.841837       1.21    
0.2772 
    M         LF           1           13640           13640      99.72    
<.0001 
 
 
                                   
 
Dependent Variable: VEGFR1Heart 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     1813495.372     1813495.372      91.28    
<.0001 
 Gender                       1       18274.471       18274.471       0.92    
0.3418 
 Strain*Gender                1       29800.299       29800.299       1.50    
0.2260 
 Diet                         1        9118.308        9118.308       0.46    
0.5010 
 Strain*Diet                  1       54031.814       54031.814       2.72    
0.1049 
 Gender*Diet                  1        6878.961        6878.961       0.35    
0.5587 
 Strain*Gender*Diet           1        7861.981        7861.981       0.40    
0.5320 
 
                                  
 
Dependent Variable: VEGFR1MT 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     152724.9063     152724.9063      12.11    
0.0010 
 Gender                       1      98753.3635      98753.3635       7.83    
0.0071 
 Strain*Gender                1     105285.4412     105285.4412       8.35    
0.0055 
 Diet                         1     113629.7210     113629.7210       9.01    
0.0041 
 Strain*Diet                  1       2730.2569       2730.2569       0.22    
0.6436 
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 Gender*Diet                  1     204536.8782     204536.8782      16.22    
0.0002 
 Strain*Gender*Diet           1      37845.4243      37845.4243       3.00    
0.0889 
 
 
                                   
 
Dependent Variable: VEGFR1GPS 
 
 
 Source                      DF     Type III SS     Mean Square    F Value    
Pr > F 
 
 Strain                       1     129688.7160     129688.7160      39.41    
<.0001 
 Gender                       1      47302.0227      47302.0227      14.37    
0.0005 
 Strain*Gender                1      44289.0722      44289.0722      13.46    
0.0008 
 Diet                         1       3319.8747       3319.8747       1.01    
0.3217 
 Strain*Diet                  1      21077.6852      21077.6852       6.40    
0.0158 
 Gender*Diet                  1        133.0642        133.0642       0.04    
0.8417 
 Strain*Gender*Diet           1       1345.3012       1345.3012       0.41    
0.5265 
 
 
                                 Least Squares Means 
 
                                        PLGFGPS         VEGFGPS       VEGFR1GPS 
     Strain      Gender    Diet          LSMEAN          LSMEAN          LSMEAN 
 
     ApoE-/-     F         HF        11.3269904      53.0742181       86.054615 
     ApoE-/-     F         LF        36.5279239      76.5676629      132.591230 
     ApoE-/-     M         HF        14.0516715      35.8994214      200.367362 
     ApoE-/-     M         LF        18.2546669      52.2784252      275.932465 
     C57BL/6J    F         HF        13.8751880      33.6422992      290.483592 
     C57BL/6J    F         LF        19.0996409      53.7598915      271.692622 
     C57BL/6J    M         HF        12.4089562      31.1323589      300.172136 
     C57BL/6J    M         LF        23.7250521      49.3478044      266.243075 
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           Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFR1Heart 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1           20941           20941       1.05    
0.3092 
   ApoE-/-     LF           1           19439           19439       0.98    
0.3270 
   C57BL/6J    HF           1           13299           13299       0.67    
0.4169 
   C57BL/6J    LF           1     5413.130859     5413.130859       0.27    
0.6038 
 
 
 
          Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFR1Heart 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1           23716           23716       1.19    
0.2794 
  ApoE-/-     M              1           22116           22116       1.11    
0.2961 
  C57BL/6J    F              1           23180           23180       1.17    
0.2849 
  C57BL/6J    M              1      479.537285      479.537285       0.02    
0.8771 
 
 
 
           Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFR1Heart 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          154966          154966       7.80    
0.0072 
    F         LF           1          544230          544230      27.39    
<.0001 
    M         HF           1          575772          575772      28.98    
<.0001 
    M         LF           1          707006          707006      35.58    
<.0001 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFR1MT 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1          352032          352032      27.91    
<.0001 
   ApoE-/-     LF           1       13.869109       13.869109       0.00    
0.9737 
   C57BL/6J    HF           1           18640           18640       1.48    
0.2294 
   C57BL/6J    LF           1           21591           21591       1.71    
0.1963 
 
 
                                   
                                  
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFR1MT 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1          228696          228696      18.13    
<.0001 
  ApoE-/-     M              1           14120           14120       1.12    
0.2947 
  C57BL/6J    F              1           71665           71665       5.68    
0.0207 
  C57BL/6J    M              1      293.760038      293.760038       0.02    
0.8793 
 
 
                                   
                                  
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFR1MT 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          197167          197167      15.63    
0.0002 
    F         LF           1           53433           53433       4.24    
0.0444 
    M         HF           1     1756.060677     1756.060677       0.14    
0.7105 
    M         LF           1           11124           11124       0.88    
0.3518 
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            Strain*Gender*Diet Effect Sliced by Strain*Diet for VEGFR1GPS 
 
                                       Sum of 
   Strain      Diet        DF         Squares     Mean Square    F Value    Pr 
> F 
 
   ApoE-/-     HF           1           35638           35638      10.83    
0.0022 
   ApoE-/-     LF           1           49312           49312      14.98    
0.0004 
   C57BL/6J    HF           1      281.603664      281.603664       0.09    
0.7715 
   C57BL/6J    LF           1       89.092682       89.092682       0.03    
0.8702 
 
 
 
           Strain*Gender*Diet Effect Sliced by Strain*Gender for VEGFR1GPS 
 
                                        Sum of 
  Strain      Gender        DF         Squares     Mean Square    F Value    Pr 
> F 
 
  ApoE-/-     F              1     4812.569914     4812.569914       1.46    
0.2342 
  ApoE-/-     M              1           17130           17130       5.21    
0.0284 
  C57BL/6J    F              1     1059.301676     1059.301676       0.32    
0.5739 
  C57BL/6J    M              1     3453.543564     3453.543564       1.05    
0.3123 
 
 
 
 
 
 
 
            Strain*Gender*Diet Effect Sliced by Gender*Diet for VEGFR1GPS 
 
                                      Sum of 
    Gender    Diet        DF         Squares     Mean Square    F Value    Pr > 
F 
 
    F         HF           1          113976          113976      34.63    
<.0001 
    F         LF           1           46438           46438      14.11    
0.0006 
    M         HF           1           29883           29883       9.08    
0.0046 
    M         LF           1      281.652836      281.652836       0.09    
0.7715 
 
 
 
Obs MNGlucose0   MNGlucose15   MNGlucose30   MNGlucose60   MNGlucose120     
MNAUC 
 
 1    158.000      379.667       388.667       288.667        151.833     
27245.00 
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 2    119.333      350.583       341.167       281.833        123.583     
24654.38 
 3    138.500      373.333       452.000       337.333        178.500     
29876.25 
 4     94.500      375.167       313.333       227.833        146.500     
23523.75 
 5    154.857      528.286       553.571       563.143        437.143     
44731.07 
 6    103.250      301.375       345.500       261.625        119.125     
23002.50 
 7    135.333      512.933       530.400       484.800        304.067     
39959.00 
 
Obs MNHOMAIR  MNPLGFHeart  MNPLGFMT  MNPLGFGPS  MNVEGFHeart  MNVEGFMT  
MNVEGFGPS 
 
 1   42.6582    12.5100     20.8402   11.3270     369.950     55.0436   53.0742 
 2    4.4962    31.7318     34.8107   36.5279     404.354     90.4381   76.5677 
 3   53.2760    14.7069     18.1892   14.0517     425.126     45.1709   35.8994 
 4    4.5099    31.4523     37.9549   18.2547     400.596     90.4053   52.2784 
 5   65.3990    33.3790     16.8157   13.8752     448.956     61.8676   33.6423 
 6   10.2889    53.8765     20.8750   19.0996     451.397     31.3213   53.7599 
 7   60.3080    32.6059     17.2121   12.4090     421.546     51.3728   31.1324 
 
Obs MNVEGFR1Heart  MNVEGFR1MT  MNVEGFR1GPS   SEChol  SEIsopro8  SETriglyc  
SEInsulin 
 
 1      789.07       689.259      86.055    14.8956   50.0993    85.9041    
0.33481 
 2      700.16       413.158     132.591    15.4925   26.7278    18.5688    
0.05668 
 3      705.52       346.704     200.367    16.6961   17.5774    15.9382    
0.44533 
 4      619.67       415.308     275.932     9.2747   21.3873    35.9609    
0.02338 
 5     1016.35       432.896     290.484    19.2615   14.0688    12.2726    
0.78329 
 6     1098.58       288.320     271.693     5.3626    5.8541    11.2258    
0.06057 
 7     1072.06       366.946     300.172    10.9187   13.0943    10.7439    
0.23215 
 
Obs SEGlucose0   SEGlucose15   SEGlucose30   SEGlucose60   SEGlucose120    
SEAUC 
 
 1     6.9138      53.1304       44.8313       37.9857        15.3045     
2806.28 
 2     4.6380      11.4720       17.0087       21.5877         2.4847     
1077.94 
 3    11.1796      36.0506       19.7653       14.5434        13.5173     
1161.49 
 4     6.9988      19.4052       24.8860       16.1068         8.1271     
1343.99 
 5     8.5730      34.5768       24.8489       18.8129        52.8044     
2316.71 
 6     8.6968      27.5557       10.0410       10.9690         9.2359      
889.86 
 7     4.3256       6.0509        9.6203       14.7446        10.7062      
741.57 
 
Obs SEHOMAIR  SEPLGFHeart  SEPLGFMT  SEPLGFGPS  SEVEGFHeart  SEVEGFMT  
SEVEGFGPS 
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 1   4.91903    0.71864     2.04305   1.46519     33.5245     7.31494    3.3711 
 2   0.29696    1.88260     3.50230   4.15454     28.5883     7.60479   12.8640 
 3   4.34220    0.39783     2.86927   1.15330     16.8030     3.09466    3.9752 
 4   0.21986    0.91630     4.03060   2.74436     25.1693     4.46130    8.4258 
 5   7.94341    2.58252     1.35575   3.17576     17.1900     2.71272    2.0572 
 6   1.17259    2.00615     1.55331   2.40753     18.0059     2.73158    5.1175 
 7   1.80778    0.76270     1.45355   1.48013     27.4424     3.37245    3.0192 
 
 
Obs SEVEGFR1Heart    SEVEGFR1MT    SEVEGFR1GPS 
 
 1     18.4409         69.0787       13.2805 
 2     45.9867         31.1847       21.3363 
 3     48.1220         48.2502       24.1288 
 4     37.1239         26.7380       19.5606 
 5     40.8073         61.9346       19.9533 
 6     47.4857         31.6552       14.6888 
 7     49.6539         27.9292       25.1148 
 
 
Obs Strain    Gender  Diet  _TYPE_  _FREQ_   MNChol  MNIsopro8  MNTriglyc  
MNInsulin 
 
 8  C57BL/6J    M      LF      0       9     104.94    84.167     94.379    
1.36202 
 
Obs MNGlucose0   MNGlucose15   MNGlucose30   MNGlucose60   MNGlucose120     
MNAUC 
 
 8    122.444      307.556       378.111       303.778        168.000     
26851.67 
 
Obs MNHOMAIR  MNPLGFHeart  MNPLGFMT  MNPLGFGPS  MNVEGFHeart  MNVEGFMT  
MNVEGFGPS 
 
 8   10.7419    52.7193     29.7660   23.7251     485.120     28.8524   49.3478 
 
Obs MNVEGFR1Heart  MNVEGFR1MT  MNVEGFR1GPS   SEChol  SEIsopro8  SETriglyc  
SEInsulin 
 
 8     1062.83       359.720     266.243     8.4265   10.9007     9.3985    
0.03895 
 
Obs SEGlucose0   SEGlucose15   SEGlucose30   SEGlucose60   SEGlucose120    
SEAUC 
 
 8    11.2189      17.0507       16.2843       17.3748        10.9430     
1125.92 
 
Obs SEHOMAIR  SEPLGFHeart  SEPLGFMT  SEPLGFGPS  SEVEGFHeart  SEVEGFMT  
SEVEGFGPS 
 
 8   1.01347    1.68193     1.85635   3.05135     31.5769     1.44763    2.5796 
 
Obs SEVEGFR1Heart    SEVEGFR1MT    SEVEGFR1GPS 
 
 8     51.9654         33.8250       39.3643 
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Analysis of repeated measures data.   
 
               Dependent Variable           Glucose 
 
 
                               Class Level Information 
 
                 Class      Levels    Values 
 
                 Week           15    0 1 2 3 4 5 7 9 11 13 15 17 19 
                                      21 23 
                 Strain          2    ApoE-/- C57BL/6J 
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                 Gender          2    F M 
                 Diet            2    HF LF 
 
 
The estimate of 0.4694 below is the correlation estimated in the autoregressive 
covariance matrix.  This is a pretty strong correlation.   
 
                           Covariance Parameter Estimates 
 
                    Cov Parm     Subject                 Estimate 
 
                    AR(1)        Mous*Stra*Gende*Diet      0.4694 
                    Residual                               289.70 
 
 
This test below is testing whether the model is significant.  A small p-value 
would indicate that the model is needed.  
 
                          Null Model Likelihood Ratio Test 
 
                            DF    Chi-Square      Pr > ChiSq 
 
                             1        187.28          <.0001 
 
For this analysis of variance, one could argue that the model could be 
simplified and main effects (at some level) be investigated.  I’ve decided to 
keep the simple effect analysis, but we can do it differently.  BW does need 
simple effects (coming later).  
 
                            Type 3 Tests of Fixed Effects 
 
                                       Num     Den 
              Effect                    DF      DF    F Value    Pr > F 
 
              Week                      14     734      17.46    <.0001 
              Strain                     1     143      32.95    <.0001 
              Week*Strain               14     734       0.83    0.6402 
              Gender                     1     143      31.55    <.0001 
              Week*Gender               14     734       1.58    0.0800 
              Strain*Gender              1     143      15.25    0.0001 
              Week*Strain*Gender        14     734       0.51    0.9273 
              Diet                       1     143     207.14    <.0001 
              Week*Diet                 14     734       6.99    <.0001 
              Strain*Diet                1     143      75.42    <.0001 
              Week*Strain*Diet          14     734       1.82    0.0324 
              Gender*Diet                1     143       0.02    0.8913 
              Week*Gender*Diet          14     734       0.47    0.9511 
              Strain*Gender*Diet         1     143       0.26    0.6080 
              Week*Stra*Gende*Diet      14     734       0.48    0.9427 
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Tests of effect slices, where comparisons of one factor given fixed levels of 
all of the other factors are made.  This is more complicated than the end point 
analyses since we are specifying week.  If you concentrate on the diet effect, 
you see a really nice result.  In the early weeks, the diets are not different.  
However, when you progress through the experiment, you see the diets start to 
have an effect, up until the point where the diets are highly significant at 
the end of the study.   
 
 
 
                               Tests of Effect Slices 
 
                                                        Num   Den 
   Effect                Strain    Gender  Diet  Week    DF    DF  F Value  Pr 
> F 
 
   Week*Stra*Gende*Diet  ApoE-/-           HF     0       1   542     0.66  
0.4159 
   Week*Stra*Gende*Diet  ApoE-/-           LF     0       1   542     1.14  
0.2858 
   Week*Stra*Gende*Diet  C57BL/6J          HF     0       1   542     3.79  
0.0520 
   Week*Stra*Gende*Diet  C57BL/6J          LF     0       1   542     5.75  
0.0168 
   Week*Stra*Gende*Diet  ApoE-/-           HF     1       1   542     0.21  
0.6472 
   Week*Stra*Gende*Diet  ApoE-/-           LF     1       1   542     0.44  
0.5086 
   Week*Stra*Gende*Diet  C57BL/6J          HF     1       1   542     5.78  
0.0166 
   Week*Stra*Gende*Diet  C57BL/6J          LF     1       1   542     4.65  
0.0315 
   Week*Stra*Gende*Diet  ApoE-/-           HF     2       1   542     0.35  
0.5530 
   Week*Stra*Gende*Diet  ApoE-/-           LF     2       1   542     2.71  
0.1005 
   Week*Stra*Gende*Diet  C57BL/6J          HF     2       1   542     6.84  
0.0091 
   Week*Stra*Gende*Diet  C57BL/6J          LF     2       1   542     9.81  
0.0018 
   Week*Stra*Gende*Diet  ApoE-/-           HF     3       1   542     0.01  
0.9190 
   Week*Stra*Gende*Diet  ApoE-/-           LF     3       1   542     1.71  
0.1921 
   Week*Stra*Gende*Diet  C57BL/6J          HF     3       1   542     7.88  
0.0052 
   Week*Stra*Gende*Diet  C57BL/6J          LF     3       1   542     3.61  
0.0578 
   Week*Stra*Gende*Diet  ApoE-/-           HF     4       1   542     0.00  
0.9730 
   Week*Stra*Gende*Diet  ApoE-/-           LF     4       1   542     0.03  
0.8654 
   Week*Stra*Gende*Diet  C57BL/6J          HF     4       1   542    19.56  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF     4       1   542     4.30  
0.0386 
   Week*Stra*Gende*Diet  ApoE-/-           HF     5       1   542     1.75  
0.1864 
   Week*Stra*Gende*Diet  ApoE-/-           LF     5       1   542     0.04  
0.8388 
   Week*Stra*Gende*Diet  C57BL/6J          HF     5       1   542     7.28  
0.0072 
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   Week*Stra*Gende*Diet  C57BL/6J          LF     5       1   542     3.39  
0.0662 
   Week*Stra*Gende*Diet  ApoE-/-           HF     7       1   542     0.61  
0.4356 
   Week*Stra*Gende*Diet  ApoE-/-           LF     7       1   542     1.98  
0.1598 
   Week*Stra*Gende*Diet  C57BL/6J          HF     7       1   542    23.43  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF     7       1   542    10.75  
0.0011 
   Week*Stra*Gende*Diet  ApoE-/-           HF     9       1   542     0.12  
0.7346 
   Week*Stra*Gende*Diet  ApoE-/-           LF     9       1   542     0.00  
1.0000 
   Week*Stra*Gende*Diet  C57BL/6J          HF     9       1   542    12.90  
0.0004 
   Week*Stra*Gende*Diet  C57BL/6J          LF     9       1   542     1.85  
0.1743 
   Week*Stra*Gende*Diet  ApoE-/-           HF    11       1   542     0.03  
0.8654 
   Week*Stra*Gende*Diet  ApoE-/-           LF    11       1   542     0.06  
0.8124 
   Week*Stra*Gende*Diet  C57BL/6J          HF    11       1   542    13.10  
0.0003 
   Week*Stra*Gende*Diet  C57BL/6J          LF    11       1   542     1.61  
0.2054 
   Week*Stra*Gende*Diet  ApoE-/-           HF    13       1   542     0.15  
0.6966 
   Week*Stra*Gende*Diet  ApoE-/-           LF    13       1   542     0.69  
0.4063 
   Week*Stra*Gende*Diet  C57BL/6J          HF    13       1   542     6.15  
0.0135 
   Week*Stra*Gende*Diet  C57BL/6J          LF    13       1   542     6.00  
0.0146 
   Week*Stra*Gende*Diet  ApoE-/-           HF    15       1   542     0.00  
0.9730 
   Week*Stra*Gende*Diet  ApoE-/-           LF    15       1   542     0.19  
0.6594 
   Week*Stra*Gende*Diet  C57BL/6J          HF    15       1   542     5.50  
0.0193 
   Week*Stra*Gende*Diet  C57BL/6J          LF    15       1   542     6.81  
0.0093 
   Week*Stra*Gende*Diet  ApoE-/-           HF    17       1   542     0.12  
0.7346 
   Week*Stra*Gende*Diet  ApoE-/-           LF    17       1   542     0.87  
0.3513 
   Week*Stra*Gende*Diet  C57BL/6J          HF    17       1   542     0.90  
0.3439 
   Week*Stra*Gende*Diet  C57BL/6J          LF    17       1   542     3.13  
0.0773 
   Week*Stra*Gende*Diet  ApoE-/-           HF    19       1   542     0.09  
0.7603 
   Week*Stra*Gende*Diet  ApoE-/-           LF    19       1   542     0.06  
0.7993 
   Week*Stra*Gende*Diet  C57BL/6J          HF    19       1   542     0.81  
0.3693 
   Week*Stra*Gende*Diet  C57BL/6J          LF    19       1   542     1.85  
0.1743 
   Week*Stra*Gende*Diet  ApoE-/-           HF    21       1   542     0.13  
0.7219 
   Week*Stra*Gende*Diet  ApoE-/-           LF    21       1   542     0.09  
0.7603 
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   Week*Stra*Gende*Diet  C57BL/6J          HF    21       1   542     0.13  
0.7167 
   Week*Stra*Gende*Diet  C57BL/6J          LF    21       1   542     2.85  
0.0917 
   Week*Stra*Gende*Diet  ApoE-/-           HF    23       1   542     0.42  
0.5195 
   Week*Stra*Gende*Diet  ApoE-/-           LF    23       1   542     0.90  
0.3426 
   Week*Stra*Gende*Diet  C57BL/6J          HF    23       1   542     0.01  
0.9066 
   Week*Stra*Gende*Diet  C57BL/6J          LF    23       1   542     1.66  
0.1977 
   Week*Stra*Gende*Diet  ApoE-/-   F              0       1   542     0.12  
0.7346 
   Week*Stra*Gende*Diet  ApoE-/-   M              0       1   542     0.01  
0.9324 
   Week*Stra*Gende*Diet  C57BL/6J  F              0       1   542     0.20  
0.6558 
   Week*Stra*Gende*Diet  C57BL/6J  M              0       1   542     0.01  
0.9186 
   Week*Stra*Gende*Diet  ApoE-/-   F              1       1   542     0.18  
0.6717 
   Week*Stra*Gende*Diet  ApoE-/-   M              1       1   542     0.39  
0.5306 
   Week*Stra*Gende*Diet  C57BL/6J  F              1       1   542     0.41  
0.5221 
   Week*Stra*Gende*Diet  C57BL/6J  M              1       1   542     0.83  
0.3630 
   Week*Stra*Gende*Diet  ApoE-/-   F              2       1   542     0.37  
0.5417 
   Week*Stra*Gende*Diet  ApoE-/-   M              2       1   542     2.76  
0.0971 
   Week*Stra*Gende*Diet  C57BL/6J  F              2       1   542     1.68  
0.1957 
   Week*Stra*Gende*Diet  C57BL/6J  M              2       1   542     0.67  
0.4122 
   Week*Stra*Gende*Diet  ApoE-/-   F              3       1   542     0.07  
0.7862 
   Week*Stra*Gende*Diet  ApoE-/-   M              3       1   542     0.87  
0.3513 
   Week*Stra*Gende*Diet  C57BL/6J  F              3       1   542     3.04  
0.0818 
   Week*Stra*Gende*Diet  C57BL/6J  M              3       1   542     8.98  
0.0028 
   Week*Stra*Gende*Diet  ApoE-/-   F              4       1   542     0.26  
0.6111 
   Week*Stra*Gende*Diet  ApoE-/-   M              4       1   542     0.09  
0.7603 
   Week*Stra*Gende*Diet  C57BL/6J  F              4       1   542     6.53  
0.0109 
   Week*Stra*Gende*Diet  C57BL/6J  M              4       1   542    30.79  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F              5       1   542     0.35  
0.5530 
   Week*Stra*Gende*Diet  ApoE-/-   M              5       1   542     2.93  
0.0873 
   Week*Stra*Gende*Diet  C57BL/6J  F              5       1   542    11.38  
0.0008 
   Week*Stra*Gende*Diet  C57BL/6J  M              5       1   542    24.49  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F              7       1   542     4.21  
0.0406 
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   Week*Stra*Gende*Diet  ApoE-/-   M              7       1   542     2.03  
0.1548 
   Week*Stra*Gende*Diet  C57BL/6J  F              7       1   542    25.27  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M              7       1   542    58.50  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F              9       1   542     0.75  
0.3874 
   Week*Stra*Gende*Diet  ApoE-/-   M              9       1   542     1.45  
0.2290 
   Week*Stra*Gende*Diet  C57BL/6J  F              9       1   542    30.36  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M              9       1   542    82.71  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             11       1   542     3.54  
0.0603 
   Week*Stra*Gende*Diet  ApoE-/-   M             11       1   542     2.18  
0.1406 
   Week*Stra*Gende*Diet  C57BL/6J  F             11       1   542    32.70  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             11       1   542    90.02  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             13       1   542     6.22  
0.0130 
   Week*Stra*Gende*Diet  ApoE-/-   M             13       1   542     4.21  
0.0406 
   Week*Stra*Gende*Diet  C57BL/6J  F             13       1   542    45.87  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             13       1   542    66.93  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             15       1   542     7.18  
0.0076 
   Week*Stra*Gende*Diet  ApoE-/-   M             15       1   542     5.17  
0.0234 
   Week*Stra*Gende*Diet  C57BL/6J  F             15       1   542    52.96  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             15       1   542    71.78  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             17       1   542     3.42  
0.0650 
   Week*Stra*Gende*Diet  ApoE-/-   M             17       1   542     5.96  
0.0149 
   Week*Stra*Gende*Diet  C57BL/6J  F             17       1   542    49.59  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             17       1   542    58.26  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             19       1   542     3.61  
0.0580 
   Week*Stra*Gende*Diet  ApoE-/-   M             19       1   542     1.80  
0.1808 
   Week*Stra*Gende*Diet  C57BL/6J  F             19       1   542    48.35  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             19       1   542    63.09  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             21       1   542     3.05  
0.0812 
   Week*Stra*Gende*Diet  ApoE-/-   M             21       1   542     1.18  
0.2782 
   Week*Stra*Gende*Diet  C57BL/6J  F             21       1   542    72.84  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             21       1   542    66.17  
<.0001 
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   Week*Stra*Gende*Diet  ApoE-/-   F             23       1   542     3.05  
0.0812 
   Week*Stra*Gende*Diet  ApoE-/-   M             23       1   542     4.21  
0.0406 
   Week*Stra*Gende*Diet  C57BL/6J  F             23       1   542    70.03  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             23       1   542    74.96  
<.0001 
   Week*Stra*Gende*Diet            F       HF     0       1   542     0.58  
0.4450 
   Week*Stra*Gende*Diet            F       LF     0       1   542     0.73  
0.3945 
   Week*Stra*Gende*Diet            M       HF     0       1   542     0.00  
0.9935 
   Week*Stra*Gende*Diet            M       LF     0       1   542     0.03  
0.8673 
   Week*Stra*Gende*Diet            F       HF     1       1   542     0.47  
0.4912 
   Week*Stra*Gende*Diet            F       LF     1       1   542     3.16  
0.0761 
   Week*Stra*Gende*Diet            M       HF     1       1   542     0.88  
0.3494 
   Week*Stra*Gende*Diet            M       LF     1       1   542     0.31  
0.5775 
   Week*Stra*Gende*Diet            F       HF     2       1   542     0.50  
0.4786 
   Week*Stra*Gende*Diet            F       LF     2       1   542     6.89  
0.0089 
   Week*Stra*Gende*Diet            M       HF     2       1   542     0.91  
0.3411 
   Week*Stra*Gende*Diet            M       LF     2       1   542     2.57  
0.1093 
   Week*Stra*Gende*Diet            F       HF     3       1   542     0.31  
0.5752 
   Week*Stra*Gende*Diet            F       LF     3       1   542     3.83  
0.0507 
   Week*Stra*Gende*Diet            M       HF     3       1   542     3.58  
0.0588 
   Week*Stra*Gende*Diet            M       LF     3       1   542     2.84  
0.0927 
   Week*Stra*Gende*Diet            F       HF     4       1   542     2.52  
0.1132 
   Week*Stra*Gende*Diet            F       LF     4       1   542    12.53  
0.0004 
   Week*Stra*Gende*Diet            M       HF     4       1   542     5.78  
0.0165 
   Week*Stra*Gende*Diet            M       LF     4       1   542     3.61  
0.0578 
   Week*Stra*Gende*Diet            F       HF     5       1   542     0.51  
0.4739 
   Week*Stra*Gende*Diet            F       LF     5       1   542    11.13  
0.0009 
   Week*Stra*Gende*Diet            M       HF     5       1   542     0.02  
0.8808 
   Week*Stra*Gende*Diet            M       LF     5       1   542     3.78  
0.0523 
   Week*Stra*Gende*Diet            F       HF     7       1   542     0.81  
0.3671 
   Week*Stra*Gende*Diet            F       LF     7       1   542    12.63  
0.0004 
   Week*Stra*Gende*Diet            M       HF     7       1   542     6.84  
0.0092 
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   Week*Stra*Gende*Diet            M       LF     7       1   542     4.67  
0.0311 
   Week*Stra*Gende*Diet            F       HF     9       1   542     0.58  
0.4465 
   Week*Stra*Gende*Diet            F       LF     9       1   542    26.42  
<.0001 
   Week*Stra*Gende*Diet            M       HF     9       1   542     4.50  
0.0344 
   Week*Stra*Gende*Diet            M       LF     9       1   542    16.11  
<.0001 
   Week*Stra*Gende*Diet            F       HF    11       1   542     0.28  
0.5977 
   Week*Stra*Gende*Diet            F       LF    11       1   542    16.09  
<.0001 
   Week*Stra*Gende*Diet            M       HF    11       1   542     9.15  
0.0026 
   Week*Stra*Gende*Diet            M       LF    11       1   542    10.25  
0.0014 
   Week*Stra*Gende*Diet            F       HF    13       1   542     0.20  
0.6565 
   Week*Stra*Gende*Diet            F       LF    13       1   542    18.35  
<.0001 
   Week*Stra*Gende*Diet            M       HF    13       1   542     1.88  
0.1711 
   Week*Stra*Gende*Diet            M       LF    13       1   542     9.25  
0.0025 
   Week*Stra*Gende*Diet            F       HF    15       1   542     0.03  
0.8623 
   Week*Stra*Gende*Diet            F       LF    15       1   542    18.39  
<.0001 
   Week*Stra*Gende*Diet            M       HF    15       1   542     3.93  
0.0479 
   Week*Stra*Gende*Diet            M       LF    15       1   542     6.11  
0.0138 
   Week*Stra*Gende*Diet            F       HF    17       1   542     0.00  
0.9619 
   Week*Stra*Gende*Diet            F       LF    17       1   542    22.31  
<.0001 
   Week*Stra*Gende*Diet            M       HF    17       1   542     1.84  
0.1750 
   Week*Stra*Gende*Diet            M       LF    17       1   542     4.78  
0.0292 
   Week*Stra*Gende*Diet            F       HF    19       1   542     0.36  
0.5498 
   Week*Stra*Gende*Diet            F       LF    19       1   542    16.13  
<.0001 
   Week*Stra*Gende*Diet            M       HF    19       1   542     3.63  
0.0572 
   Week*Stra*Gende*Diet            M       LF    19       1   542     9.86  
0.0018 
   Week*Stra*Gende*Diet            F       HF    21       1   542     2.27  
0.1326 
   Week*Stra*Gende*Diet            F       LF    21       1   542    22.65  
<.0001 
   Week*Stra*Gende*Diet            M       HF    21       1   542     3.30  
0.0699 
   Week*Stra*Gende*Diet            M       LF    21       1   542    13.35  
0.0003 
   Week*Stra*Gende*Diet            F       HF    23       1   542     1.90  
0.1688 
   Week*Stra*Gende*Diet            F       LF    23       1   542    22.39  
<.0001 
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   Week*Stra*Gende*Diet            M       HF    23       1   542     5.04  
0.0251 
   Week*Stra*Gende*Diet            M       LF    23       1   542     6.86  
0.0090 
 
 
Analysis of body weight response: 
 
 
               Dependent Variable           BW 
 
Wow, the 0.83 correlation is HUGE! 
 
                           Covariance Parameter Estimates 
 
                    Cov Parm     Subject                 Estimate 
 
                    AR(1)        Mous*Stra*Gende*Diet      0.8390 
                    Residual                               3.7940 
 
 
 
                          Null Model Likelihood Ratio Test 
 
                            DF    Chi-Square      Pr > ChiSq 
 
                             1        947.19          <.0001 
 
Here the four factor interaction is significant, so we must analyze simple 
effects. 
 
                            Type 3 Tests of Fixed Effects 
 
                                       Num     Den 
              Effect                    DF      DF    F Value    Pr > F 
 
              Week                      14     755     164.88    <.0001 
              Strain                     1    76.5      27.12    <.0001 
              Week*Strain               14     755      10.30    <.0001 
              Gender                     1    76.5     254.48    <.0001 
              Week*Gender               14     755       7.87    <.0001 
              Strain*Gender              1    76.5       2.67    0.1062 
              Week*Strain*Gender        14     755       3.21    <.0001 
              Diet                       1    76.5     268.41    <.0001 
              Week*Diet                 14     755      19.61    <.0001 
              Strain*Diet                1    76.5       1.90    0.1725 
              Week*Strain*Diet          14     755       6.04    <.0001 
              Gender*Diet                1    76.5       2.20    0.1419 
              Week*Gender*Diet          14     755       2.36    0.0033 
              Strain*Gender*Diet         1    76.5       1.09    0.2994 
              Week*Stra*Gende*Diet      14     755       1.74    0.0434 
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                               Tests of Effect Slices 
 
                                                        Num   Den 
   Effect                Strain    Gender  Diet  Week    DF    DF  F Value  Pr 
> F 
 
   Week*Stra*Gende*Diet  ApoE-/-           HF     0       1   191    17.22  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF     0       1   191    22.35  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     0       1   191     5.50  
0.0200 
   Week*Stra*Gende*Diet  C57BL/6J          LF     0       1   191     6.80  
0.0098 
   Week*Stra*Gende*Diet  ApoE-/-           HF     1       1   191     3.01  
0.0845 
   Week*Stra*Gende*Diet  ApoE-/-           LF     1       1   191    21.11  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     1       1   191     6.39  
0.0123 
   Week*Stra*Gende*Diet  C57BL/6J          LF     1       1   191    14.60  
0.0002 
   Week*Stra*Gende*Diet  ApoE-/-           HF     2       1   191     1.41  
0.2372 
   Week*Stra*Gende*Diet  ApoE-/-           LF     2       1   191    25.54  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     2       1   191     9.90  
0.0019 
   Week*Stra*Gende*Diet  C57BL/6J          LF     2       1   191    18.36  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF     3       1   191     0.04  
0.8359 
   Week*Stra*Gende*Diet  ApoE-/-           LF     3       1   191    22.35  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     3       1   191     6.91  
0.0093 
   Week*Stra*Gende*Diet  C57BL/6J          LF     3       1   191    21.11  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF     4       1   191     0.27  
0.6046 
   Week*Stra*Gende*Diet  ApoE-/-           LF     4       1   191    19.11  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     4       1   191    10.15  
0.0017 
   Week*Stra*Gende*Diet  C57BL/6J          LF     4       1   191    26.61  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF     5       1   191     0.49  
0.4869 
   Week*Stra*Gende*Diet  ApoE-/-           LF     5       1   191    23.77  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     5       1   191    12.67  
0.0005 
   Week*Stra*Gende*Diet  C57BL/6J          LF     5       1   191    32.08  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF     7       1   191    10.15  
0.0017 
   Week*Stra*Gende*Diet  ApoE-/-           LF     7       1   191    23.20  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     7       1   191    15.63  
0.0001 
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   Week*Stra*Gende*Diet  C57BL/6J          LF     7       1   191    29.37  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF     9       1   191    44.28  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF     9       1   191    33.75  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF     9       1   191    20.25  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF     9       1   191    34.96  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    11       1   191    69.62  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    11       1   191    37.28  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    11       1   191    16.12  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    11       1   191    45.98  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    13       1   191    75.43  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    13       1   191    40.42  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    13       1   191    18.08  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    13       1   191    47.02  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    15       1   191    89.13  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    15       1   191    40.05  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    15       1   191    31.69  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    15       1   191    64.88  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    17       1   191    97.13  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    17       1   191    51.45  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    17       1   191    43.71  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    17       1   191    78.82  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    19       1   191    92.52  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    19       1   191    52.09  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    19       1   191    45.09  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    19       1   191    83.79  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    21       1   191    88.01  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    21       1   191    52.31  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          HF    21       1   191    70.51  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    21       1   191    89.14  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           HF    23       1   191    92.52  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-           LF    23       1   200    48.36  
<.0001 
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   Week*Stra*Gende*Diet  C57BL/6J          HF    23       1   191    96.91  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J          LF    23       1   198    85.81  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F              0       1   191     0.39  
0.5344 
   Week*Stra*Gende*Diet  ApoE-/-   M              0       1   191     0.00  
0.9646 
   Week*Stra*Gende*Diet  C57BL/6J  F              0       1   191     0.87  
0.3517 
   Week*Stra*Gende*Diet  C57BL/6J  M              0       1   191     0.47  
0.4927 
   Week*Stra*Gende*Diet  ApoE-/-   F              1       1   191    10.92  
0.0011 
   Week*Stra*Gende*Diet  ApoE-/-   M              1       1   191     0.20  
0.6571 
   Week*Stra*Gende*Diet  C57BL/6J  F              1       1   191     2.36  
0.1258 
   Week*Stra*Gende*Diet  C57BL/6J  M              1       1   191     0.05  
0.8204 
   Week*Stra*Gende*Diet  ApoE-/-   F              2       1   191    17.84  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M              2       1   191     0.13  
0.7225 
   Week*Stra*Gende*Diet  C57BL/6J  F              2       1   191     2.89  
0.0907 
   Week*Stra*Gende*Diet  C57BL/6J  M              2       1   191     0.32  
0.5724 
   Week*Stra*Gende*Diet  ApoE-/-   F              3       1   191    36.56  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M              3       1   191     2.33  
0.1285 
   Week*Stra*Gende*Diet  C57BL/6J  F              3       1   191     6.12  
0.0142 
   Week*Stra*Gende*Diet  C57BL/6J  M              3       1   191     0.35  
0.5524 
   Week*Stra*Gende*Diet  ApoE-/-   F              4       1   191    49.98  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M              4       1   191     4.75  
0.0306 
   Week*Stra*Gende*Diet  C57BL/6J  F              4       1   191     7.84  
0.0056 
   Week*Stra*Gende*Diet  C57BL/6J  M              4       1   191     0.91  
0.3421 
   Week*Stra*Gende*Diet  ApoE-/-   F              5       1   191    47.70  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M              5       1   191     7.44  
0.0070 
   Week*Stra*Gende*Diet  C57BL/6J  F              5       1   191    11.04  
0.0011 
   Week*Stra*Gende*Diet  C57BL/6J  M              5       1   191     2.00  
0.1587 
   Week*Stra*Gende*Diet  ApoE-/-   F              7       1   191    42.33  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M              7       1   191    23.77  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F              7       1   191    15.67  
0.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M              7       1   191     8.45  
0.0041 
   Week*Stra*Gende*Diet  ApoE-/-   F              9       1   191    20.84  
<.0001 
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   Week*Stra*Gende*Diet  ApoE-/-   M              9       1   191    29.26  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F              9       1   191    26.37  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M              9       1   191    19.14  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             11       1   191    20.84  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             11       1   191    46.28  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             11       1   191    60.83  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             11       1   191    37.43  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             13       1   191    22.07  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             13       1   191    49.35  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             13       1   191    99.21  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             13       1   191    79.93  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             15       1   191    18.73  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             15       1   191    55.35  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             15       1   191   135.32  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             15       1   191   123.38  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             17       1   191    20.70  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             17       1   191    52.31  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             17       1   191   169.14  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             17       1   191   166.66  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             19       1   191    23.92  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             19       1   191    53.17  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             19       1   191   211.91  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             19       1   191   213.42  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             21       1   191    31.22  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             21       1   191    59.85  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             21       1   191   222.14  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             21       1   191   273.24  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   F             23       1   191    38.56  
<.0001 
   Week*Stra*Gende*Diet  ApoE-/-   M             23       1   200    74.69  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  F             23       1   197   215.40  
<.0001 
   Week*Stra*Gende*Diet  C57BL/6J  M             23       1   191   327.10  
<.0001 
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   Week*Stra*Gende*Diet            F       HF     0       1   191     0.43  
0.5120 
   Week*Stra*Gende*Diet            F       LF     0       1   191     0.20  
0.6550 
   Week*Stra*Gende*Diet            M       HF     0       1   191     3.92  
0.0491 
   Week*Stra*Gende*Diet            M       LF     0       1   191     5.36  
0.0216 
   Week*Stra*Gende*Diet            F       HF     1       1   191     2.41  
0.1220 
   Week*Stra*Gende*Diet            F       LF     1       1   191     0.21  
0.6464 
   Week*Stra*Gende*Diet            M       HF     1       1   191     2.15  
0.1441 
   Week*Stra*Gende*Diet            M       LF     1       1   191     1.08  
0.3001 
   Week*Stra*Gende*Diet            F       HF     2       1   191     4.51  
0.0349 
   Week*Stra*Gende*Diet            F       LF     2       1   191     0.49  
0.4866 
   Week*Stra*Gende*Diet            M       HF     2       1   191     0.78  
0.3788 
   Week*Stra*Gende*Diet            M       LF     2       1   191     0.76  
0.3847 
   Week*Stra*Gende*Diet            F       HF     3       1   191     9.52  
0.0023 
   Week*Stra*Gende*Diet            F       LF     3       1   191     0.84  
0.3614 
   Week*Stra*Gende*Diet            M       HF     3       1   191     1.72  
0.1915 
   Week*Stra*Gende*Diet            M       LF     3       1   191     0.00  
0.9957 
   Week*Stra*Gende*Diet            F       HF     4       1   191    13.50  
0.0003 
   Week*Stra*Gende*Diet            F       LF     4       1   191     1.19  
0.2774 
   Week*Stra*Gende*Diet            M       HF     4       1   191     0.35  
0.5548 
   Week*Stra*Gende*Diet            M       LF     4       1   191     1.17  
0.2805 
   Week*Stra*Gende*Diet            F       HF     5       1   191     9.65  
0.0022 
   Week*Stra*Gende*Diet            F       LF     5       1   191     1.00  
0.3195 
   Week*Stra*Gende*Diet            M       HF     5       1   191     1.08  
0.3006 
   Week*Stra*Gende*Diet            M       LF     5       1   191     0.82  
0.3673 
   Week*Stra*Gende*Diet            F       HF     7       1   191     2.33  
0.1284 
   Week*Stra*Gende*Diet            F       LF     7       1   191     2.52  
0.1139 
   Week*Stra*Gende*Diet            M       HF     7       1   191     3.32  
0.0702 
   Week*Stra*Gende*Diet            M       LF     7       1   191     1.82  
0.1794 
   Week*Stra*Gende*Diet            F       HF     9       1   191     3.12  
0.0789 
   Week*Stra*Gende*Diet            F       LF     9       1   191     3.16  
0.0769 
   Week*Stra*Gende*Diet            M       HF     9       1   191     2.74  
0.0997 
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   Week*Stra*Gende*Diet            M       LF     9       1   191     0.83  
0.3644 
   Week*Stra*Gende*Diet            F       HF    11       1   191    21.29  
<.0001 
   Week*Stra*Gende*Diet            F       LF    11       1   191     4.66  
0.0321 
   Week*Stra*Gende*Diet            M       HF    11       1   191     0.73  
0.3943 
   Week*Stra*Gende*Diet            M       LF    11       1   191     3.15  
0.0775 
   Week*Stra*Gende*Diet            F       HF    13       1   191    44.91  
<.0001 
   Week*Stra*Gende*Diet            F       LF    13       1   191     5.67  
0.0183 
   Week*Stra*Gende*Diet            M       HF    13       1   191     1.87  
0.1731 
   Week*Stra*Gende*Diet            M       LF    13       1   191     3.23  
0.0740 
   Week*Stra*Gende*Diet            F       HF    15       1   191    68.68  
<.0001 
   Week*Stra*Gende*Diet            F       LF    15       1   191     4.06  
0.0452 
   Week*Stra*Gende*Diet            M       HF    15       1   191    12.93  
0.0004 
   Week*Stra*Gende*Diet            M       LF    15       1   191     6.55  
0.0112 
   Week*Stra*Gende*Diet            F       HF    17       1   191    93.03  
<.0001 
   Week*Stra*Gende*Diet            F       LF    17       1   191     5.46  
0.0205 
   Week*Stra*Gende*Diet            M       HF    17       1   191    31.29  
<.0001 
   Week*Stra*Gende*Diet            M       LF    17       1   191     7.41  
0.0071 
   Week*Stra*Gende*Diet            F       HF    19       1   191   109.38  
<.0001 
   Week*Stra*Gende*Diet            F       LF    19       1   191     4.21  
0.0416 
   Week*Stra*Gende*Diet            M       HF    19       1   191    47.78  
<.0001 
   Week*Stra*Gende*Diet            M       LF    19       1   191     6.95  
0.0091 
   Week*Stra*Gende*Diet            F       HF    21       1   191    93.59  
<.0001 
   Week*Stra*Gende*Diet            F       LF    21       1   191     2.74  
0.0994 
   Week*Stra*Gende*Diet            M       HF    21       1   191    62.19  
<.0001 
   Week*Stra*Gende*Diet            M       LF    21       1   191     6.14  
0.0141 
   Week*Stra*Gende*Diet            F       HF    23       1   191    87.89  
<.0001 
   Week*Stra*Gende*Diet            F       LF    23       1   197     4.30  
0.0395 
   Week*Stra*Gende*Diet            M       HF    23       1   191    74.48  
<.0001 
   Week*Stra*Gende*Diet            M       LF    23       1   202     8.97  
0.0031 
 
 
Here are the means and standard errors: 
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   Obs Week Strain   Gender Diet _TYPE_ _FREQ_ MNGlucose   MNBW  SEGlucose   
SEBW 
 
     1   0  ApoE-/-    F     HF     0      6    128.667  16.7167   7.2003  
0.51343 
     2   0  ApoE-/-    F     LF     0      6    125.333  16.0167   4.1446  
0.62579 
     3   0  ApoE-/-    M     HF     0      6    136.667  21.3833  10.1116  
0.75251 
     4   0  ApoE-/-    M     LF     0      6    135.833  21.3333   5.0558  
0.40716 
     5   0  C57BL/6J   F     HF     0      7    121.429  17.4286   7.5997  
0.63983 
     6   0  C57BL/6J   F     LF     0      8    117.500  16.4875   6.6171  
0.49224 
     7   0  C57BL/6J   M     HF     0     15    136.600  19.5200   6.7222  
0.45010 
     8   0  C57BL/6J   M     LF     0      9    137.333  18.9556  10.6406  
0.43593 
     9   1  ApoE-/-    F     HF     0      6    129.667  19.9833   5.0509  
0.25484 
    10   1  ApoE-/-    F     LF     0      6    133.833  16.2667  13.1591  
0.54508 
    11   1  ApoE-/-    M     HF     0      6    134.167  21.9333  10.2710  
0.87965 
    12   1  ApoE-/-    M     LF     0      6    140.333  21.4333   9.5347  
0.38093 
    13   1  C57BL/6J   F     HF     0      7    123.143  18.3000   6.8571  
0.90816 
    14   1  C57BL/6J   F     LF     0      8    117.500  16.7500   5.7508  
0.38219 
    15   1  C57BL/6J   M     HF     0     15    141.867  20.5533   4.9539  
0.41552 
    16   1  C57BL/6J   M     LF     0      9    135.333  20.3667  10.3789  
0.43397 
    17   2  ApoE-/-    F     HF     0      6    136.000  21.6167   6.0992  
0.43083 
    18   2  ApoE-/-    F     LF     0      6    142.000  16.8667   9.5044  
0.53208 
    19   2  ApoE-/-    M     HF     0      6    141.833  22.9500   9.1921  
1.01251 
    20   2  ApoE-/-    M     LF     0      6    158.167  22.5500   4.8745  
0.38449 
    21   2  C57BL/6J   F     HF     0      7    129.286  19.3143   4.3409  
0.52027 
    22   2  C57BL/6J   F     LF     0      8    117.875  17.6000   3.2151  
0.47056 
    23   2  C57BL/6J   M     HF     0     15    149.667  22.1200   5.6220  
0.34808 
    24   2  C57BL/6J   M     LF     0      9    143.778  21.6556   6.6558  
0.52125 
    25   3  ApoE-/-    F     HF     0      6    145.167  24.5000   5.0294  
0.61101 
    26   3  ApoE-/-    F     LF     0      6    142.500  17.7000   6.1577  
0.56095 
    27   3  ApoE-/-    M     HF     0      6    146.167  24.7333   4.0201  
0.85894 
    28   3  ApoE-/-    M     LF     0      6    155.333  23.0167   6.0424  
0.34873 
    29   3  C57BL/6J   F     HF     0      7    139.857  21.1571   5.6334  
0.65205 
    30   3  C57BL/6J   F     LF     0      8    124.500  18.6625   4.0576  
0.49531 
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    31   3  C57BL/6J   M     HF     0     15    161.733  23.5000   5.0948  
0.25448 
    32   3  C57BL/6J   M     LF     0      9    140.222  23.0111   5.5297  
0.48317 
    33   4  ApoE-/-    F     HF     0      6    161.167  26.1667   3.3408  
0.75351 
    34   4  ApoE-/-    F     LF     0      6    156.167  18.2167   1.8514  
0.49694 
    35   4  ApoE-/-    M     HF     0      6    160.833  25.5833   5.3380  
0.80433 
    36   4  ApoE-/-    M     LF     0      6    157.833  23.1333   2.3298  
0.31376 
    37   4  C57BL/6J   F     HF     0      7    146.143  22.1857   5.6671  
1.08922 
    38   4  C57BL/6J   F     LF     0      8    123.625  19.3625   3.2179  
0.41702 
    39   4  C57BL/6J   M     HF     0     15    180.600  25.0267   6.0481  
0.23993 
    40   4  C57BL/6J   M     LF     0      9    140.778  24.2444   5.6070  
0.49836 
    41   5  ApoE-/-    F     HF     0      6    163.500  26.6667   5.4206  
0.81432 
    42   5  ApoE-/-    F     LF     0      6    157.667  18.9000   2.9851  
0.52978 
    43   5  ApoE-/-    M     HF     0      6    176.500  27.4500   7.2146  
0.41773 
    44   5  ApoE-/-    M     LF     0      6    159.667  24.3833   6.0369  
0.55403 
    45   5  C57BL/6J   F     HF     0      7    156.714  23.3000   3.7526  
0.95319 
    46   5  C57BL/6J   F     LF     0      8    127.000  19.9500   2.7646  
0.55485 
    47   5  C57BL/6J   M     HF     0     15    177.733  26.4733   7.6479  
0.35637 
    48   5  C57BL/6J   M     LF     0      9    142.222  25.3111   3.2905  
0.52213 
    49   7  ApoE-/-    F     HF     0      6    171.833  26.6833   3.9951  
0.47848 
    50   7  ApoE-/-    F     LF     0      6    151.667  19.3667   4.8212  
0.59759 
    51   7  ApoE-/-    M     HF     0      6    179.500  30.2667   4.6673  
0.56667 
    52   7  ApoE-/-    M     LF     0      6    165.500  24.7833   5.0448  
0.41906 
    53   7  C57BL/6J   F     HF     0      7    163.286  25.0286   2.2542  
1.14844 
    54   7  C57BL/6J   F     LF     0      8    119.000  21.0375   2.8661  
0.38957 
    55   7  C57BL/6J   M     HF     0     15    201.000  28.5533   6.0063  
0.59240 
    56   7  C57BL/6J   M     LF     0      9    146.111  26.1667   3.6150  
0.59114 
    57   9  ApoE-/-    F     HF     0      6    177.500  25.1000   2.5917  
0.66282 
    58   9  ApoE-/-    F     LF     0      6    169.000  19.9667   3.6968  
0.61950 
    59   9  ApoE-/-    M     HF     0      6    180.833  32.5833   3.4585  
0.90753 
    60   9  ApoE-/-    M     LF     0      6    169.000  26.5000   3.6968  
0.47258 
    61   9  C57BL/6J   F     HF     0      7    170.286  27.0143   3.5571  
1.21976 
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    62   9  C57BL/6J   F     LF     0      8    121.750  21.8375   4.0916  
0.39683 
    63   9  C57BL/6J   M     HF     0     15    198.267  31.0267   4.4126  
0.58305 
    64   9  C57BL/6J   M     LF     0      9    133.000  27.4333   4.5826  
0.63944 
    65  11  ApoE-/-    F     HF     0      6    182.000  25.3000   4.7889  
0.68944 
    66  11  ApoE-/-    F     LF     0      6    163.500  20.1667   6.2650  
0.60974 
    67  11  ApoE-/-    M     HF     0      6    180.333  34.6833   4.4920  
1.33402 
    68  11  ApoE-/-    M     LF     0      6    165.833  27.0333   6.7795  
0.37918 
    69  11  C57BL/6J   F     HF     0      7    177.000  30.3000   5.6904  
0.67893 
    70  11  C57BL/6J   F     LF     0      8    126.625  22.4375   5.2574  
0.34689 
    71  11  C57BL/6J   M     HF     0     15    205.200  33.8800   6.7154  
0.41129 
    72  11  C57BL/6J   M     LF     0      9    137.111  28.8556  5.06196  
0.78388 
    73  13  ApoE-/-    F     HF     0      6    182.500  26.1667  9.42249  
0.59423 
    74  13  ApoE-/-    F     LF     0      6    158.000  20.8833  4.67618  
0.67103 
    75  13  ApoE-/-    M     HF     0      6    186.333  35.9333  7.00793  
1.25875 
    76  13  ApoE-/-    M     LF     0      6    166.167  28.0333  5.51009  
0.41846 
    77  13  C57BL/6J   F     HF     0      7    178.286  33.4286  3.59705  
1.71904 
    78  13  C57BL/6J   F     LF     0      8    118.625  23.3875  4.89146  
0.32974 
    79  13  C57BL/6J   M     HF     0     15    197.600  37.2200  7.77713  
0.50824 
    80  13  C57BL/6J   M     LF     0      9    138.889  29.8778  6.67176  
0.85955 
    81  15  ApoE-/-    F     HF     0      6    183.500  26.5333  2.45967  
0.63805 
    82  15  ApoE-/-    F     LF     0      6    157.167  21.6667  6.10146  
0.56135 
    83  15  ApoE-/-    M     HF     0      6    183.833  37.1500  7.78638  
1.26905 
    84  15  ApoE-/-    M     LF     0      6    161.500  28.7833  8.65929  
0.43160 
    85  15  C57BL/6J   F     HF     0      7    181.857  35.5143  4.92046  
1.53164 
    86  15  C57BL/6J   F     LF     0      8    117.750  23.7875  4.95606  
0.28312 
    87  15  C57BL/6J   M     HF     0     15    200.133  40.5333  4.69535  
0.64429 
    88  15  C57BL/6J   M     LF     0      9    139.333  31.4111  3.08221  
0.94007 
    89  17  ApoE-/-    F     HF     0      6    183.833  26.9333  6.52900  
0.66767 
    90  17  ApoE-/-    F     LF     0      6    165.667  21.8167  5.54176  
0.62898 
    91  17  ApoE-/-    M     HF     0      6    180.500  38.0167  3.96443  
1.08272 
    92  17  ApoE-/-    M     LF     0      6    156.500  29.8833  4.89047  
0.45049 
243 
 
    93  17  C57BL/6J   F     HF     0      7    184.286  37.3857  2.23302  
1.84796 
    94  17  C57BL/6J   F     LF     0      8    122.250  24.2750  3.25549  
0.33793 
    95  17  C57BL/6J   M     HF     0     15    191.667  43.2800  3.96853  
0.66578 
    96  17  C57BL/6J   M     LF     0      9    136.889  32.6778  3.94914  
0.87967 
    97  19  ApoE-/-    F     HF     0      6    179.333  28.1667  4.47710  
0.45436 
    98  19  ApoE-/-    F     LF     0      6    160.667  22.6667  3.50872  
0.53831 
    99  19  ApoE-/-    M     HF     0      6    176.333  38.9833  2.13957  
1.20234 
   100  19  ApoE-/-    M     LF     0      6    163.167  30.7833  5.72955  
0.43005 
   101  19  C57BL/6J   F     HF     0      7    185.000  39.5000  3.35942  
1.19960 
   102  19  C57BL/6J   F     LF     0      8    123.750  24.8250  3.47311  
0.37261 
   103  19  C57BL/6J   M     HF     0     15    192.000  45.4867  7.31990  
0.63710 
   104  19  C57BL/6J   M     LF     0      9    135.000  33.4889  3.98957  
0.74320 
   105  21  ApoE-/-    F     HF     0      6    177.167  29.6167  4.16667  
0.65849 
   106  21  ApoE-/-    F     LF     0      6    160.000  23.3333  2.14476  
0.53333 
   107  21  ApoE-/-    M     HF     0      6    173.667  40.1667  5.43855  
1.05977 
   108  21  ApoE-/-    M     LF     0      6    163.000  31.4667  1.84391  
0.44397 
   109  21  C57BL/6J   F     HF     0      7    191.429  40.1000  5.63094  
1.19363 
   110  21  C57BL/6J   F     LF     0      8    116.250  25.0750  3.46281  
0.32500 
   111  21  C57BL/6J   M     HF     0     15    188.600  47.5867  5.62207  
0.65530 
   112  21  C57BL/6J   M     LF     0      9    130.222  34.0111  2.73241  
0.74451 
   113  23  ApoE-/-    F     HF     0      6    181.667  30.7833  6.24322  
0.59856 
   114  23  ApoE-/-    F     LF     0      6    164.500  23.8000  4.08860  
0.62397 
   115  23  ApoE-/-    M     HF     0      6    175.333  41.6000  4.93739  
1.21874 
   116  23  ApoE-/-    M     LF     0      6    155.167  31.5800  4.82643  
0.59783 
   117  23  C57BL/6J   F     HF     0      7    194.714  40.9429  5.09301  
1.23940 
   118  23  C57BL/6J   F     LF     0      8    121.000  25.9857  2.22807  
0.46824 
   119  23  C57BL/6J   M     HF     0     15    193.800  49.7200  3.63344  
0.67020 
   120  23  C57BL/6J   M     LF     0      9    131.667  34.8667  3.00463  
0.59442 
 
 
   Chapter 4  
 
Strain      Diet    MNCholesterol    SECholesterol PVALUE 
 
                 ApoE -/-     HF        1104.58 a         38.9848  <.0001 
                 ApoE -/-     LF         547.49 b         23.4126 
                 C57BL6/J     HF         282.32 c         10.0409 
                 C57BL6/J     LF          80.36 d          4.4490 
 
 
                 Strain      Diet    MNIsoprostane    SEIsoprostane  PVALUE  
 
                 ApoE -/-     HF        498.707 a         16.8268  <.0001 
                 ApoE -/-     LF        314.718 b         12.4189 
                 C57BL6/J     HF        276.226 c          8.1880 
                 C57BL6/J     LF         64.717 d          2.1724 
 
 
                Strain      Diet    MNTriglyceride    SETriglyceride  PVALUE  
 
                ApoE -/-     HF         568.480 a          39.1558  <.0001 
                ApoE -/-     LF         226.850 b          14.5049 
                C57BL6/J     HF          95.479 c           5.2049 
                C57BL6/J     LF          88.779 c           4.6307 
 
 
                     Strain      Diet    MNInsulin    SEInsulin  PVALUE  
 
                     ApoE -/-     HF      4.16909 b     0.28544 <.0001 
                     ApoE -/-     LF      0.81188 c     0.07702 
                     C57BL6/J     HF      5.59904 a     0.33356 
                     C57BL6/J     LF      1.44417 c     0.05238 
 
 
                                          MNBW24th    SEBW24th 
                      Strain      Diet      Week        Week  PVALUE  
 
                      ApoE -/-     HF      41.7559 b    0.60774 <.0001 
                      ApoE -/-     LF      31.0162 d    0.42266 
                      C57BL6/J     HF      47.6417 a    0.73334 
                      C57BL6/J     LF      33.3029 c    0.47260 
 
 
                       Strain      Diet      MNAUC      SEAUC  PVALUE  
 
                       ApoE -/-     HF     33136.29 b   658.084 <.0001 
                       ApoE -/-     LF     29096.46 c   556.949 
                       C57BL6/J     HF     49950.66 a   577.844 
                       C57BL6/J     LF     31657.74 b   766.646                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                  Day    Strain      Diet    MNPLGFlig    SEPLGFlig PVALUE 
 
                    3    ApoE -/-     HF      21.3593 ab    3.03914 0.0119 
                    3    ApoE -/-     LF      27.0317 a     3.10836 
                    3    C57BL6/J     HF      16.2020 b     1.86411 
                    3    C57BL6/J     LF      28.5958 a     3.63877 
 
                    5    ApoE -/-     HF      18.6036 b     3.07157 <.0001 
                    5    ApoE -/-     LF      31.4602 a     3.15487 
                    5    C57BL6/J     HF      15.7600 b     2.53840 
                    5    C57BL6/J     LF      29.1990 a     3.41256 
 
                    7    ApoE -/-     HF      19.9932 b     1.38722 <.0001 
                    7    ApoE -/-     LF      31.9086 a     2.54776 
                    7    C57BL6/J     HF      13.3684 b     1.95309 
                    7    C57BL6/J     LF      50.0469 a     2.83439 
 
                   10    ApoE -/-     HF      18.1821 c     1.20157 <.0001 
                   10    ApoE -/-     LF      26.8077 b     1.25451 
                   10    C57BL6/J     HF       9.2315 d     1.20539 
                   10    C57BL6/J     LF      49.2405 a     3.80469 
 
                   14    ApoE -/-     HF      18.3432 b     1.87402 0.0374 
                   14    ApoE -/-     LF      28.8627 a     2.95398 
                   14    C57BL6/J     HF      24.2022 ab    3.03842 
                   14    C57BL6/J     LF      27.7423 a     2.42431 
 
                   21    ApoE -/-     HF      17.3372 c     1.58567 <.0001 
                   21    ApoE -/-     LF      31.4154 b     1.61761 
                   21    C57BL6/J     HF      48.1325 a     4.46425 
                   21    C57BL6/J     LF      24.5627 bc    3.07373 
 
                   28    ApoE -/-     HF      20.6537 a     2.11636 <.0001 
                   28    ApoE -/-     LF      26.5103 a     0.92185 
                   28    C57BL6/J     HF       8.0697 b     1.43146 
                   28    C57BL6/J     LF      20.2665 a     2.93964 
 
 
 
  
  
 
 
                Day    Strain      Diet    MNPLGFratio    SEPLGFratio  PVALUE 
 
                  3    ApoE -/-     HF       0.85479 a       0.05046 0.7557 
                  3    ApoE -/-     LF       1.05441 a       0.02668 
                  3    C57BL6/J     HF       0.93872 a       0.04398 
                  3    C57BL6/J     LF       0.94751 a       0.05713 
 
                  5    ApoE -/-     HF       1.05403 a       0.08174 0.9065 
                  5    ApoE -/-     LF       1.06889 a       0.15646 
                  5    C57BL6/J     HF       0.95613 a       0.09038 
                  5    C57BL6/J     LF       1.00893 a       0.04073 
 
                  7    ApoE -/-     HF       0.98010 b       0.10360 <.0001 
                  7    ApoE -/-     LF       1.24717 b       0.17690 
                  7    C57BL6/J     HF       0.93891 b       0.06204 
                  7    C57BL6/J     LF       1.92363 a       0.18251 
 
                 10    ApoE -/-     HF       1.11521 b       0.06155 <.0001 
                 10    ApoE -/-     LF       1.02503 b       0.08356 
                 10    C57BL6/J     HF       0.92203 b       0.07595 
                 10    C57BL6/J     LF       2.33510 a       0.30947 
 
                 14    ApoE -/-     HF       0.95900 a       0.02572 0.3904 
                 14    ApoE -/-     LF       1.18202 a       0.11194 
                 14    C57BL6/J     HF       1.20103 a       0.09239 
                 14    C57BL6/J     LF       1.02134 a       0.04462 
 
                 21    ApoE -/-     HF       0.90920 b       0.06148 0.0015 
                 21    ApoE -/-     LF       1.11396 b       0.13528 
                 21    C57BL6/J     HF       1.56815 a       0.12176 
                 21    C57BL6/J     LF       1.07958 b       0.08076 
 
                 28    ApoE -/-     HF       1.06799 a       0.06699 0.4416 
                 28    ApoE -/-     LF       1.04616 a       0.06331 
                 28    C57BL6/J     HF       0.83000 a       0.07500 
                 28    C57BL6/J     LF       0.89852 a       0.06207 
 
 
  
  
 
                  Day    Strain      Diet    MNVEGFlig    SEVEGFlig  PVALUE 
 
                    3    ApoE -/-     HF       37.660 a      5.3056 0.1968 
                    3    ApoE -/-     LF       50.480 a      8.3818 
                    3    C57BL6/J     HF       37.105 a      1.3777 
                    3    C57BL6/J     LF       24.847 a      1.9228 
 
                    5    ApoE -/-     HF       38.419 b      2.8210 0.0023 
                    5    ApoE -/-     LF       74.454 a     11.0378 
                    5    C57BL6/J     HF       33.157 b      3.2893 
                    5    C57BL6/J     LF       34.338 b      0.7038 
 
                    7    ApoE -/-     HF       46.597 b     12.7684 <.0001 
                    7    ApoE -/-     LF      100.347 a     16.4300 
                    7    C57BL6/J     HF       32.576 b      4.7982 
                    7    C57BL6/J     LF       42.844 b      5.9600 
 
                   10    ApoE -/-     HF       58.198 b     13.7757 <.0001 
                   10    ApoE -/-     LF       89.899 a     11.4078 
                   10    C57BL6/J     HF       27.700 c      3.9486 
                   10    C57BL6/J     LF       26.968 c      4.6076 
 
                   14    ApoE -/-     HF       65.241 b      8.4806 <.0001 
                   14    ApoE -/-     LF      114.928 a     14.5129 
                   14    C57BL6/J     HF       39.926 c      8.1809 
                   14    C57BL6/J     LF       68.564 b      7.3678 
 
                   21    ApoE -/-     HF       56.839 bc    13.5634 <.0001 
                   21    ApoE -/-     LF       94.144 a      6.7208 
                   21    C57BL6/J     HF       33.218 c      8.8264 
                   21    C57BL6/J     LF       59.850 b      9.4865 
 
                   28    ApoE -/-     HF       50.938 b      7.3574 <.0001 
                   28    ApoE -/-     LF      107.712 a      7.9333 
                   28    C57BL6/J     HF       32.517 b      3.3465 
                   28    C57BL6/J     LF       36.488 b      9.2520 
 
 
  
  
 
                Day    Strain      Diet    MNVEGFratio    SEVEGFratio  PVALUE 
 
                  3    ApoE -/-     HF       1.23929 a       0.03854 0.9851 
                  3    ApoE -/-     LF       1.18323 a       0.06518 
                  3    C57BL6/J     HF       1.09739 a       0.06906 
                  3    C57BL6/J     LF       1.13100 a       0.09181 
 
                  5    ApoE -/-     HF       1.19895 a       0.10259 0.3675 
                  5    ApoE -/-     LF       1.08740 a       0.16441 
                  5    C57BL6/J     HF       1.23888 a       0.08464 
                  5    C57BL6/J     LF       1.75546 a       0.20428 
 
                  7    ApoE -/-     HF       1.37039 a       0.15202 0.1759 
                  7    ApoE -/-     LF       1.56165 a       0.25579 
                  7    C57BL6/J     HF       1.16866 a       0.10803 
                  7    C57BL6/J     LF       1.88258 a       0.26770 
 
                 10    ApoE -/-     HF       1.82969 a       0.50455 0.4451 
                 10    ApoE -/-     LF       1.26964 a       0.12698 
                 10    C57BL6/J     HF       1.55569 a       0.24150 
                 10    C57BL6/J     LF       1.78642 a       0.38083 
 
                 14    ApoE -/-     HF       1.86372 b       0.16437 <.0001 
                 14    ApoE -/-     LF       2.04895 b       0.48101 
                 14    C57BL6/J     HF       1.42494 b       0.31844 
                 14    C57BL6/J     LF       3.93659 a       0.54305 
 
                 21    ApoE -/-     HF       1.82735 a       0.26636 0.0823 
                 21    ApoE -/-     LF       1.61343 a       0.25921 
                 21    C57BL6/J     HF       1.70393 a       0.53604 
                 21    C57BL6/J     LF       2.49681 a       0.16116 
 
                 28    ApoE -/-     HF       1.20807 a       0.05941 0.7715 
                 28    ApoE -/-     LF       1.45430 a       0.11522 
                 28    C57BL6/J     HF       1.09254 a       0.15778 
                 28    C57BL6/J     LF       1.37487 a       0.37781 
 
 
  
  
 
                Day    Strain      Diet    MNVEGFR1lig    SEVEGFR1lig  PVALUE 
 
                  3    ApoE -/-     HF       327.247 a       12.8602 0.6013 
                  3    ApoE -/-     LF       422.040 a       59.1821 
                  3    C57BL6/J     HF       391.805 a       56.8594 
                  3    C57BL6/J     LF       402.401 a       33.3849 
 
                  5    ApoE -/-     HF       320.159 a       26.2540 0.8334 
                  5    ApoE -/-     LF       348.158 a       16.3432 
                  5    C57BL6/J     HF       329.581 a       55.9341 
                  5    C57BL6/J     LF       383.415 a       27.4992 
 
                  7    ApoE -/-     HF       339.245 a       15.8918 0.3200 
                  7    ApoE -/-     LF       469.531 a       49.2973 
                  7    C57BL6/J     HF       391.232 a       36.8743 
                  7    C57BL6/J     LF       408.544 a       36.0741 
 
                 10    ApoE -/-     HF       362.187 b       48.3677 0.0214 
                 10    ApoE -/-     LF       517.196 a       67.0749 
                 10    C57BL6/J     HF       380.819 b       48.5201 
                 10    C57BL6/J     LF       520.354 a       28.8945 
 
                 14    ApoE -/-     HF       390.082 bc      53.3636 <.0001 
                 14    ApoE -/-     LF       465.545 b       49.3842 
                 14    C57BL6/J     HF       309.332 c       31.1990 
                 14    C57BL6/J     LF       617.460 a       43.1947 
 
                 21    ApoE -/-     HF       398.451 b       13.9570 <.0001 
                 21    ApoE -/-     LF       434.563 b       36.1775 
                 21    C57BL6/J     HF       370.455 b       19.5865 
                 21    C57BL6/J     LF       704.986 a       64.9496 
 
                 28    ApoE -/-     HF       488.526 b       23.7721 0.0011 
                 28    ApoE -/-     LF       530.441 b       45.7456 
                 28    C57BL6/J     HF       673.007 a       84.0295 
                 28    C57BL6/J     LF       733.440 a       96.1104 
 
  
  
              Day    Strain      Diet    MNVEGFR1ratio    SEVEGFR1ratio  PVALUE 
 
                3    ApoE -/-     HF        1.20441 a         0.08899 0.2655 
                3    ApoE -/-     LF        1.01824 a         0.18283 
                3    C57BL6/J     HF        1.09634 a         0.29500 
                3    C57BL6/J     LF        1.45082 a         0.20546 
 
                5    ApoE -/-     HF        1.00600 a         0.01890 0.4953 
                5    ApoE -/-     LF        0.98527 a         0.14584 
                5    C57BL6/J     HF        0.93658 a         0.09438 
                5    C57BL6/J     LF        1.26160 a         0.18065 
 
                7    ApoE -/-     HF        1.05954 a         0.05964 0.4330 
                7    ApoE -/-     LF        0.97313 a         0.11836 
                7    C57BL6/J     HF        0.98117 a         0.05146 
                7    C57BL6/J     LF        1.30703 a         0.17392 
 
               10    ApoE -/-     HF        1.21362 b         0.08647 0.0073 
               10    ApoE -/-     LF        1.10361 b         0.11554 
               10    C57BL6/J     HF        0.97622 b         0.08406 
               10    C57BL6/J     LF        1.66448 a         0.21396 
 
               14    ApoE -/-     HF        1.09679 b         0.09762 0.0029 
               14    ApoE -/-     LF        1.20292 b         0.17656 
               14    C57BL6/J     HF        0.91889 b         0.11566 
               14    C57BL6/J     LF        1.67837 a         0.12681 
 
               21    ApoE -/-     HF        1.49350 b         0.24603 <.0001 
               21    ApoE -/-     LF        1.08618 b         0.09813 
               21    C57BL6/J     HF        1.14786 b         0.06235 
               21    C57BL6/J     LF        2.24112 a         0.19360 
 
               28    ApoE -/-     HF        1.67076 b         0.11469 <.0001 
               28    ApoE -/-     LF        1.22471 c         0.11853 
               28    C57BL6/J     HF        1.42181 bc        0.19552 
               28    C57BL6/J     LF        2.20620 a         0.20487 
 
 
  
  
                  Day    Strain      Diet    MNMCP1lig    SEMCP1lig  PVALUE 
 
                    3    ApoE -/-     HF      132.178 b     45.2449 0.0052 
                    3    ApoE -/-     LF       95.692 b     20.1969 
                    3    C57BL6/J     HF      155.040 b     33.1480 
                    3    C57BL6/J     LF      229.604 a     34.9374 
 
                    5    ApoE -/-     HF      113.266 c     42.2936 0.0007 
                    5    ApoE -/-     LF      253.370 a     47.8718 
                    5    C57BL6/J     HF      189.125 ab    46.8542 
                    5    C57BL6/J     LF      134.718 bc    22.0139 
 
                    7    ApoE -/-     HF       37.864 a     16.4324 0.2029 
                    7    ApoE -/-     LF       80.215 a     26.0223 
                    7    C57BL6/J     HF       96.472 a     30.7498 
                    7    C57BL6/J     LF       37.964 a     14.5126 
 
                   10    ApoE -/-     HF       16.978 a      8.0202 0.1587 
                   10    ApoE -/-     LF       81.839 a     35.6486 
                   10    C57BL6/J     HF       63.724 a     20.7988 
                   10    C57BL6/J     LF       16.956 a      4.4160 
 
                   14    ApoE -/-     HF       19.721 a     11.3389 0.2885 
                   14    ApoE -/-     LF       68.223 a     19.1366 
                   14    C57BL6/J     HF       69.115 a     16.6501 
                   14    C57BL6/J     LF       17.550 a      4.8655 
 
                   21    ApoE -/-     HF       24.608 a     12.4486 0.8331 
                   21    ApoE -/-     LF       47.695 a     20.4045 
                   21    C57BL6/J     HF       35.942 a     14.9533 
                   21    C57BL6/J     LF       17.044 a      3.8523 
 
                   28    ApoE -/-     HF       33.587 a     14.5222 0.8033 
                   28    ApoE -/-     LF       19.369 a      8.8730 
                   28    C57BL6/J     HF       45.609 a     16.6643 
                   28    C57BL6/J     LF       13.658 a      2.5836 
 
 
  
  
 
                Day    Strain      Diet    MNMCP1ratio    SEMCP1ratio  PVALUE 
 
                  3    ApoE -/-     HF        5.4704 b       1.85573 <.0001 
                  3    ApoE -/-     LF        6.4195 b       1.39473 
                  3    C57BL6/J     HF       28.4734 a       5.99182 
                  3    C57BL6/J     LF       27.8457 a       5.49411 
 
                  5    ApoE -/-     HF        6.1443 b       2.85516 <.0001 
                  5    ApoE -/-     LF       10.8204 b       1.95703 
                  5    C57BL6/J     HF       24.9312 a       5.86281 
                  5    C57BL6/J     LF       13.1568 b       2.57029 
 
                  7    ApoE -/-     HF        1.2136 a       0.46419 0.0829 
                  7    ApoE -/-     LF        3.4466 a       1.09619 
                  7    C57BL6/J     HF        9.0269 a       2.32790 
                  7    C57BL6/J     LF        8.0670 a       2.24110 
 
                 10    ApoE -/-     HF        0.6241 a       0.20494 0.4077 
                 10    ApoE -/-     LF        5.2428 a       2.86344 
                 10    C57BL6/J     HF        5.9708 a       1.96509 
                 10    C57BL6/J     LF        2.3151 a       0.59751 
 
                 14    ApoE -/-     HF        1.0566 a       0.41186 0.2752 
                 14    ApoE -/-     LF        4.5376 a       1.47988 
                 14    C57BL6/J     HF        8.1537 a       3.27730 
                 14    C57BL6/J     LF        4.2094 a       3.08941 
 
                 21    ApoE -/-     HF        1.1208 a       0.24256 0.5921 
                 21    ApoE -/-     LF        5.5007 a       3.44555 
                 21    C57BL6/J     HF        2.6289 a       2.13553 
                 21    C57BL6/J     LF        1.2871 a       0.15056 
 
                 28    ApoE -/-     HF        2.0149 a       1.02341 0.9985 
                 28    ApoE -/-     LF        1.5679 a       0.57467 
                 28    C57BL6/J     HF        1.8440 a       0.73839 
                 28    C57BL6/J     LF        2.1831 a       0.77706 
 
 
 
 
 
  
  
 
                         Day    TRT     MNPLGFRATIO    SEPLGFRATIO PVALUE 
 
                        7    SHAM      0.94470        0.06042 0.0004 
                        7    TRT       2.16628        0.22291 
 
                       10    SHAM      1.08488        0.20970 0.0014 
                       10    TRT       2.13462        0.30436 
 
                       21    SHAM      1.02716        0.18112 0.8944 
                       21    TRT       1.06468        0.10247 
 
 
 
 
 
                         TRT     MNVEGFRATIO    SEVEGFRATIO  PVALUE  
 
                         SHAM      0.96243        0.05453  0.0016 
                         TRT       3.93659        0.54305 
 
 
 
 
 
 
                    Day    TRT     MNVEGFR1RATIO    SEVEGFR1RATIO  PVALUE  
 
                      7    SHAM       1.00748          0.10623 0.2394 
                      7    TRT        1.35688          0.23564 
 
                     10    SHAM       0.80425          0.09564 0.0078 
                     10    TRT        1.64761          0.27536 
 
 
 
 
 
                     Diet    TRT     MNMCP1RATIO    SEMCP1RATIO  PVALUE  
 
                      HF     SHAM       4.6145        3.22657 0.0072 
                      HF     TRT       27.2898        7.58299 
 
                      LF     SHAM       3.8147        0.57906 0.0050 
                      LF     TRT       27.8457        5.49411 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 --------------------------------------- Day=3 ---------------------------------
------ 
 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000     -0.13526        0.13140      0.21887       -
0.19882 
                                  0.6175         0.6407       0.4154         
0.5149 
                         16           16             15           16             
13 
 
  VEGFratio        -0.13526      1.00000        0.05448     -0.33924        
0.36926 
                     0.6175                      0.8412       0.1684         
0.1447 
                         16           20             16           18             
17 
 
  VEGFR1ratio       0.13140      0.05448        1.00000      0.23717       -
0.26004 
                     0.6407       0.8412                      0.3765         
0.3909 
                         15           16             16           16             
13 
 
  MCP1ratio         0.21887     -0.33924        0.23717      1.00000       -
0.64862 
                     0.4154       0.1684         0.3765                      
0.0066 
                         16           18             16           19             
16 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio          -0.19489         -0.26189     -0.44042     -0.11524     -
0.32447 
                      0.5234           0.3657       0.1519       0.6709       
0.2380 
                          13               14           12           16           
15 
 
 VEGFratio           0.27784          0.30492     -0.07618     -0.23150     -
0.01558 
                      0.2802           0.2186       0.7792       0.3261       
0.9495 
                          17               18           16           20           
19 
 
  VEGFR1ratio        -0.33294         -0.02504     -0.22128     -0.00137     -
0.09740 
                      0.2663           0.9323       0.4895       0.9960       
0.7298 
                          13               14           12           16           
15 
 
 MCP1ratio          -0.63099         -0.53579      0.30327      0.48124      
0.55321 
                      0.0088           0.0266       0.2718       0.0370       
0.0172 
                          16               17           15           19           
18 
 
 
  
  
--------------------------------------- Day=3 ---------------------------------
------ 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol      -0.19882      0.36926       -0.26004     -0.64862        
1.00000 
                     0.5149       0.1447         0.3909       0.0066 
                         13           17             13           16             
18 
 
  Isoprostane      -0.19489      0.27784       -0.33294     -0.63099        
0.95390 
                     0.5234       0.2802         0.2663       0.0088         
<.0001 
                         13           17             13           16             
18 
 
  Triglyceride     -0.26189      0.30492       -0.02504     -0.53579        
0.89651 
                     0.3657       0.2186         0.9323       0.0266         
<.0001 
                         14           18             14           17             
18 
 
  Insulin          -0.44042     -0.07618       -0.22128      0.30327        
0.08073 
                     0.1519       0.7792         0.4895       0.2718         
0.7581 
                         12           16             12           15             
17 
 
  BW24thWeek       -0.11524     -0.23150       -0.00137      0.48124       -
0.13723 
                     0.6709       0.3261         0.9960       0.0370         
0.5871 
                         16           20             16           19             
18 
 
  AUC              -0.32447     -0.01558       -0.09740      0.55321       -
0.13955 
                     0.2380       0.9495         0.7298       0.0172         
0.5808 
                         15           19             15           18             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.95390          0.89651      0.08073     -0.13723     -
0.13955 
                       <.0001           <.0001       0.7581       0.5871       
0.5808 
                          18               18           17           18           
18 
 
 Isoprostane         1.00000          0.87527      0.27039      0.04497      
0.01783 
                                       <.0001       0.2939       0.8594       
0.9440 
                          18               18           17           18           
18 
 
 Triglyceride        0.87527          1.00000      0.12417      0.01269     -
0.05227 
                      <.0001                        0.6349       0.9589       
0.8368 
                          18               19           17           19           
18 
 
 Insulin             0.27039          0.12417      1.00000      0.70192      
0.85748 
                      0.2939           0.6349                    0.0017       
<.0001 
                          17               17           17           17           
17 
 
 BW24thWeek          0.04497          0.01269      0.70192      1.00000      
0.82388 
                      0.8594           0.9589       0.0017                    
<.0001 
                          18               19           17           21           
20 
 
 AUC                 0.01783         -0.05227      0.85748      0.82388      
1.00000 
                      0.9440           0.8368       <.0001       <.0001 
                          18               18           17           20           
20 
 
 
--------------------------------------- Day=5 ---------------------------------
------ 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000     -0.12539       -0.13817      0.09471        
0.05651 
                                  0.6201         0.6098       0.7085         
0.8294 
                         18           18             16           18             
17 
 
  VEGFratio        -0.12539      1.00000        0.03330      0.06909       -
0.36050 
                     0.6201                      0.9026       0.7853         
0.1552 
                         18           18             16           18             
17 
  
  VEGFR1ratio      -0.13817      0.03330        1.00000     -0.28668       -
0.21115 
                     0.6098       0.9026                      0.2817         
0.4500 
                         16           16             16           16             
15 
 
  MCP1ratio         0.09471      0.06909       -0.28668      1.00000       -
0.37616 
                     0.7085       0.7853         0.2817                      
0.1367 
                         18           18             16           19             
17 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio           0.09151          0.33758     -0.36886     -0.23964     -
0.12030 
                      0.7269           0.2185       0.1761       0.3382       
0.6344 
                          17               15           15           18           
18 
 
 VEGFratio          -0.46574         -0.25020     -0.13720     -0.13718     -
0.09227 
                      0.0595           0.3684       0.6258       0.5873       
0.7158 
                          17               15           15           18           
18 
 
 VEGFR1ratio        -0.44266         -0.21348     -0.32038     -0.08888     -
0.18499 
                      0.0985           0.4637       0.2641       0.7434       
0.4928 
                          15               14           14           16           
16 
 
 MCP1ratio          -0.08681         -0.32207      0.44906      0.28610      
0.72582 
                      0.7404           0.2417       0.0931       0.2351       
0.0006 
                          17               15           15           19           
18 
 
 
  
 --------------------------------------- Day=5 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol       0.05651     -0.36050       -0.21115     -0.37616        
1.00000 
                     0.8294       0.1552         0.4500       0.1367 
                         17           17             15           17             
17 
 
  Isoprostane       0.09151     -0.46574       -0.44266     -0.08681        
0.85774 
                     0.7269       0.0595         0.0985       0.7404         
<.0001 
                         17           17             15           17             
17 
 
  Triglyceride      0.33758     -0.25020       -0.21348     -0.32207        
0.78460 
                     0.2185       0.3684         0.4637       0.2417         
0.0005 
                         15           15             14           15             
15 
 
  Insulin          -0.36886     -0.13720       -0.32038      0.44906        
0.18505 
                     0.1761       0.6258         0.2641       0.0931         
0.5091 
                         15           15             14           15             
15 
 
  BW24thWeek       -0.23964     -0.13718       -0.08888      0.28610        
0.14995 
                     0.3382       0.5873         0.7434       0.2351         
0.5657 
                         18           18             16           19             
17 
 
  AUC              -0.12030     -0.09227       -0.18499      0.72582       -
0.36015 
                     0.6344       0.7158         0.4928       0.0006         
0.1556 
                         18           18             16           18             
17 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.85774          0.78460      0.18505      0.14995     -
0.36015 
                       <.0001           0.0005       0.5091       0.5657       
0.1556 
                          17               15           15           17           
17 
 
 Isoprostane         1.00000          0.79084      0.46137      0.32171     -
0.06897 
                                       0.0004       0.0834       0.2080       
0.7925 
                          17               15           15           17           
17 
 
 Triglyceride        0.79084          1.00000      0.08352     -0.01278     -
0.47131 
                      0.0004                        0.7673       0.9639       
0.0762 
                          15               15           15           15           
15 
 
 Insulin             0.46137          0.08352      1.00000      0.73087      
0.69626 
                      0.0834           0.7673                    0.0020       
0.0039 
                          15               15           15           15           
15 
 
 BW24thWeek          0.32171         -0.01278      0.73087      1.00000      
0.72377 
                      0.2080           0.9639       0.0020                    
0.0007 
                          17               15           15           19           
18 
 
 AUC                -0.06897         -0.47131      0.69626      0.72377      
1.00000 
                      0.7925           0.0762       0.0039       0.0007 
                          17               15           15           18           
18 
 
--------------------------------------- Day=7 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000      0.46993        0.67798      0.19865       -
0.37737 
                                  0.0316         0.0039       0.3880         
0.0917 
                         22           21             16           21             
21 
 
  VEGFratio         0.46993      1.00000        0.69405      0.01521       -
0.33545 
                     0.0316                      0.0029       0.9478         
0.1371 
                         21           22             16           21             
21 
  
  VEGFR1ratio       0.67798      0.69405        1.00000      0.15793       -
0.15242 
                     0.0039       0.0029                      0.5449         
0.5731 
                         16           16             17           17             
16 
 
  MCP1ratio         0.19865      0.01521        0.15793      1.00000       -
0.54183 
                     0.3880       0.9478         0.5449                      
0.0112 
                         21           21             17           22             
21 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio          -0.57133         -0.39376     -0.64021     -0.43639     -
0.40204 
                      0.0085           0.1059       0.0042       0.0423       
0.0981 
                          20               18           18           22           
18 
 
 VEGFratio          -0.54345         -0.25974     -0.58009     -0.50125     -
0.23197 
                      0.0133           0.2979       0.0116       0.0175       
0.3393 
                          20               18           18           22           
19 
 
 VEGFR1ratio        -0.20187         -0.20471     -0.25302     -0.25159     -
0.04365 
                      0.4706           0.4827       0.3828       0.3300       
0.8822 
                          15               14           14           17           
14 
 
 MCP1ratio          -0.49326         -0.55432     -0.15144      0.16315      
0.36777 
                      0.0271           0.0170       0.5486       0.4682       
0.1213 
                          20               18           18           22           
19 
 
 
  
 --------------------------------------- Day=7 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol      -0.37737     -0.33545       -0.15242     -0.54183        
1.00000 
                     0.0917       0.1371         0.5731       0.0112 
                         21           21             16           21             
22 
 
  Isoprostane      -0.57133     -0.54345       -0.20187     -0.49326        
0.90066 
                     0.0085       0.0133         0.4706       0.0271         
<.0001 
                         20           20             15           20             
21 
 
  Triglyceride     -0.39376     -0.25974       -0.20471     -0.55432        
0.86698 
                     0.1059       0.2979         0.4827       0.0170         
<.0001 
                         18           18             14           18             
19 
 
  Insulin          -0.64021     -0.58009       -0.25302     -0.15144        
0.22087 
                     0.0042       0.0116         0.3828       0.5486         
0.3635 
                         18           18             14           18             
19 
 
  BW24thWeek       -0.43639     -0.50125       -0.25159      0.16315        
0.15436 
                     0.0423       0.0175         0.3300       0.4682         
0.4928 
                         22           22             17           22             
22 
 
  AUC              -0.40204     -0.23197       -0.04365      0.36777       -
0.17021 
                     0.0981       0.3393         0.8822       0.1213         
0.4995 
                         18           19             14           19             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.90066          0.86698      0.22087      0.15436     -
0.17021 
                       <.0001           <.0001       0.3635       0.4928       
0.4995 
                          21               19           19           22           
18 
 
 Isoprostane         1.00000          0.69912      0.55506      0.41592      
0.16603 
                                       0.0009       0.0136       0.0608       
0.5242 
                          21               19           19           21           
17 
 
 Triglyceride        0.69912          1.00000      0.23830      0.12833     -
0.23638 
                      0.0009                        0.3259       0.6006       
0.3963 
                          19               19           19           19           
15 
 
 Insulin             0.55506          0.23830      1.00000      0.60729      
0.59187 
                      0.0136           0.3259                    0.0058       
0.0201 
                          19               19           19           19           
15 
 
 BW24thWeek          0.41592          0.12833      0.60729      1.00000      
0.77954 
                      0.0608           0.6006       0.0058                    
<.0001 
                          21               19           19           23           
19 
 
 AUC                 0.16603         -0.23638      0.59187      0.77954      
1.00000 
                      0.5242           0.3963       0.0201       <.0001 
                          17               15           15           19           
19 
 
 
-------------------------------------- Day=10 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000      0.20235        0.67320     -0.23917       -
0.44730 
                                  0.4061         0.0016       0.3241         
0.0718 
                         19           19             19           19             
17 
 
  VEGFratio         0.20235      1.00000        0.26722     -0.17814        
0.00922 
                     0.4061                      0.2687       0.4656         
0.9720 
                          19           19             19           19             
17 
 
  VEGFR1ratio       0.67320      0.26722        1.00000     -0.11239       -
0.17127 
                     0.0016       0.2687                      0.6371         
0.4968 
                         19           19             20           20             
18 
 
  MCP1ratio        -0.23917     -0.17814       -0.11239      1.00000       -
0.21293 
                     0.3241       0.4656         0.6371                      
0.3963 
                         19           19             20           20             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio          -0.71689         -0.31500     -0.51496     -0.39563     -
0.20342 
                      0.0018           0.2528       0.0495       0.0936       
0.4036 
                          16               15           15           19           
19 
 
 VEGFratio          -0.03473          0.20694     -0.08728      0.24648      
0.02853 
                      0.8984           0.4593       0.7571       0.3090       
0.9077 
                          16               15           15           19           
19 
 
 VEGFR1ratio        -0.48071         -0.08307     -0.29019     -0.29287     -
0.13654 
                      0.0508           0.7685       0.2941       0.2102       
0.5659 
                          17               15           15           20           
20 
 
 MCP1ratio          -0.03498         -0.37691      0.05226     -0.03416      
0.21576 
                      0.8940           0.1661       0.8532       0.8863       
0.3609 
                          17               15           15           20           
20 
 
 
  
 -------------------------------------- Day=10 ---------------------------------
------ 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol      -0.44730      0.00922       -0.17127     -0.21293        
1.00000 
                     0.0718       0.9720         0.4968       0.3963 
                         17           17             18           18             
18 
 
  Isoprostane      -0.71689     -0.03473       -0.48071     -0.03498        
0.89848 
                     0.0018       0.8984         0.0508       0.8940         
<.0001 
                         16           16             17           17             
17 
 
  Triglyceride     -0.31500      0.20694       -0.08307     -0.37691        
0.94594 
                     0.2528       0.4593         0.7685       0.1661         
<.0001 
                         15           15             15           15             
15 
 
  Insulin          -0.51496     -0.08728       -0.29019      0.05226        
0.33736 
                     0.0495       0.7571         0.2941       0.8532         
0.2188 
                         15           15             15           15             
15 
 
  BW24thWeek       -0.39563      0.24648       -0.29287     -0.03416        
0.29484 
                     0.0936       0.3090         0.2102       0.8863         
0.2349 
                         19           19             20           20             
18 
 
  AUC              -0.20342      0.02853       -0.13654      0.21576       -
0.26192 
                     0.4036       0.9077         0.5659       0.3609         
0.2937 
                         19           19             20           20             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.89848          0.94594      0.33736      0.29484     -
0.26192 
                      <.0001           <.0001       0.2188       0.2349       
0.2937 
                           17               15           15           18           
18 
 
 Isoprostane         1.00000          0.77716      0.40891      0.46920     -
0.09740 
                                       0.0007       0.1302       0.0574       
0.7100 
                          17               15           15           17           
17 
 
 Triglyceride        0.77716          1.00000      0.24252      0.23826     -
0.34307 
                      0.0007                        0.3838       0.3925       
0.2106 
                          15               15           15           15           
15 
 
 Insulin             0.40891          0.24252      1.00000      0.86772      
0.73809 
                      0.1302           0.3838                    <.0001       
0.0017 
                          15               15           15           15           
15 
 
 BW24thWeek          0.46920          0.23826      0.86772      1.00000      
0.68776 
                      0.0574           0.3925       <.0001                    
0.0008 
                          17               15           15           20           
20 
 
 AUC                -0.09740         -0.34307      0.73809      0.68776      
1.00000 
                      0.7100           0.2106       0.0017       0.0008 
                          17               15           15           20           
20 
 
 
-------------------------------------- Day=14 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000     -0.59905        0.06237      0.11557       -
0.06773 
                                  0.0067         0.7998       0.6479         
0.7829 
                         20           19             19           18             
19 
 
  VEGFratio        -0.59905      1.00000        0.50852     -0.26109       -
0.34018 
                     0.0067                      0.0312       0.2953         
0.1672 
                         19           19             18           18             
18 
 
   VEGFR1ratio       0.06237      0.50852        1.00000     -0.20044       -
0.34759 
                     0.7998       0.0312                      0.4252         
0.1448 
                         19           18             20           18             
19 
 
  MCP1ratio         0.11557     -0.26109       -0.20044      1.00000       -
0.37900 
                     0.6479       0.2953         0.4252                      
0.1209 
                         18           18             18           19             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio          -0.01811         -0.08992      0.06918      0.16729      
0.27392 
                      0.9413           0.7143       0.7919       0.4808       
0.2565 
                          19               19           17           20           
19 
 
 VEGFratio          -0.55018         -0.21188     -0.42487     -0.52577     -
0.49249 
                      0.0180           0.3986       0.1009       0.0208       
0.0379 
                          18               18           16           19           
18 
 
 VEGFR1ratio        -0.60443         -0.11031     -0.38898     -0.43634     -
0.48877 
                      0.0061           0.6530       0.1228       0.0544       
0.0337 
                          19               19           17           20           
19 
 
 MCP1ratio          -0.18261         -0.27419      0.34428      0.11133      
0.38353 
                      0.4683           0.2709       0.1760       0.6500       
0.1161 
                          18               18           17           19           
18 
 
 
  
 -------------------------------------- Day=14 ---------------------------------
------ 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol      -0.06773     -0.34018       -0.34759     -0.37900        
1.00000 
                     0.7829       0.1672         0.1448       0.1209 
                         19           18             19           18             
20 
 
  Isoprostane      -0.01811     -0.55018       -0.60443     -0.18261        
0.88696 
                     0.9413       0.0180         0.0061       0.4683         
<.0001 
                         19           18             19           18             
20 
 
  Triglyceride     -0.08992     -0.21188       -0.11031     -0.27419        
0.75494 
                     0.7143       0.3986         0.6530       0.2709         
0.0001 
                         19           18             19           18             
20 
 
  Insulin           0.06918     -0.42487       -0.38898      0.34428        
0.07177 
                     0.7919       0.1009         0.1228       0.1760         
0.7772 
                         17           16             17           17             
18 
 
  BW24thWeek        0.16729     -0.52577       -0.43634      0.11133        
0.13167 
                     0.4808       0.0208         0.0544       0.6500         
0.5800 
                         20           19             20           19             
20 
 
  AUC               0.27392     -0.49249       -0.48877      0.38353       -
0.19038 
                     0.2565       0.0379         0.0337       0.1161         
0.4214 
                         19           18             19           18             
20 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.88696          0.75494      0.07177      0.13167     -
0.19038 
                      <.0001           0.0001       0.7772       0.5800       
0.4214 
                           20               20           18           20           
20 
 
 Isoprostane         1.00000          0.63794      0.31199      0.36096      
0.11743 
                                       0.0025       0.2075       0.1179       
0.6220 
                          20               20           18           20           
20 
 
 Triglyceride        0.63794          1.00000     -0.13014     -0.04585     -
0.39216 
                      0.0025                        0.6068       0.8478       
0.0872 
                          20               20           18           20           
20 
 
 Insulin             0.31199         -0.13014      1.00000      0.90263      
0.82130 
                      0.2075           0.6068                    <.0001       
<.0001 
                          18               18           18           18           
18 
 
 BW24thWeek          0.36096         -0.04585      0.90263      1.00000      
0.70336 
                      0.1179           0.8478       <.0001                    
0.0005 
                          20               20           18           21           
20 
 
 AUC                 0.11743         -0.39216      0.82130      0.70336      
1.00000 
                      0.6220           0.0872       <.0001       0.0005 
                          20               20           18           20           
20 
 
 
-------------------------------------- Day=21 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000     -0.12461       -0.16453      0.22495       -
0.28830 
                                  0.6113         0.5009       0.3545         
0.2618 
                         19           19             19           19             
17 
 
  VEGFratio        -0.12461      1.00000        0.49873      0.04567       -
0.16614 
                     0.6113                      0.0297       0.8527         
0.5239 
                         19           19             19           19             
17 
 
   VEGFR1ratio      -0.16453      0.49873        1.00000     -0.17633       -
0.18558 
                     0.5009       0.0297                      0.4571         
0.4610 
                         19           19             20           20             
18 
 
  MCP1ratio         0.22495      0.04567       -0.17633      1.00000        
0.00091 
                     0.3545       0.8527         0.4571                      
0.9971 
                         19           19             20           20             
18 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio          -0.15365         -0.25226      0.10055      0.28745      
0.74137 
                      0.5560           0.4289       0.7558       0.2328       
0.0004 
                          17               12           12           19           
18 
 
 VEGFratio          -0.25218         -0.06627      0.04020     -0.07388     -
0.14609 
                      0.3288           0.8379       0.9013       0.7637       
0.5630 
                          17               12           12           19           
18 
 
 VEGFR1ratio        -0.45579          0.25324     -0.33728     -0.14365     -
0.28289 
                      0.0573           0.4271       0.2837       0.5457       
0.2406 
                          18               12           12           20           
19 
 
 MCP1ratio          -0.10583          0.00836     -0.03067     -0.20819     -
0.00351 
                      0.6760           0.9794       0.9246       0.3784       
0.9886 
                          18               12           12           20           
19 
 
 
  
 -------------------------------------- Day=21 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol      -0.28830     -0.16614       -0.18558      0.00091        
1.00000 
                     0.2618       0.5239         0.4610       0.9971 
                         17           17             18           18             
18 
 
  Isoprostane      -0.15365     -0.25218       -0.45579     -0.10583        
0.86011 
                     0.5560       0.3288         0.0573       0.6760         
<.0001 
                         17           17             18           18             
18 
 
  Triglyceride     -0.25226     -0.06627        0.25324      0.00836        
0.93133 
                     0.4289       0.8379         0.4271       0.9794         
<.0001 
                         12           12             12           12             
12 
 
  Insulin           0.10055      0.04020       -0.33728     -0.03067        
0.32355 
                     0.7558       0.9013         0.2837       0.9246         
0.3049 
                         12           12             12           12             
12 
 
  BW24thWeek        0.28745     -0.07388       -0.14365     -0.20819        
0.34875 
                     0.2328       0.7637         0.5457       0.3784         
0.1561 
                         19           19             20           20             
18 
 
  AUC               0.74137     -0.14609       -0.28289     -0.00351       -
0.19765 
                     0.0004       0.5630         0.2406       0.9886         
0.4470 
                         18           18             19           19             
17 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.86011          0.93133      0.32355      0.34875     -
0.19765 
                       <.0001           <.0001       0.3049       0.1561       
0.4470 
                          18               12           12           18           
17 
 
 Isoprostane         1.00000          0.75614      0.56986      0.39200      
0.07427 
                                       0.0044       0.0531       0.1076       
0.7770 
                          18               12           12           18           
17 
 
 Triglyceride        0.75614          1.00000      0.27316      0.31347     -
0.07620 
                      0.0044                        0.3903       0.3211       
0.8238 
                          12               12           12           12           
11 
 
 Insulin             0.56986          0.27316      1.00000      0.73645      
0.64015 
                      0.0531           0.3903                    0.0063       
0.0339 
                          12               12           12           12           
11 
 
 BW24thWeek          0.39200          0.31347      0.73645      1.00000      
0.72094 
                      0.1076           0.3211       0.0063                    
0.0005 
                          18               12           12           20           
19 
 
 AUC                 0.07427         -0.07620      0.64015      0.72094      
1.00000 
                      0.7770           0.8238       0.0339       0.0005 
                          17               11           11           19           
19 
 
 
-------------------------------------- Day=28 ---------------------------------
------ 
 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  PLGFratio         1.00000      0.00975       -0.24920     -0.01288        
0.43575 
                                  0.9694         0.3187       0.9596         
0.1568 
                         18           18             18           18             
12 
 
  VEGFratio         0.00975      1.00000        0.30965     -0.05520        
0.00934 
                     0.9694                      0.1970       0.8224         
0.9758 
                          18           19             19           19             
13 
 
  VEGFR1ratio      -0.24920      0.30965        1.00000     -0.05178       -
0.54159 
                     0.3187       0.1970                      0.8332         
0.0559 
                         18           19             19           19             
13 
 
  MCP1ratio        -0.01288     -0.05520       -0.05178      1.00000       -
0.16812 
                     0.9596       0.8224         0.8332                      
0.5830 
                         18           19             19           19             
13 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 PLGFratio           0.21042          0.65431     -0.45570     -0.22071     -
0.44335 
                      0.4703           0.0401       0.2177       0.3946       
0.1123 
                          14               10            9           17           
14 
 
 VEGFratio           0.13187          0.45675     -0.46773     -0.25290     -
0.48965 
                      0.6395           0.1579       0.1728       0.3113       
0.0755 
                          15               11           10           18           
14 
 
 VEGFR1ratio        -0.41186         -0.69068      0.13052     -0.08784      
0.05587 
                      0.1272           0.0186       0.7193       0.7289       
0.8495 
                          15               11           10           18           
14 
 
 MCP1ratio           0.07799          0.06690     -0.01044      0.03662      
0.04957 
                      0.7823           0.8450       0.9772       0.8853       
0.8664 
                          15               11           10           18           
14 
 
 
  
 -------------------------------------- Day=28 ---------------------------------
------ 
 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                  PLGFratio    VEGFratio    VEGFR1ratio    MCP1ratio    
Cholesterol 
 
  Cholesterol       0.43575      0.00934       -0.54159     -0.16812        
1.00000 
                     0.1568       0.9758         0.0559       0.5830 
                         12           13             13           13             
13 
 
  Isoprostane       0.21042      0.13187       -0.41186      0.07799        
0.78087 
                     0.4703       0.6395         0.1272       0.7823         
0.0027 
                         14           15             15           15             
12 
 
  Triglyceride      0.65431      0.45675       -0.69068      0.06690        
0.94585 
                     0.0401       0.1579         0.0186       0.8450         
<.0001 
                         10           11             11           11             
10 
 
  Insulin          -0.45570     -0.46773        0.13052     -0.01044       -
0.45399 
                     0.2177       0.1728         0.7193       0.9772         
0.2196 
                          9           10             10           10              
9 
 
  BW24thWeek       -0.22071     -0.25290       -0.08784      0.03662        
0.01433 
                     0.3946       0.3113         0.7289       0.8853         
0.9629 
                         17           18             18           18             
13 
 
  AUC              -0.44335     -0.48965        0.05587      0.04957       -
0.17093 
                     0.1123       0.0755         0.8495       0.8664         
0.6153 
                         14           14             14           14             
11 
 
                          Pearson Correlation Coefficients 
                             Prob > |r| under H0: Rho=0 
                               Number of Observations 
 
                                                                 BW24th 
                 Isoprostane     Triglyceride      Insulin         Week          
AUC 
 
 Cholesterol         0.78087          0.94585     -0.45399      0.01433     -
0.17093 
                       0.0027           <.0001       0.2196       0.9629       
0.6153 
                          12               10            9           13           
11 
 
 Isoprostane         1.00000          0.42567      0.05558      0.25354      
0.00762 
                                       0.1918       0.8788       0.3619       
0.9803 
                          15               11           10           15           
13 
 
 Triglyceride        0.42567          1.00000     -0.71739     -0.53358     -
0.63909 
                      0.1918                        0.0195       0.0909       
0.0639 
                          11               11           10           11            
9 
 
 Insulin             0.05558         -0.71739      1.00000      0.94199      
0.88781 
                      0.8788           0.0195                    <.0001       
0.0032 
                          10               10           10           10            
8 
 
 BW24thWeek          0.25354         -0.53358      0.94199      1.00000      
0.86763 
                      0.3619           0.0909       <.0001                    
<.0001 
                          15               11           10           18           
14 
 
 AUC                 0.00762         -0.63909      0.88781      0.86763      
1.00000 
                      0.9803           0.0639       0.0032       <.0001 
                          13                9            8           14           
14 
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